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Cancer is one of the primary causes of human death worldwide.  Acute myeloid leukaemia 
(AML), one of the most severe types of blood/bone marrow cancers, is derived from 
transformed human myeloid precursor cells which developed mechanisms allowing them to 
escape host immune surveillance by inactivating cytotoxic lymphoid cells. Further studies 
suggested that solid tumours operate similar immune escape strategies. Molecular mechanisms 
of the immune evasion by malignant cells are poorly understood, however a better 
comprehension of the biochemistry underlying these processes are vital for development of 
anti-cancer immunotherapy – a cure of new generation.  
Recent evidence suggested the crucial involvement of Tim-3 and galectin-9 proteins in the 
immunosuppression operated by malignant cells. Therefore, the aim of our work was to 
investigate the activity of Tim-3-galectin-9 immunosuppressive pathway in human malignant 
cells and biochemical functions of its crucial components. 
We discovered that triggering of the receptor called latrophilin (LPHN) 1, expressed in AML 
cells but absent in healthy leukocytes, induces biosynthesis and exocytosis of T-
cell immunoglobulin and mucin domain 3 (Tim-3) and galectin-9. Galectin-9 suppresses anti-
cancer immunity by impairing anti-cancer activities of cytotoxic lymphoid cells. Tim-3 is 
trafficking galectin-9 but also can act on its own and prevent generation of interleukin-2 (IL-
2) required for activation of cytotoxic lymphoid cells. Furthermore, AML cells recruit crucial 
components of normal human metabolism to escape surveillance and progress the disease. In 
particular, human adrenal cortex hormone cortisol upregulates LPHN1 expression in AML 
cells; blood-available fibronectin leucine rich transmembrane protein 3 (FLRT3) interacts with 
LPHN1 leading to galetin-9/Tim-3 synthesis and exocytosis in AML cells. Crucial components 
of FLRT3/LPHN/Tim-3/galectin-9 pathway are expressed in the majority of cancer cell lines 
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and thus may be common for a variety of malignant tumours.  Tim-3-galectin-9 pathway is 
active in breast cancer and variety of other solid tumour cells and is used to protect malignant 
cells from host immune attack. However, unlike some other members of galectin family of 
proteins (for example, galectin-3), galectin-9 doesn’t protect cancer cells against apoptosis via 
mitochondrial defunctionalisation. On the other hand, mitochondrial defunctionalisation 
reduces galectin-9 surface expression and leads to its accumulation in mitochondria in 
malignant cells but not in healthy ones. Therefore, targeted mitochondrial defunctionalisation 
may be a novel strategy for anti-cancer immunotherapy, since it would reduce galectin-9 
surface expression allowing better elimination of cancer cells by immune system cells. Taken 
together our work demonstrates for the first time that Tim-3-galectin-9 immunosuppressive 
pathway plays a pivotal role in protection of AML and various solid tumour cells towards host 
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Munc18 leading to the formation of SNARE complexes, which tether cytosolic vesicles to the 
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Abl: Gene Abelson 
ADAM: a disintegrin and metalloproteinase domain-containing proteins 
AGEs: Advanced glycation end products 
ALL: Acute lymphoid leukaemia 
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Bat3: HLA- B associated transcript 3 
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BCR: Breakpoint cluster region 
BID: BH3 Interacting Domain Death Agonist 
BSA: Bovine serum albumin 
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CKI: Cyclin-dependent kinase inhibitors 
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DAG: Diacyl glycerol 
DAMPs: Damage-associated molecular patterns 
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ERK: Extracellular signal–regulated kinases 
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FADD: Fas-associated protein with death domain 
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FLRT3: Fibronectin leucine rich transmembrane protein 3 
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HCV: Hepatitis C virus 
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HD: Healthy donors 
HIF-1: Hypoxia-inducible factor 1 
HMGB1: High-mobility group box 1 
HPA: Hypothalamic-pituitary-adrenal axis 
HPV: Human genital papillomavirus 
HRP: Horse radish peroxidase 
HSC: Hematopoietic stem cell 
HTLV-1: Human T-lymphotropic virus-1 
IDO1: Indoleamine 2,3-dioxegenase 
IFN-γ: Interferon γ 
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IL-1β: Interleukin 1β 
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MHC: Major histocompatibility complex 
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MICB: MHC class I chain-related protein B 
MSCs: Mesenchymal cells 
mTOR: Mammalian target of rapamycin 
MW: Molecular weight 
xxxiv 
 
NFκB: Nuclear factor kappa-B 
NK: Natural Killer 
NKG2D: Natural Killer Group 2D 
NSCLC: Non-small-cell lung carcinoma 
OPD: Orto-phenylenediamine 
PARP: Poly ADP ribose polymerase 
PBS: Phosphate-buffered saline 
PD-1: Protein cell death 1 
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PD-L1: PD ligand 1 
PD-L2: PD ligand 2 
PES: Phenazine ethosulfate 
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Cancer is a wide group of systemic disorders resulting from growth of abnormal cells which 
have a potential to invade and/or spread to other parts of the body. 
Taken together, cancers are the second leading cause of death worldwide and remain a serious 
medical burden in countries of all income levels (WHO, 2018; IARC, 2018) 
Until the middle of XX century cancer incidence and mortality rates were almost the same. 
Since then, great effort has been made to uncover fundamental mechanisms underlying cancer 
physiopathology for the development of the treatments for different types of malignancies 
(Richiardi & Terracini, 2015). Although cancer prognosis is no longer as catastrophic as in the 
past, there are still a huge number of individuals dying because of the cancer each year. 
Approximately 18.1 million cancer diagnoses and 9.1 million cancer-associated deaths were 
registered in 2018 worldwide (IARC, 2018). Just ten years earlier (2008), these numbers were 
considerably lower: 12.7 million cancer cases and 7.6 cancer-related deaths (Ferlay et al., 
2010). Indeed, cancer incidence and mortality are unceasingly increasing globally as reported 
in Figure 1 (Ferlay et al., 2010; Fitzmaurice et al., 2015; IARC, 2018; Parkin et al., 2005; 
Parkin, 2001; Torre et al., 2016). Furthermore, cancers are expected to become the first leading 
cause of death, principally, as a result of considerable reduction in mortality rates of other 




Figure 1: Cancer Global Incidence and Mortality. Incidence and mortality are reported as absolute 
numbers of new cancer cases and cancer-related deaths, respectively, per annum (Ferlay et al., 2010; 
Fitzmaurice et al., 2015; IARC, 2018; Parkin et al., 2005; Parkin, 2001; Torre et al., 2016). 
Although the absolute number of cancer-related deaths is increasing globally, the mortality 
rate, expressed as the ratio between the number of deaths and the number of new cancer cases, 
is plateauing or decreasing for various types of malignancies in higher income countries (HIC) 
(Fitzmaurice, 2017; Torre et al., 2016). This phenomenon is due to several factors. Firstly, the 
development of more effective treatments, as a result of massive advances in cancer research, 
has led to significant improvements in cancer survival rates (Arruebo et al., 2011; Falzone, 
Salomone, & Libra, 2018). Furthermore, the progress in medical technologies as well as the 
discovery of specific cancer antigens has given the opportunity to detect earlier and faster 
diverse malignancies contributing positively on patient life expectancy (Hazelton & Luebeck, 
2011; Hofvind, et al., 2013; Landy, et al., 2016; Loud & Murphy, 2017; Marmot et al., 2013; 
Ouakrim et al., 2015; Paci, Broeders, et al., 2012). Finally, the prevention has an important 
impact on cancer incidence and has the potential to considerably reduce future cancer burden. 
Epidemiological studies predict that promoting healthy life style (eliminating the habits of 
smoking tobacco, decreasing alcohol drinking, practicing regularly physical activity and 












1995 2000 2005 2010 2015 2020





Loftfield, 2018). Moreover, anti-cancer vaccination and effective treatments of cancer-
associated infections are expected to play an important role in prevention of neoplasia 
transformations (Doorakkers, et al., 2018; Howley, 2015; Wroblewski, et al., 2010; Zhao B, et 
al., 2019). 
However, despite great strides in the fight against cancer, much still needs to be achieved. 
Diagnosis of some types of malignancies, such as pancreatic or lung cancers, is frequently 
translated in a death sentence (Ansari et al., 2016; Bray et al., 2018; Wong, et al., 2017; Zappa 
& Mousa, 2016). In addition, current therapies frequently cause short and long term side effects 
(Devlin, et al., 2017; Nurgali, et al., 2018). Thus, the development of innovative anti-cancer 
strategies with higher efficiency and lower toxicity is required. Encouraging outcomes obtained 
from the molecularly targeted therapies suggest that this goal can be achieved through better 
exploration of the differences between malignant and healthy cells as well as the enhancement 
of host immune system defences (Arruebo et al., 2011; Falzone et al., 2018). 
1.1 Cancer development and metastasis (stages of cancer development) 
Most tissues in the human body possess the ability to regenerate (Rue & Martinez Arias, 2015).  
Older cells are continuously replaced with  new ones in the majority of our organs during 
physiological cell turnover (Pellettieri & Alvarado, 2007; Spalding, et al., 2005). Moreover, 
damaged tissues or partially or totally removed organs can regenerate reacquiring initial 
dimensions and functions (Baddour, et al., 2012). 
Since the number of the cells has to be usually constant in the adult organism, there has to be 
a balance between cell proliferation and programmed cell death (tissue homeostasis). Indeed, 
these processes are tightly controlled in the living beings, ensuring structural and functional 
stability of the systems forming any organism (Liu, et al., 2001; Rue & Martinez Arias, 2015). 
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Deregulation of the normal tissue homeostasis can lead to various consequences, including 
tumorigenesis. Organ or tissue enlargement, as a result of uncontrolled cell proliferation, can 
turn, initially, in primary tumour development, and then, might contribute to secondary tumour 
formation (metastasis) (Basanta & Anderson, 2017). 
Broadly, oncogenesis is a multistep process starting with a mutational event in a single cell and 
then progressing through acquisition of further genetic and/or epigenetic alterations, that are 
transmitted to the progeny of that cell when it divides (Barrett, 1993; Karakosta, 2005). These 
aberrations, typically, involve three types of genes (Pelengaris & Khan, 2013): 
- Proto-oncogenes – are the genes, which encode proteins participating in promotion of 
cell survival, growth and proliferation and thus have a potential to become oncogenic; 
- Tumour suppressor genes – are the genes responsible for inhibition of cell proliferation 
and/or activation of programmed cell death; 
- Caretaker genes – include genes implicated in detection and reparation of DNA 
damage. 
For instance, aberrations of the oncogene c-MYC, “master regulator” of cell growth, 
proliferation and dedifferentiation of pre-malignant cells during tumorigenesis, have been 
found in many human cancers, which prognosis is frequently conditioned by the rate of c-MYC 
oncoprotein expression (Chen, et al., 2018; Grotzer et al., 2001; Miller, et al., 2012; Schlotter, 
et al., 2003). Similarly, deregulations of the onco-suppressor p53, also called “the guardian of 
the genome”, have been observed in a number of malignancies and are recognised to be 
essential for cancer progression (Efeyan & Serrano, 2007). The fact that p53 possesses both, 
caretaker and tumour suppressor gene capabilities, renders it particularly important for the 
prevention of genome mutations required for malignant transformations (Ozaki & 
Nakagawara, 2011).  
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However, alterations of a single gene are, usually, insufficient for the transformation of a 
healthy cell into a malignant one. A cell needs to overcome numerous “obstacles” in order to 
be able (1) to avoid programmed death caused by various factors, (2) to proliferate and (3) to 
adapt to putative new microenvironments. Therefore, numerous mutations involving a variety 
of genes are required for tumorigenesis and cancer progression.  
In fact, natural selection theory has been widely accepted for cancer development. It assumes 
that cancer origin and advancement are evolutionary processes driven by acquisition of 
progressively more advantageous alterations, responsible for selective growth of the cells with 
better survival characteristics (Arneth, 2018). 
Initial genetic or epigenetic alterations are, frequently, phenotypically “silent” implying that 
the cell remains perfectly differentiated and completely functional within the tissue [Figure 2 
b)]. Further mutations affecting key regulatory genes might trigger oncogenic pathways and 
inhibit tumour suppressor ones [Figure 2 c)]. This results in clonal expansion of the 
premalignant cells consequentially followed by primary tumour formation (benign tumour) 
[Figure 2 d)]. An important feature of benign tumours consists in their inability to invade 
surrounding tissues. Indeed, the mass of cells composing benign tumour is well circumscribed 
and, usually, grows slowly. Although this type of tumour is generally not life-threatening, it 
provides a fertile ground for malignant transformation. Indeed, downregulation of DNA repair 
and tumour suppressive mechanisms, occurring during the early stages of benign tumour 
development, makes pre-malignant cells more susceptible to acquire new mutations compared 
to normal cells. Faster and easier accumulation of further alterations results, then, in the 
creation of various pre-malignant sub-clones with different survival characteristics, which are 
proportional to their cell population rates within the benign tumour. In addition, some 
mutations contribute to the acquisition of new properties, which allow those specific subclones 
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to infiltrate in the surrounding tissues [Figure 2 e)]. This results in malignant tumour formation 
(cancer) (Pelengaris & Khan, 2013).  
 
Figure 2: Schematic model of cancer initiation and progression – from a healthy tissue (a), to the first 
mutations of a single somatic cell (b and c), able to promote clonal expansion causing benign tumour 




Malignant transformation is usually accompanied by cell de-differentiation, which increases 
progressively during neighbouring tissue invasion. Importantly, malignancies with lower cell 
differentiation are more aggressive and are associated with poorer cancer survival rates (D. 
Yang et al., 2011; Yoshida, et al., 2011). Indeed, greater de-differentiation is also correlated 
with higher proliferation speed, which leads to faster cancer development (Jilkine & 
Gutenkunst, 2014).   
Abnormal proliferation occurring during both, pre-malignant and malignant stages, requires 
constant provision of oxygen and nutrients from blood vessels. However, energy requirements 
for effective cell growth and proliferation become insufficient over time, due to inadequate 
number of capillaries for the increased dimensions of the tumour. Therefore, blood vessels 
development (angiogenesis) plays a crucial role from the early stages of oncogenesis [Figure 
2d2) and 2f)]. Taken together, number of the tumour cells rapidly increases, while the number 
of blood vessels supplying oxygen/nutrients remains unchanged in the first instance. Thus the 
amount of oxygen delivered to each cell goes down and the way to overcome this issue is to: 
1) implement stress signalling relying mainly on glycolysis (oxygen-free glucose degradation 
resulting in ATP production; 2) build up new blood vessels (induce angiogenesis) in order to 
meet requirements of each cell in oxygen/nutrients.  
Indeed, reduced oxygen availability leads to activation of hypoxic signalling pathways 
requiring activation of hypoxia-inducible factor 1 (HIF-1). HIF-1 is a heterodimeric protein 
(transcription complex), composed of two subunits: HIF-1β, which is constitutively expressed, 
and HIF-1α, which is up-regulated in response to low oxygen concentrations. In normoxia 
conditions, HIF-1α is continuously hydroxylated by prolyl hydroxylases (PHDs), which 
employ cellular O2 as a co-substrate. Hydroxylated HIF-1α is, then, recognised and 
polyubiquitinated by specific complexes and, subsequently, degraded by proteasomes. This 
prevents HIF-1 dimerization, requirement necessary for its activation [Figure 3a)]. Hypoxic 
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environment, instead, leads to down-regulation of oxygen-dependent HIF-1α degradation due 
to restricted availability of O2. Activated HIF-1 complex, resulting from of HIF-1α and HIF-
1β dimerization, is, then, able to promote transcription of numerous genes, including vascular 
endothelial growth factor (VEGF). Finally, triggering of VEGF receptors expressed by vascular 
endothelial cells activates signalling pathways responsible for new blood vessel formation 
[Figure 3b)] (Krock, Skuli, & Simon, 2011). 
 
Figure 3: Processes underwent by HIF-1α protein under normal oxygen availability (a) and hypoxic 
conditions (b) 
In addition to the mechanism associated with decreased oxygen levels, neovascularization can 
be induced, directly, by mutations regarding key regulatory genes of angiogenesis and, 
indirectly, by oncogenes, such as RAS and Myc, able to upregulate expression of angiogenic 
factors (Hanahan & Weinberg, 2011; Uthoff et al., 2002). 
Formation of new blood vessels contributes as well to further steps of cancer progression: 
malignant cell dissemination from the original site of tumour formation to distant organs 
(metastasis) [Figure 2g)] (Bielenberg & Zetter, 2015).  
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However, before metastasis occur, malignant cells need to acquire a number of mutations 
allowing them (1) to win cell-cell and cell-extracellular matrix (ECM) interactions, (2) to 
survive in blood or lymphatic vessels and, finally, (3) to be able to invade (and to proliferate 
in) distant organs. Deregulation of metastases suppressor genes plays also a crucial role in 
cancer spread in different organs (Seyfried & Huysentruyt, 2013).  
Indeed, it is hypothesised that a number of various malignant subclones extravasate in 
lymphatic or blood vessels during cancer progression. Nonetheless, most of them don’t survive 
in the new environments for different reasons (Luzzi et al., 1998).  For example, wide 
population of cytotoxic CD8 T cells affects considerably survival and proliferation of 
malignant cells entering the lymph nodes (Pelengaris & Khan, 2013). Another factor 
responsible for the death of migrating cancer cells is represented by their biochemical 
incompatibility with a potential site of colonization, such as lack of specific adhesive 
interactions with the new microenvironment (Q. Liu et al., 2017; Pelengaris & Khan, 2013). 
Thus, only “the fittest” and most aggressive cancer cells are able to metastasise successfully. 
Indeed, the ability to adapt in the new “habitat” is correlated with improved avoidance of 
suicide pathways and evasion of host immune attack, rendering malignant cells stronger and 
capable to proliferate faster (Arneth, 2018). For this reason, metastatic cancers are associated 
with poorer prognosis and higher mortality rates. Approximately 90% of cancer deaths are due 
to secondary (metastases) rather than the primary tumours (Seyfried & Huysentruyt, 2013). 
Therefore, early detection of cancer, before it has spread, is critical for patient life expectancy 
(Coumans, Siesling, & Terstappen, 2013; Hiom, 2015). In addition, an accurate identification 
of malignancy type ensures the undertaking of correct therapeutic measurements, and 
consequently, increases the chances for successful outcome. 
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1.1.1 Types of cancer – “solid” and “liquid” tumours 
Cancers are classified by the type of tissue in which the initial malignant transformation occurs. 
Indeed, although the epigenetic plasticity and genetic diversity observed for a specific type of 
cancer in different patients, malignant cells almost always retain some of the peculiar features 
of the normal cell types from which they have originated. These specific features can be 
identified by histological and/or cytological examinations, allowing, in this way, to characterise 
the type of malignant neoplasm (Arneth, 2018; Ramsay, 1990; Weinberg, 2007). 
The commonest cancer types and corresponding healthy tissues from which they evolve are 
outlined in Table 1 (Ramsay, 1990). 
Table 1 Cancer classification (Ramsay, 1990)  
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Germ cells Teratoma  
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Most of human tumours originate in epithelial tissues and are called carcinomas. These 
malignancies can be further sub-classified according to biological functions associated with 
epithelia. For instance, malignant transformations of glandular cells, sub-type of epithelial cells 
responsible for both exocrine and endocrine secretions, generate adenocarcinomas. On the 
other hand, tumorigenesis of epithelial cells with protective functions of the underlying tissues 
usually induces squamous cell carcinoma (Weinberg, 2007).   
Generally, organ main functions reflect the type of carcinoma that may develop with higher 
probability. Indeed, most cancers occurring in the organs, such as stomach or pancreas, which 
predominant role consists in the release of gastric or pancreatic juices by epithelial cells, are  
adenocarcinomas (Dicken et al., 2005; Smith, et al., 2015). Conversely, tumorigenesis of 
oropharyngeal epithelia, which provide mechanical barriers protecting from pathogens 
deriving from air or food, usually lead to squamous cell carcinoma (Panarese et al., 2019). 
However, mixed carcinomas, malignancies characterized by coexistence of both, 
adenocarcinoma and squamous carcinoma cells, have been also reported to develop in some 
organs, such as lung and cervix (Bastide, et al., 2010; Choo & Naylor, 1984).  
Another class of cancers arises from mesenchymal cells (MSCs). These malignancies, called 
sarcomas, constitute approximately 21% of all paediatric solid malignant cancers and around 
1% of all adult solid malignant cancers (Burningham, et al., 2012; Weinberg, 2007). Sarcomas 
can be also sub-classified into two groups: soft tissue sarcomas (STS) and sarcomas of the bone 
(Hui, 2016).  
The commonest soft tissue sarcomas include liposarcoma, tumour involving adipocyte 
oncogenesis, leiomyosarcoma and rhabdomyosarcoma, which arise from malignant 
transformations of striated and smooth muscle tissues, respectively (Hoang, et al., 2018). 
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Most frequent sarcomas of the bone are, instead, osteosarcoma and chondrosarcoma (Hui, 
2016). The former is thought to derive from osteoblastic lineages of cells or undifferentiated 
MSCs, while the latter develops from cartilage tumorigenesis. Osteosarcoma affects 
predominantly adolescents and children, while chondrosarcoma is more frequent in elderly 
population (Abarrategi et al., 2016; Hui, 2016).  
Third class of cancers regards oncogenesis of diverse elements composing nervous system 
(Weinberg, 2007). Glioblastoma, astrocytoma and oligodendroglioma, malignancies 
originating from various types of glial cells, are among the most frequent cancer types of this 
class (Patel et al., 2019).  
Another group of cancers is represented by haematopoietic malignancies. There are two main 
blood-forming lineages deriving from the differentiation of hematopoietic stem cells:  
lymphoid and myeloid lineages. Oncogenesis of these two categories of blood cells can induce 
four main types of haematopoietic tumours: acute lymphoblastic, acute myelogenous, chronic 
lymphocytic, and chronic myelogenous leukaemia. Acute lymphoblastic leukaemia is the 
commonest blood cancer in childhood, while acute myeloid leukaemia occurs more frequently 
in the adults (Davis, et al., 2014). 
This classification, based on the type of tissue/cell in which tumorigenesis initiates, reflects 
also some specific tissue-dependent gene mutations (Schaefer & Serrano, 2016). For example, 
aberrations of BRCA1 gene, which product is involved in DNA repair and apoptosis regulation, 
occur mostly in breast and ovarian cancers (E. Y.-H. P. Lee & Abbondante, 2014). Similarly, 
aberrations of ABL1, a gene encoding a tyrosine kinase implicated in a variety of cellular 
process, such as genome reparation and apoptosis regulation,  are predominantly associated 
with leukaemia (Dasgupta et al., 2016; Shaul & Ben-Yehoyada, 2005). 
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However, despite diverse cell origin, different cancer types can also share some common 
tissue-independent mutations (Schaefer & Serrano, 2016). Consequently, different categories 
of malignant neoplasms, might be unified under the same roof based on their mutations. For 
example, alterations of the genes coding for the tumour suppressor p53 were reported to occur 
quite in all the cancer types (Rivlin, et al., 2011). Similarly, aberrations of the oncogene c-Myc 
were found in more than 50% of human tumours (Chen et al., 2018).  
High conservation of some gene alterations in different cancer types is a consequence of their 
involvement in key pathways of cell cycle. Indeed, most oncogenic mutations regard genes 
implicated in crucial mechanisms enabling the cell to prevent abnormal cell growth and 
proliferation (Pelengaris & Khan, 2013). 
1.2 Normal physiological barriers preventing cancer development 
The human body is continuously exposed to a multitude of carcinogens able to promote genetic 
and/or epigenetic alterations (Pelengaris & Khan, 2013). Moreover, DNA replication is error 
prone (Tippin, et al., 2004). Nonetheless tumorigenesis is a relatively rare event considering 
the number of cells undergoing mitosis in the human body every day. Indeed, cells possess 
multiple quality-control mechanisms allowing them to prevent alterations during cell 
replication and abnormal cell proliferation. Moreover, an additional “extracellular” quality-
control system is available in case previous checkpoints result to be ineffective. This 
supplementary biological barrier is represented by immune system cells, which are able to 
eliminate promptly any anomalous cell appearing in the body (Pelengaris & Khan, 2013). 
Thus, it is possible to divide cancer biological barriers in two categories: 
- Cell-cycle checkpoints; 
- Immune system “quality control” or cancer immunosurveillance. 
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1.2.1 Cell-cycle checkpoints 
Each cell receives continuously various intra- and extra-cellular stimuli, which are then 
integrated to produce an adequate response. One part of the inputs intercepted by the cell is 
responsible for cell cycle regulation and progression. This part of signals can be broadly 
divided in inhibitory and stimulatory factors of cell proliferation. Indeed, the commitment of 
the cell to divide is meticulously regulated by the balance of negative and positive growth 
factors in the tissue microenvironment (Duronio & Xiong, 2013). 
When the proliferative inputs prevail on the inhibitory growth signals, the cell activates 
pathways which lead to DNA replication and cell division. These processes are part of cell 
cycle, which progresses through consecutive phases:  
1. G1 – “gap 1” period in which the cell synthetases mRNA and proteins necessary for 
genome replication; 
2. S – stage in which DNA synthesis occurs; 
3. G2 – “gap 2” phase in which the cell grows and prepares for mitosis; 
4. M – mitosis.  
The cell can stay in a quiescent state (phase G0) for a relatively indefinite interval of time, until 
the mixture of inputs favours proliferative signals, forcing such cell to re-enter in G1 phase, 
proceed through S and G2 stages, and, finally, to undergo mitosis  (Pelengaris & Khan, 2013). 
Intracellularly, this progression is associated with different levels of specific cyclins, proteins 
termed in this way because of their periodical synthesis and degradation related to the cell 
cycle. Indeed, the concentrations of three major types of cyclins (G1/S, S and M cyclins) 
oscillate during the cell cycle progression. 
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Growth factors can stimulate the synthesis of G1 cyclins, which are then able to bind specific 
cyclin-dependent kinases (CDK). These enzymes are usually inactive in resting cells and their 
levels are stable throughout the cell cycle. The interaction of specific cyclin with its respective 
CDK leads to the formation of an active complex able to phosphorylate a variety of proteins, 
essential for each stage of cell cycle [Figure 4] (Boyle, 2008). 
 
                                       Figure 4: Cell cycle progression (Boyle, 2008) 
Upon mitogenic stimulation, one of the first targets of G1 cyclin/CDK phosphorylation is 
retinoblastoma (RB) protein, tumour suppressor ubiquitously expressed in human body 
(Cordon-Cardo & Richont, 1994; Giacinti & Giordano, 2006).  
Prior to proliferative signals, unphosphorylated RB proteins are constitutively bound to E2 
transcription factors (E2Fs) that are required for expression of S-phase genes [Figure 5a)]. This 
interaction precludes E2F binding to DNA and, thus, prevents gene transcription. 
Phosphorylation of RB protein, upon growth factor downstream signalling, provokes 
conformational changes that decrease RB affinity to its natural E2F, and thus, cause RB-E2F 
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dissociation. In this way, E2F transcription factors, released from phosphorylated RB proteins, 
are able to interact with DNA and initiate specific gene transcription [Figure 5b)]. 
 
Figure 5: Restriction point – RB phosphorylation, conditioned by the levels of growth-regulating 
signals, represents the point in which the cell commits to cell-cycle division in extracellular-
independent manner. 
Therefore, the phosphorylation state of RB proteins, tumour suppressors responsive to the 
balance of growth-stimulatory and inhibitory factors, represents the first restriction point of 
cell division. After RB phosphorylation, followed by initiation of E2F-mediated transcription, 
the cell becomes irreversibly committed to enter S phase and to complete cell division without 
being any longer dependent on stimulation of external growth factors (Lara-Gonzalez, et al., 
2012).  
However, before genome replication initiates, some intracellular signals, such as “genotoxic 
stress” (DNA damage), can promote cell cycle arrest in G1 phase. This occurs generally through 
inhibition of cyclin/CDK complexes by cyclin-dependent kinase inhibitors (CKI). Indeed, 
accumulation of specific CKIs, consequent to detection of genome damage, leads to cell cycle 
arrest providing time “to fix” DNA before its replication. If DNA reparation is successful, the 
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cell recovers and proceeds in S phase, while if it fails, the cell usually undergoes apoptosis. 
These regulatory systems, responsible for control of DNA integrity before replication, belong 
to G1/S checkpoints. 
Importantly, DNA stability is verified during the whole progression of cell cycle through 
multiple control quality systems, which can be further grouped in intra-S and G2/M 
checkpoints. These regulatory mechanisms operate in analogous way to G1/S checkpoint, 
upregulating various types of CKI able to inhibit cell cycle-specific effectors necessary for cell 
cycle arrest and DNA reparation. General scheme of the mechanism through which all these 
control-quality systems operate is represented in Figure 6 (Pelengaris & Khan, 2013).  
 
Figure 6: General scheme of the mechanism through which cell cycle checkpoints operate. 
Finally, after genome replication, during M phase, chromosome partition between two daughter 
cells is controlled by so called “spindle” checkpoints. This group of control-quality systems 
assesses that mitotic spindle, necessary for chromosome partition, is assembled correctly 
ensuring that each daughter cell gets the right number and configuration of chromosomes 
(Lara-Gonzalez, et al., 2012). 
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Despite multiple checkpoints present during all the steps of cell cycle, some genome 
aberrations can be “missed” by these control-quality systems leading to survival of cells with 
acquired mutations. In this case host immune system plays a crucial role in detection and 
elimination of these aberrant cells. 
1.2.2 Immune system “quality” control 
Although tumours develop from healthy tissues recognised as self by the host immune system, 
cancer cells can still elicit an immune response through expression of anomalous products and 
through creation of an inflammatory environment, as a result of tissue disruption consequent 
to the invasion by malignant cells (Pelengaris & Khan, 2013). 
Tumours are complex microenvironments characterised by hypoxia and nutrition deprivation, 
which cause constant cellular stress. Consequently, despite the high proliferation rate, one part 
of malignant cells dies continuously because of metabolic adversities encountered during 
cancer development and progression. In addition, genomic instability, typical of oncogenic 
cells, may also contribute to the death of cancer clones which acquired disadvantageous 
mutations. Moreover, malignant cells, not only compete for nutrients with normal cells, but 
also damage them, when invading healthy tissues. Therefore, opposite processes, such as 
abnormal growth/proliferation, and apoptosis/necrosis, can be identified in tumorigenic tissues 
(Coussens & Werb, 2002; Fonseca & Dranoff, 2008; Reuter, et al., 2010). 
These events contribute to the generation of damage-associated molecular patterns (DAMPs), 
molecules released by stressed, dying or injured cells. These chemically unrelated mediators 
are usually retained intracellularly in healthy cells and released in the extracellular space only 
in specific circumstances, such as tissue damage and metabolic stress. Their main function, 
once liberated from the cells, consists in recruitment and activation of innate immune defences 
in tumorigenesis sites. Indeed, DAMPs elicit host immune response by binding specific pattern 
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recognition receptors (PRRs), expressed by Natural Killer (NK) cells, macrophages and 
dendritic cells (He et al., 2017; Roh & Sohn, 2018; Sato, et al., 2009). 
Major DAMPs and their respective receptors are reported in Table 2 (He et al., 2017; Roh & 
Sohn, 2018). 
Table 2: List of major DAMPs and their respective PRRs (Roh & Sohn, 2018). 
Intracellular location DAMP PPR 
cytosol S100 proteins TLR2, TLR4, RAGE 
HSP TLR2, TLR4, RAGE 
ATP P2X7, P2Y2 
Nucleus Histones  TLR2, TLR4 
HMGB1 TLR2, TLR4, RAGE, TIM-3 
HMGN1 TLR4 
DNA TLR9, AIM2 
RNA TLR3, TLR7, TLR8, RIG-I, MDA5 
Mitochondria ER mtDNA TLR9 
TFAM RAGE 
Importantly, all these molecules binding PRRs have different physiological intracellular roles 
and act as DAMPs only when released in extracellular space.  For example, high-mobility 
group box 1 (HMGB1), ubiquitously expressed non-histone DNA-binding protein, is normally 
located in the cell nucleus. HMGB1 is involved in many DNA activities, such as DNA repair 
and genome stability maintenance, when localised inside the nucleus (He et al., 2017).  
The human HMGB1 is a small protein of 245 aa, composed of three distinct domains: A box, 
B box and acidic C-terminal tail (containing numerous glutamic and aspartic acid residues) 
[Figure 7]. Nuclearly, HMGB1 binds directly to DNA employing its positively charged A and 
B boxes, while acidic C-terminal tail enhances the specificity of this interaction (He et al., 
2017; Wang, et al., 2007). 
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In addition to nuclear functions, HMGB1 is involved in the promotion of autophagy in response 
to oxidative stress, when translocated in cytosol. Increased ROS levels, consequent to hypoxia 
and cell starvation, cause oxidation of two highly conserved aminoacidic residues, cysteine 23 
(C23) and cysteine 45 (C45), leading to formation of disulphide bond in A box of HMGB1. 
Subsequently, ROS promote also its translocation from nucleus to cytosol, where disulphide 
bridge (C23/C45) is able to interact with Beclin-1, disrupting its interaction with Bcl-2 and, 
thus, promoting autophagy (D. Tang et al., 2010). 
Finally, in extracellular space, HMGB1 acts as an alarmin, able to recruit and activate the innate 
immune response. Once released, from dying or injured cell, HMGB1 interacts with following 
receptors (He et al., 2017):   
- the receptor for advanced glycation end products (RAGE), which binds residues 150-
183 of HMGB1; 
- Toll-like receptors (TLRs), TLR2 and TLR4, which bind residues 89-108 of HMGB1. 
 
Figure 7: HMGB1 structure 
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TLRs are transmembrane glycoproteins constituted of three main domains: extracellular 
domain containing leucine rich repeats (LRR), transmembrane domain and intracellular Toll-
interleukin 1 (IL-1) receptor domain (TIR). The interaction of LRR with the ligand induces 
conformational changes leading to dimerization of two receptors of TLR. This results in the 
association of two TIR domains, which together form a platform able to interact with specific 
intracellular adaptor proteins. Downstream signalling following TIR/adaptor protein complex 
formation leads to gene transcription and translation of different cytokines necessary at various 
stages of inflammation process (Dajon, et al., 2017).  
The TLR family comprises ten members (TLR1-TLR10), two of which, TLR2 and TLR4, have 
been reported to interact with HMGB1 (He et al., 2017; Moresco, et al., 2017). Main effects of 
TLR2/TLR4 triggering by this alarmin during the early stages of inflammation is reported in 
Figure 8 and Table 3 (Dumitriu, et al., 2006; He et al., 2017; G. Li, et al., 2013; J. Li et al., 
2003; S. Yang, et al., 2014).  
RAGE is a transmembrane protein able to bind a variety of ligands. The first ones to be 
identified were advanced glycation end products (AGEs), macromolecules obtained through 
non enzymatic reaction between reducing sugars and proteins, lipids or nucleic acids. 
Subsequently, RAGE has been reported to bind other ligands, such as HMGB1 and other 
DAMPs (Gkogkolou & Böhm, 2012; E. J. Lee & Park, 2013; Xie et al., 2008). 
RAGE is a member of the immunoglobulin superfamily and is ubiquitously expressed at low 
levels in adults but is upregulated following cellular stress. Triggering of RAGE stimulates the 
propagation of various intracellular signalling pathways leading to the activation of the 
transcription factor nuclear factor kappa-B (NFκB), which promotes expression of numerous 
genes during the inflammation process [Figure 8 and Table 3] (Kierdorf & Fritz, 2013; Narumi 




Figure 8: HMGB1 effects in early stages of inflammation 
Table 3: Main functions of HMGB1-induced cytokines in early stages of inflammation 
(Dinarello, 2009; Ding et al., 2011; Kursunel & Esendagli, 2016; Janeway, 2012; Tanaka, et 
al., 2014; van Horssen, et al., 2006) 
 IL-6 (interleukin 6) • promotes differentiation of naïve CD4 T cells into effector cells, 
of CD8 T cells into cytotoxic T cells and of activated B cells into 
antibody-producing plasma cells; 
• inhibits TGF-β-induced T regulatory differentiation; 
• promotes megakaryocyte maturation required for the platelets 
production. 
 TNF-α (tumour 
necrosis factor α) 
• induces programmed cell death of aberrant cells through direct 
interaction with TNF receptors (TNFR) ubiquitously expressed in 
different tissues of human body; 
• promotes dendritic cell maturation (CD80↑, CD83↑, MHC↑, 
CD40↑); 
• activates vascular endothelium and increases vascular 
permeability facilitating accumulation of immune system 
components in the site of tumorigenesis;  
• promotes synthesis of numerous pro-inflammatory cytokines. 
 IL-1β (interleukin 
1β) 
• activates vascular endothelium and increases vascular 
permeability 
• activates immune cells 
 IFN-γ (interferon γ) • promotes differentiation of T cells into effector cells; 
• upregulates MHC expression of antigen presenting cells (APCs); 
• stimulates further chemotactic factors production and promotes 
immune cells recruitment. 
 IL-8 (interleukin 8) • chemotactic factor  
 VEGF (vascular 
endothelial growth 
factor) 
• growth factor inducing new blood vessels formation 
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Activation and recruitment of NK cells, macrophages and dendritic cells leads usually to a 
rapid elimination of anomalous cells (H. Yang & Tracey, 2010). Indeed, stressed cells typically 
express danger-activated signals (DASs) on their surfaces, which can be recognised by innate 
immune system cells. DASs are self-proteins that are poorly expressed by healthy cells but are 
upregulated on the surface of stressed and transformed cells. Major histocompatibility complex 
(MHC) class I chain-related protein A and B (MICA and MICB) are among the commonest 
DASs, that can bind (Natural Killer Group 2D) NKG2D receptor present on NK cells. This 
interaction activates NK cells leading to instant death of carcinogenic cells (Corthay, 2014). 
MICA and MICB are considered non-classical MHC class I molecules, which are structurally 
similar to self-MHC-I expressed by almost all the cell types of the human body. Both, MICA/B 
and self-MHC-I contain one membrane-spanning α chain (heavy chain) consisting of three 
extracellular immunoglobulin-like domains, a transmembrane domain and intracellular 
cytoplasmatic tail. Differently from MICA/B, self-MHC-I is also bound to β2 micro-globulin 
(extracellular light chain) and exhibits a small oligopeptide (8-11 aa) obtained from self-protein 
proteasomal degradation occurring routinely in healthy cells [Figure 9] (Ghadially et al., 2017; 
Weinberg, 2007). 
 
Figure 9: Structure of MCH class I and MICA/B 
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Healthy cells display relatively high concentration of self-MHC class I molecules able to bind 
different types of NK inhibitory receptors, such as a subgroup of killer-cell immunoglobulin-
like receptors (KIRs). This inhibitory interaction prevents NK cells in destroying normal 
tissues. Contrarily, transformed cells frequently express significantly lower levels of self-MHC 
class I molecules or present aberrant oligopeptides, which aren’t recognised as self by immune 
system cells. Downregulation of inhibitory signals in addition to upregulation of activating 
ligands, such as MICA/B, on aberrant cells shifts the balance toward NK cell activation and 
consequent elimination of these anomalous cells [Figure 10] (Long, 2002; Pegram, Andrews, 
Smyth, Darcy, & Kershaw, 2011; Pelengaris & Khan, 2013).  
 
Figure 10: Discrimination between healthy and transformed cells by NK cells 
Upon recognition and activation, NK cells can induce apoptosis in transformed cells through 
(1) degranulation, process inducing release of cytotoxic molecules such as perforin and 
granzyme, or (2) through interaction of death receptors expressed by aberrant cells and their 
ligands upregulated in activated immune cells (Paul & Lal, 2017). 
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Perforin is 60-70-kDa glycoprotein, able to polymerise and form pores in target cells. Resulting 
disruption of the membrane, consequent to perforin congregation, leads to passive 
transportation of ions, water, enzymes and other molecules through the pores. Granzymes 
represent the most important components delivered by NK cells into transformed cells 
employing these non-selective passages (Osińska, et al., 2014; Paul & Lal, 2017). Granzymes 
belong to serine-protease family able to cleave specific peptide bonds dependent on the type of 
granzyme. For instance, granzyme B, the commonest enzyme of cytolytic granules, specifically 
cleaves peptide bonds after aspartic acid residues of their substrates. Indeed, once delivered 
into a target cell, granzyme B recognises and cleaves these peptide bonds in several substrates, 
such as the pro-apoptotic protein Bid and pro-caspase 3. Truncated Bid (tBid) proteins bind 
then their mitochondrial partners, such as B-cell lymphoma-extra-large (Bcl-xL) proteins, 
promoting oligomerization of no longer constrained mitochondrial transmembrane 
macromolecules, such as BAK proteins. Association of BAK proteins results in formation of 
channels, which allow cytochrome c release from mitochondria. Once liberated in the cytosol, 
cytochrome c binds apoptotic protease activating factor-1 (Apaf-1). Conformational changes 
resulting from this interaction uncover specific domains necessary for oligomerization of Apaf-
1/cytochrome c complex with consequent formation of apoptosome. This heterogeneous 
complex binds procaspase-9 molecules and converts them into active caspase 9 enzymes 
leading to construction of proteolytic platform (active apoptosome) able to catalyse procaspase 
3 cleavage. Active caspase 3 triggers proteolytic cascade which finally leads to cell death. In 
addition, as mentioned above, intrinsic pathway of NK cell-mediated apoptosis can occur 
through direct cleavage of procaspase 3 by granzyme B (Boyle, 2008; Krzewski & Coligan, 
2012; Wei et al., 2000).  
Moreover, upregulation of death receptor ligands on NK cells consequent to their activation 
during inflammation can promote extrinsic pathways of apoptosis in transformed cells. 
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One of the most studied death receptors expressed by human cells is apoptosis antigen 1 (Apo-
1), also called CD95 or Fas. This transmembrane receptor belongs to TNF receptor (TNFR) 
superfamily and is expressed by majority of human cells in inactive state (as monomer). Its 
interaction with trimeric Fas ligand (FasL) expressed by activated NK cells induces Fas 
trimerization in target cells. This provokes clustering of Fas cytoplasmatic death domains (DD) 
allowing to recruit intracellular adaptor proteins (FADD). Conformational changes resulting 
from the latter interaction leads to exposure of FADD death effector domains (DED) able to 
recruit the initiator caspases, such as pro-caspase 8. Following Fas–FADD–caspase 8 complex, 
called the death-inducing signalling complex (DISC), caspase 8 undergoes self-cleavage with 
consequent formation of active proteolytic enzyme. Activated caspase 8 is able then to catalyse 
cleavage of effector pro-apoptotic enzymes, such as caspase 3, leading to initiation of 
proteolytic cascade, which culminates with death of the transformed cell (Boyle, 2008; 
Kominami et al., 2012; Krzewski & Coligan, 2012; Susan, 2007).  
Schematic representation of NK-cell mediated extrinsic and intrinsic apoptosis pathways is 









In addition to previously described recognition mechanisms typical during the early stages of 
inflammation (MHC I downregulation and DASs upregulation), NK cells can identify and kill 
anomalous cells through antibody-dependent cellular cytotoxicity (ADCC) in following stages 
of inflammation characterised by adaptive immune responses. In this case, NK cell surface 
receptor CD16 (FcγRIII) interacts with Fc region of the antibody (ab) bound to target antigens 
expressed by transformed cells. Triggering of CD16 induces the release of cytotoxic granules 
by NK cells leading to rapid elimination of abnormal cells (W. Wang, et al., 2015). 
Adaptive immune responses are initiated after antigen presenting cells (APCs), such as 
dendritic cells (DCs), migrate to the lymph nodes and interact with specific T and B cell 
subpopulation contributing to their activation and proliferation(Weinberg, 2007).  
APCs recognise transformed cells in similar way to NK cells. Triggering of their PRRs and 
stimulation by inflammatory cytokines induces DC maturation. This process involves 
(Pelengaris & Khan, 2013; ten Broeke, et al., 2013):   
- upregulation of MHC II molecules, bearing antigens derived from engulfed and 
phagocytosed anomalous cells; 
- upregulation of co-stimulatory T cell molecules, such as CD80, CD83, CD86 and 
CD40; 
- synthesis and release of cytokines facilitating T cell activation, such as IL-7 and IL-12; 
- increased potential to migrate from tumorigenic tissues to the neighbouring lymph 
nodes for the interaction with B and T cells. 
Indeed, DCs are amongst the few cell types able to express both MHC I and II class molecules. 
Once endocytosed soluble and particulate matter of tumorigenic environment or internalised 
aberrant cells, APCs fragment ingested proteins into small peptides of 18-22 aa, which are 
assembled intracellularly with MHC II molecules. The complex MHC II/antigen is then 
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expressed on APCs cell surface. Moreover, DCs possess a unique capacity to display antigens 
derived from endocytosed material also on MHC I molecules.  
Considering that malignant cells arise from healthy tissues, most of these oligopeptides carried 
on MHC I and MCH II molecules are self-protein and don’t evoke immune response. However, 
some of tumour-derived antigens are recognised as non-self upon interaction with specific B 
cell receptors (BCR) and T cell receptors (TCR) contributing to the activation and proliferation 
of featured lymphocytes.  
Broadly, cancer-related immunogenic oligopeptides derive from proteins that can be grouped 
in several classes (Blankenstein, Gilboa, & Jaffee, 2012; Vigneron, 2015): 
- phenotypically altered normal proteins; 
- virus oncoproteins; 
- macromolecules expressed exclusively during embryonic development; 
- proteins that are usually expressed at low concentrations but are upregulated during 
tumorigenesis. 
Genetic mutations can lead to altered amino acid sequences in tumour-expressed proteins, that 
have the potential to be identified as foreign and therefore induce adaptive immune responses. 
Indeed, numerous cytotoxic T cells (CTLs) and peculiar antibodies for tumour-specific 
antigens can be identified in the blood of cancer patients. Phenotypically altered protein can 
arise from modifications of nucleic sequence within one specific gene. For example, DNA 
alterations of the gene codifying for glycolytic enzyme triosephosphate isomerase (TPI) leads 
to chemically changed TPI mutant. Oligopeptides obtained from TPI processing by APCs has 
been reported to be highly immunogenic and represent tumour-specific melanoma antigens 
(Pieper et al., 1999). Moreover, structurally altered proteins can result also from chromosomal 
translocations occurring, for example, in chronic myelogenous leukaemia (CML). In the latter 
case, amino acid sequence of proteins codified by gene Abelson (Abl) normally present on 
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chromosome 9 and breakpoint cluster region (BCR) located on chromosome 22, are identical 
to those found in BCR-Abl fusion protein resulting from chromosomal translocation. 
Nevertheless, the small region where BCR and Abl are fused constitutes novel amino acid 
sequence that can be possibly recognised as non-self by immune system cells (Salesse & 
Verfaillie, 2002; Weinberg, 2007). 
Tumour-specific antigens can also arise from oncovirus-infected cells. Seven types of viruses 
have been found to be tumorigenic [Table 4]. Once internalised inside the cell, oncoviruses can 
stimulate oncogenic pathways inducing overexpression of already existing host proto-
oncogenes and/or producing specific oncoproteins codified by viral genes. Fragmentation of 
viral oncoproteins by APCs can give rise to immunogenic peptides able to stimulate anti-
tumour defences through specific T and B cell activation and proliferation (Chang, et al., 2017; 
Krump & You, 2018).  
Table 4: Virus associated tumours (Chang et al., 2017) 
Virus Main virus-induced malignancies 
Epstein–Barr virus (EBV) Several lymphoma types, nasopharyngeal and gastric cancers 
Hepatitis B virus (HBV) hepatocellular carcinoma 
Human T-lymphotropic 
virus-1 (HTLV-1) 
adult T-cell leukaemia (ATL) 
Human genital 
papillomavirus (HPV) 
cervical carcinoma, squamous cell head and neck cancers, 
squamous cell anal cancer, vulvar cancer 
Hepatitis C virus (HCV) hepatocellular carcinoma 
Carcinogenesis is usually associated with dedifferentiation, that somatic cells undergo 
acquiring proliferative capabilities typical of stem cells. Numerous cancer types have been also 
reported to activate embryonic pathways (Kelleher, et al., 2006). Some embryonic proteins are 
physiologically expressed only during early stages of embryonic progression, before 
immunological tolerance is developed. Therefore, it has been suggested that these proteins 
might be recognised as non-self if expressed in adults. Indeed, early foetal protein-derived 
oligopeptides don’t interact with specific immune cell receptors necessary for elimination of 
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autoreactive lymphocytes and thus can be highly immunogenic. Similarly, this concept has 
been proposed for proteins that are usually expressed at very low concentrations. In this case 
developing lymphocyte populations hardly encounter these proteins leading to survival of B 
and T cells, which are able to bind weakly expressed macromolecules. Upregulated levels of 
proteins, that are silent or expressed at very low levels in healthy tissues, have been found in 
different types of cancers and reported as possibly immunogenic (Aurisicchio et al., 2013; 
Criscitiello, 2012; John et al., 2008; Vigneron, 2015).  
As mentioned above, oligopeptides deriving from these cancer-specific proteins are displayed 
by APCs which present them to peculiar lymphocytes in the lymph nodes. This encounter 
stimulates activation of several types of lymphocytes: 
- CD4 or T helper (Th) cells, which are further classified in (1) Th1 lymphocytes 
responsible for CD8 T cell activation and (2) Th2 lymphocytes that induce B cell 
differentiation in plasma cells releasing cancer antigen-specific antibodies; 
- CD8 T cells, which differentiate in cytotoxic T cells upon their activation. 
T cell activation starts with the engagement of MHC-antigen complexes and specific T cell 
receptor (TCR), which leads to upregulation of CD40 ligand (CD40L) by TH1 cells. This 
interaction leads to increased expression of APCs surface molecules, such B7-1 (CD80) or B7-
2 (CD86), able to bind T cell receptor CD28 and promote further lymphocyte differentiation. 
Moreover, CD80/CD86-CD28 interaction enhances T-cell survival upregulating anti-apoptotic 
proteins, such BcL-xL. In addition, mature DCs release stimulatory cytokines, such as IL-12 
and IL-7, which contribute to T cell activation. However, complete CD8 T cell maturation and 
differentiation in cytotoxic T cells requires a supplementary CD4 T cell “licensing”. Indeed, 
IL-2 and other cytokines expression by activated Th1 cells are required for complete CD8 




Figure 12: T cell activation 
Once activated, cytotoxic T cells (CTCs) migrate in tumorigenic tissues to kill transformed 
cells. Upon antigen-specific recognition, CTCs can induce apoptosis in cancer cells by 
triggering their death receptors or releasing cytotoxic granules, similarly to NK cells. In 
addition to specific recognition of antigens expressed by malignant cells, CTCs can bind also 
DASs through their constitutively expressed receptors, such as NKGD2. 
Once eliminated tumorigenic cells, hyperactivated immune cells have to be “stopped” to 
prevent excessive tissue damage. Therefore, physiological immunosuppressive systems are 
activated in the final stages of the inflammation. In addition, tissue regeneration and reparation 
mechanisms are promoted with the purpose of restoring normal tissue functionality. 
1.3 Physiological immunosuppression and immune evasion of malignant cells 
Since tumorigenesis is usually accompanied by inflammation, malignant cell growth and 
development is continuously threatened by host immune systems. For this reason, only the 
clones that can successfully escape anti-tumour immunity are able to survive and proliferate. 
Indeed, cancer cells acquire mechanisms allowing them to upregulate immunosuppressive 
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systems and to shape inflammatory responses for their own growth advantages (Coussens & 
Werb, 2002). 
1.3.1 PD-1 and CTLA-4 mediated immunosuppression 
One of the mechanisms employed by cancer cells to escape host immune attack consists in 
expressing immunosuppressive proteins on their surfaces. Some of these inhibitory 
macromolecules belong to B7 family ligands and to their partner receptors. 
The members of B7 family are usually upregulated during inflammatory responses and can 
induce both costimulatory and coinhibitory signals in lymphocytes and NK cells. Major B7 
molecules and their binding partners are reported in Table 5 (Seliger, et al., 2008). 
Table 5: Major B7 ligands and their binding partners (Seliger et al., 2008) 
B7 ligand Cells expressing 
B7 ligand 
Binding partner 
of B7 molecule 
Cells expressing B7 
binding partner 
Function 
B7-1 (CD80) Activated APCs CD28 T cells Stimulation 
CTLA4 Activated T cells Inhibition 
B7-2 (CD86) Activated APCs CD28 T cells Stimulation 
  CTLA4 Activated T cells Inhibition 
B7-H1 (PD-L1) APCs, non-
lymphoid tissues 
PD-1 Activated T cells, B 
cells, NK cells 
Inhibition 
B7-DC (PD-L2) APCs PD-1 Activated T cells, B 
cells, NK cells 
Inhibition 
As mentioned above, B7-1 and B7-2, proteins upregulated on APCs surface after the 
stimulation by DAMPs or CD40 triggering, can interact with CD28 expressed on naïve T cells 
contributing to their activation in the initial stages of adaptive immune responses. However, 
this binding (B7-1 or B7-2 with CD28) triggers also transient surface expression of cytotoxic 
T lymphocyte antigen-4 (CTLA-4) on activated lymphocytes in delayed manner. CTLA-4 
(CD152) interacts with B7-1 and B7-2 with significantly higher affinity compared to CD28. 
Therefore, once expressed on the membrane, CTLA-4 replaces CD28 in the interaction with 
B7-1 and B7-2 proteins leading effector T cell inhibition (Chambers, et al., 2001). Indeed, 
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CTLA-4 downstream signalling blocks T cell proliferation by impeding its entry into cell cycle 
and downregulates the production of stimulatory cytokines, such as IL-2 (Sansom, 2000). 
Similarly, protein cell death 1 (PD-1), also called CD279, is upregulated on the surface of T 
cells constantly exposed to the antigen and on the membrane of hyper-stimulated NK cells. 
PD-1 triggering by PD ligands (PD-L1 and PD-L2), small B7 glycoproteins expressed on 
APCs, causes rapid inactivation of immune cells in analogous way to CTLA-4 signalling 
(Salmaninejad et al., 2019; Seliger, et al., 2008) [Figure 13]. 
 
Figure 13: Immune cell physiological inactivation 
Frequently, malignant cells employ these physiological pathways to escape the immune attack. 
Surface expression of PD-1 ligands and CD80/CD86 has been found in various cancer types. 
Therefore, monoclonal antibodies able to prevent inactivation of immune cells have been 
developed for this kind of malignancies and have shown efficacy for several types of cancer 
[Table 6, Figure 14] (Blank & Enk, 2014; Buchbinder & Desai, 2016; European Medicines 
Agency (EMA); Hsu et al., 2018; Seliger et al., 2008; Thomson, Allison, et al., 2006). 
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Table 6: Anti-CTLA-4 and anti-PD-1 monoclonal antibodies approved by European Medicine 
Agency (EMA) for cancer treatment 
Antibody (ab) Ab target Cancer types, for which the ab has been approved (EMA) 
Ipilimumab 
(Yervoy) 
CTLA-4 Melanoma and advanced renal cell carcinoma 
Nivolumab 
(Opdivo) 
PD-1 Melanoma, non-small-cell lung carcinoma (NSCLC), advanced renal 
carcinoma, Hodking lymphoma, squamous cell cancer of the head 
and neck (SCCHN), urothelial cancer 
Atezolizumab 
(Tecentriq) 
PD-1 NSCLC and urothelial cancer 
Pembrolizumab 
(Keytruda) 
PD-1 Melanoma, NSCLC, Hodking lymphoma, SCCHN, urothelial cancer 
Avelumab 
(Bavencio) 
PD-1 Merkel cell carcinoma 
 
Figure 14: Cancer cell evasion through surface expression of immunosuppressive molecules. 
Prolonged stimulation of immune cells by cancer cells can cause upregulated PD-1 and CTLA-4 
expression on the surface of CTCs and NK cells. Transformed cells can be still recognised and killed 
by hyper-activated immune cells, if the latter don’t encounter APCs or T regulatory cells, which are 
able to inhibit over-stimulated lymphocytes or NK cells (a). Cancer cells expressing CD80/CD86 and/or 
PD-L1/PD-L2 inactivate immune system cells and thus escape host anti-tumour immunity (b). Anti-
CTLA-4 and anti-PD-1 antibodies prevent inhibitory interactions of immune cells with cancer cells 
expressing CD80/CD86 and/or PD-L1/PD-L2 and thus facilitate malignant cells elimination by CTCs 
and NK cells (c). 
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1.3.2 Tim-3/galectin-9 mediated immunosuppression 
Another mechanism allowing tumorigenic cells to escape host immune attack consists in their 
increased surface expression of transmembrane protein T cell immunoglobulin and mucin 
domain 3 (Tim-3). Indeed, it has been reported that soluble form of Tim-3 (sTim-3) is able to 
attenuate immune cells proliferation and to reduce the secretion of IL-2, a crucial cytokine 
necessary for the activation of NK cells and effector T cells (Geng et al., 2006). Presumably, 
once shed from the membrane of malignant cells, sTim-3 is able to interact with surface 
receptors expressed by immune system cells and downregulate their anti-tumour responses. 
Indeed, Tim-3 upregulation by malignant cells is also often correlated with poorer patient 
prognosis (Du et al., 2017; Peng, Li, & Sun, 2017; Sumbayev et al., 2016; Zhuang et al., 2012).  
Human Tim-3 is a type 1 cell-surface glycoprotein containing 302 aa, that are structurally 
divided in four domains: extracellular N-terminal immunoglobulin variable (IgV) domain and 
a mucin domain, a transmembrane domain and a cytoplasmic tail containing six tyrosine 
residues and an Src homology 2 (SH2) binding motif (Kikushige & Miyamoto, 2013).  
In absence of Tim-3 binding ligands, the intracellular domain is bound to HLA- B associated 
transcript 3 (Bat3), which precludes the phosphorylation of Tyr256 and Tyr263 present in the 
cytoplasmatic tail preventing Tim-3 downstream signalling. The binding of Tim-3 extracellular 
domain by its endogenous ligands can induce conformational changes that result in the release 
of Bat-3 allowing the phosphorylation of specific tyrosine residues present in the cytoplasmatic 
tail of Tim-3. Phosphorylated intracellular Tim-3 domain is then able to recruit specific SH2 
domain-containing Src kinases which may lead to distinct downstream signalling depending 
on the Tim-3-bound ligand and on cell type expressing this transmembrane receptor (Das, et 
al., 2017; Ocaña-Guzman, et al., 2016) [Figure 15]. Indeed, Tim-3 has been associated with 
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both inhibitory and co-stimulatory function, depending in part on the specific cell type, in 
which this receptor is expressed (Banerjee, et al., 2018). 
In myeloid AML cells, triggering of membrane-associated Tim-3 by its endogenous ligand, 
galectin-9, a β-galactoside-binding lectin, induces an activating signalling. Indeed, Tim-3 
forms an autocrine loop with galectin-9 in AML cells inducing mammalian target of rapamycin 
(mTOR) pathway activation and promoting self-renewal and growth (Gonçalves Silva, et al., 
2016; Kikushige et al., 2015). 
In addition to myeloid cells, Tim-3 has been shown to be expressed in Th1 cells, cytotoxic T 
cells and NK cells. However, contrarily to myeloid cells, Tim-3 triggering in these lymphocytes 
and NK cells has been shown to induce inhibitory downstream responses (Das, et al., 2017; Du 
et al., 2017; Kang et al., 2015). Tim-3 surface upregulation was found in “exhausted” CTCs 
and in hyper-stimulated NK cells and its triggering can provoke functional inactivation and 
inhibition of cytokine production (Du et al., 2017; Gallois, et al., 2014, Kang et al., 2015). 
This differential signalling in distinct cell types might be explained by the fact that 
phosphorylated Tim-3 domain recruits different Src kinases in immune system cells and 
myeloid cells as proposed by Ocaña-Guzman and colleagues (Ocaña-Guzman, et al., 2016). 
As mentioned above, one of the endogenous ligands of Tim-3 is galectin-9. Thus, it is 
reasonable to assume that galectin-9 (and possibly other endogenous ligands) is involved in 
Tim-3 triggering also CTCs and NK cells. 
Importantly, galectin-9 can bind Tim-3 only when IgV domain is glycosylated (Ocaña-
Guzman, et al., 2016). Indeed, extracellular domains of Tim-3 can be subjected to O- and N-
glycosylation. For this reason, the molecular weight (MW) of Tim-3 can vary depending on 
the levels of glycosylation. The lowest MW of full-length Tim-3 is 33 kDa, which corresponds 
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to mono-glycosylated protein. Since the MW of each glycan is around 2-3 kDa, it is possible 
to estimate the number of sugars bound to Tim-3 considering the MW of the full-length 
glycoprotein (Clayton et al., 2015) [Figure 15]. 
 
Figure 15: Tim-3 structure and its interaction with galectin-9 on immune system cells. 
Since cancer is associated with chronic inflammation, prolonged hyperactivation of 
lymphocytes and NK cells leads to surface upregulation of Tim-3 during tumorigenesis.  This 
feature is frequently exploited by malignant cells, which suppress anti-tumour immunity 
through expression of galectin-9 using its intracellular trafficker Tim-3 (Gonçalves Silva, et 
al., 2016; Z. Liu et al., 2016).  Indeed, galectins lack signal sequence necessary for their 
transport into the endoplasmic reticulum (ER) and thus necessitate a trafficking protein for 
their surface expression (Gonçalves Silva et al., 2017). It means that Tim-3 acts as both, 
endogenous receptor and trafficking protein of galectin-9. 
To date, 15 mammalian galectins have been identified that all share a conserved carbohydrate 
recognition domain (CRD) and exhibit high affinity for β-galactosides present on 
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glycoconjugates. Galectins can be classified into 3 groups according to their structure and 
number of CRDs: 
- Prototype galectins, consisting of a single CRD; 
- tandem repeat galectins, consisting of 2 different but homologous CRDs, connected by 
a linker region;  
- chimera galectins, which have a tail of short tandem repeats fused to a single CRD. 
The prototype galectins (galectins -1, -2, -5, -7, -10, -11, -13) usually self-associate and form 
dimers. Tandem-repeat galectins (galectins -4, -6, -8, -9) contain CRDs connected by a variable 
length linker peptide. Usually, galectin-9 is monomeric. However, galectin-9 has been reported 
to self-associate and form dimers (in mouse) and multimers (in human). The only chimera Gal-
3 has a C-terminal CRD linked to N-terminal tail, that can exist as monomer, dimer or higher 
order oligomer state, such as tetramer and pentamer [Figure 16] (Dings, et al., 2018; N. et al., 
2007; Nagae et al., 2006; Thijssen, et al., 2007). 
Galectins are involved in various basic cellular mechanisms, such as cell aggregation, 
proliferation, migration and apoptosis. Deregulation of galectin levels has been observed in 
several malignancies. Indeed, galectins have been reported to contribute to tumour progression 
as a result of their immunosuppressive properties and control of cell proliferation/apoptosis 




Figure 16: Classification of galectins into three main groups based on their domain structural 
organisation (A) (Heusschen, Griffioen, & Thijssen, 2013). Galectin-9 structure: in green – sugar 
molecules, which can possible interact with a glycoprotein, are situated in proximity to carbohydrate 
binding sites (B) (Gonçalves Silva et al., 2017) 
As mentioned above, galectins accumulate intracellularly and are secreted only when bound to 
their cytoplasmatic traffickers. This suggests that galectins may have also an intracellular role. 
Recently it has been reported that galectin-3 is able to protect acute myeloid leukaemia (AML), 
prostate and colorectal cancer cells from anticancer drug-induced apoptosis (Fukumori et al., 
2006; Harazono, et al., 2014). Galectin-3 has been shown to sustain mitochondrial integrity 
possibly through direct binding to BCL2 proteins. Indeed, galectin-3 contains the NWGR anti-
death motif of the Bcl-2 family. Galectin-3 can bind to BCL2 proteins, such Bax, through the 
NWGR motif and inhibit cancer cell death induced by anticancer drugs. In addition, galectin-
3 has been reported to be able to decrease Bad expression preventing mitochondrial 
depolarization. Moreover, phosphorylated galectin-3, formation of which can result from DNA 
damage induced by anticancer drugs, is able to stimulate extracellular signal–regulated kinases 
(ERK) pathway and induce Bad phosphorylation, promoting mitochondrial stabilization 
(Harazono, et al., 2014; Ruvolo, 2016). However, this anti-apoptotic property hasn’t been 
investigated yet in other galectins, such as galectin-9.  
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In AML cells, it has been shown that galectin-9, in addition to immunosuppressive properties, 
forms an autocrine loop with its endogenous receptor and trafficker Tim-3, leading to the 
promotion of NF-ΚB and β-catenin signalling, which are critical for AML self-renewal and 
survival (Gonçalves Silva, et al., 2016; Yasinska, et al., 2018).  
Understanding the mechanisms implemented by malignant cells in order to escape host 
immune surveillance can be best achieved by the investigation of biochemical pathways 
implemented by blood cancer cells. Cells causing these systemic malignancies are under 
constant exposure to cytotoxic lymphoid cells and thus become a subject for immune attack.  
1.4 Blood cancer as a systemic malignancy facing permanent interaction with the 
immune system from the very beginning 
Intensive production of immunosuppressive molecules is pivotal for the progression of 
hematopoietic malignancies. Indeed, transformed blood cells are circulating in close contact to 
immune system cells, which can potentially eliminate cancer cells in absence of 
immunosuppressive mechanisms (Gonçalves Silva, et al., 2016; Yasinska, et al., 2018). 
It is assumed that leukaemia arises from accumulation of mutations in hematopoietic stem cells 
(HSCs) rather than in mature blood cells. This hypothesis is supported by the fact that 
leukaemia cells usually preserve the capacity to express the Kit receptor (stem cell factor 
receptor), which is responsible for cell self-renewal. Contrarily, differentiation of HSCs into 
specialised blood cells results in the loss of their ability in Kit receptor expression. For this 
reason mature blood cells can’t proliferate ensuring relatively constant number of specialised 
haematopoietic cells in the human body (Passegué, et al., 2003).   
Initial differentiation of HSCs can lead to myeloid stem cell or to lymphoid stem cell, both still 
expressing Kit receptor. The myeloid stem cells can then differentiate into myeloid leukocytes 
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(monocytes, neutrophils, eosinophils and basophils), erythrocytes and platelets. On the other 
hand, the maturation of lymphoid stem cells can lead to lymphocytes and NK cells development 
(Janeway et al., 2012). 
Based on the type of haematopoietic stem cell undergoing malignant transformation and on the 
velocity of progression (acute or chronic), leukaemia is classified in four main groups: acute 
myeloid leukaemia (AML), chronic myeloid leukaemia (CML), acute lymphoid leukaemia 
(ALL) and chronic lymphoid leukaemia (CLL) (Szczepański, et al., 2003).  
Among these four types of leukaemia, AML is the commonest one in the adults. Each year a 
significant number of new AML cases is registered all over the world. Unfortunately, the 
survival rates for this malignancy remain very low. Rapid progression and multiple 
immunosuppressive mechanisms characterising AML result, indeed, in poor prognosis and 
high mortality rates (Estey & Döhner, 2006; WHO, 2018). 
High proliferation rate and survival of AML cells is a consequence of specialised mechanisms 
acquisition by malignant cells, which leads to continuous self-renewal and protect from host 
immune attack. Indeed, AML cells express immunosuppressive ligands, such as CD86, PD-L1 
and PD-L2, able to inactivate lymphocytes and NK cells as described before [Figure 17] 




Figure 17: Inhibitory interactions via PD-1 and CTLA-4 receptors lead to immune cells inactivation 
by direct binding to respective ligands and through suppression of IL-2 secretion 
Moreover, as previously described, AML cells express high surface levels of Tim-3/galectin-9 
complex, that can be shed leading to the release of Tim-3 and galectin-9, which can induce 
apoptosis in  T cells and inactivates NK cells circulating in the bloodstream (Yasinska, et al., 
2018). 
Moreover, it has been recently reported that galectin-9 can promote downstream signalling 
when interacting with its endogenous Tim-3 receptor on AML cells. Indeed, this complex 
formation on the surface of AML cells stimulates the phosphorylation in Ser2448 residue of 
mammalian target of rapamycin (mTOR) (Gonçalves Silva, I., et al., 2016). Active mTOR 
(phosphorylated in Ser2448) is then able to promote phosphorylation of various substrates, 
such as eukaryotic translation initiation factor 4E (eIF4E) binding protein (BP). Indeed, hypo-
phosphorylated eIF4E-BPs interacts avidly with eIF4E protein preventing its interaction with 
cap structure at 5’ end of specific mRNAs (Jossé, et al., 2016). Phosphorylation of Ser65, Thr70 
and possibly other aa residues of eIF4E-BP by active mTOR induces conformational changes 
in eIF4E-BPs that lead to the loss of affinity for eIF4E. Released eIF4E is then able to bind 
mRNAs and promote translation of various proteins necessary for AML cell survival and 
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proliferation. Another important target of active mTOR is the ribosomal protein S6 kinase beta-
1 (S6K1), also called p70S6 kinase. Active S6K1 promotes the phosphorylation of e S6 
ribosomal protein, which leads to specific protein synthesis. The mTOR induced protein 
synthesis leads to increased levels of various proteins, including Hif-1α, thus promoting VEGF 
transcription and future angiogenesis. Moreover, active mTOR positively affects glycolysis 
rendering it more efficient (Gonçalves Silva, et al., 2016, Prokhorov et al., 2015). 
Consequently, galectin-9/Tim-3 signalling is pivotal for AML progression. However, the 
mechanisms underlying its surface expression remains still unclear. Neuronal receptor 
neuronal receptor latrophilin 1 (LPHN1) has been proposed to be responsible for galectin-9 
secretion. 
LPHN1 is G-protein-coupled receptor physiologically expressed in neurons, where it is 
involved in neurotransmitter release in Ca2+ dependent manner. Recently, it was discovered 
that the neuronal receptor latrophilin 1 (LPHN1) is expressed in human monocytic cells (THP-
1) and in primary human AML cells, but is absent in mature healthy leukocytes. It has been 
shown that its triggering by latrotoxin, compound present in the venom of black widow spider, 
leads to Ca2+ mobilisation and cytokine exocytosis by AML cells (Sumbayev et al., 2016). 
Moreover, since these cells are circulating in the blood, it is obvious that LPHN1 ligands should 
be present as well in the vessels or expressed by endothelial cells. To date, two LPHN 
endogenous ligands of nervous tissue have been identified: Lasso/teneurin-2 and fibronectin 
leucine rich transmembrane protein 3 (FLRT3) (O’Sullivan et al. 2012; Silva et al. 2011). 
Western blot analysis of in myeloid leukaemia cell lines (THP-1 and U-937), primary healthy 
leukocytes or blood plasma obtained from healthy donors showed that teneurin-2 was absent 
(Sumbayev et al. 2016). For this reason, our second candidate as possible stimulatory LPHN1 
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ligand on AML cells was FLRT3. However, its presence in the blood or on circulating cells 
haven’t been examined yet. Also, FLRT3 effects on AML cells haven’t been studied yet. 
FLRTs are transmembrane proteins containing an extracellular leucine-rich repeat (LRR) 
domain, able to interact with proteins containing olfactomedin domain. Structural studies of 
LPHNs revealed the presence of an external olfactomedin domain in all the three isoforms of 
this receptor (LPHN1-3). Indeed, the interaction between FLRT3 LRR domain and LPHNs 
olfactomedin domain has been reported (Krasnoperov, et al. 1999; Lelianova, et al. 1997; 
O’Sullivan, et al. 2012). 
Additionally, the transcription factor(s) associated with LPHN1 expression in AML cells 
remain(s) still unknown.  
We hypothesised, that cortisol could be involved in LPHN1 regulation. Indeed, abnormal 
cortisol levels were detected in several cancer types, but these have never been reported for 
AML (Mazzoccoli, et al., 2003; Sephton, et al., 2013; Schrepf, et al., 2015).  
Cortisol is a glucocorticoid hormone produced by adrenal gland. The hypothalamic-pituitary-
adrenal (HPA) axis tightly controls cortisol levels, which increase in response to numerous 
stimuli such as stress and energetic deficiency (Bamberger, 1996).  
Cancer cells use high amounts of glucose, main energy source of the body, in order to 
proliferate rapidly. Therefore, anomalous reduction of hematic glucose occurs during cancer 
development. Hypoglycaemia, resulting from this process, stimulates HPA axis with 
consequent cortisol release by adrenal gland (Greenwood, et al., 1966; Koenig, et al., 2005). 
One of the cortisol functions, indeed, is to increase glucose levels in the blood, mainly by 
promoting glycogenolysis and gluconeogenesis (Garber, et al., 1976). 
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Although its concentration in the blood oscillates during the day, cortisol is an always 
circulating hormone and, thus, can regularly interact with glucocorticoid receptors present in 
myeloid and other blood cells. Depending on the cell type, this hormone can promote 
differential gene transcription leading to cell-specific responses. For instance, T cells activity 
and proliferation was found to be suppressed by glucocorticoid treatment (Herold, et al., 2006; 
Davis, et al., 2014). Contrarily, white blood cells proliferation was shown to be significantly 
upregulated by glucocorticoids. Indeed, it was found that glucocorticoids are able induce 
haematopoiesis of myeloid lineage cells (Rinehart, 1997). 
Thus, cortisol could potentially support AML cell progression by suppressing anti-tumour 
immunity and by stimulating malignant cells proliferation. In addition, as mentioned above, 
cortisol is able to stimulate the expression of numerous proteins inside the cells. 
For all these reasons, we thought to test cortisol also as a potential regulator of LPHN1 
expression. 
Finally, Tim-3 and galectin-9 proteins have been characterised in different solid tumours, but 
mechanisms underlying regulation of their biochemical activities remain unknown.
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2. AIMS AND OBJECTIVES 
The aim of this PhD programme was to investigate the Tim-3-galectin-9 immunosuppressive 
pathway in human malignant cells and the biochemical functions of its crucial components. 
The following objectives were addressed in order to achieve this aim: 
1) To investigate the biochemistry and function of the Tim-3-galectin-9 secretory pathway in 
human AML cells which are in permanent contact with cytotoxic lymphoid cells. 
2) To investigate the ability of human AML cells to recruit crucial components of normal 
metabolism to escape immune surveillance and progress the disease. In particular: 
A) To study the effects of cortisol (hormone of adrenal cortex with crucial physiological 
function) on the activation of galectin-9 secretion by AML cells and possible recruitment of 
this hormone as an AML cell survival/immune escape factor.  
B) To investigate the biochemical mechanisms underlying recruitment of stem cell factor (SCF, 
main normal haematopoietic growth factor) by human AML cells for the purposes of survival, 
proliferation and immune escape. In particular, the study focuses on the role of danger signal 
HMGB1 produced by AML cells in activation of SCF production by healthy tissues. 
3) To study the expression and activity of the Tim-3-galectin-9 immunosuppressive pathway 
in human solid tumour cells in order to understand whether is unique for AML or ubiquitous 
and common for a variety of malignant tumours.  
4) To investigate the behaviour of Tim-3-galectin-9 immunosuppressive pathway in healthy 
and malignant human cells in the case of mitochondrial dysfunction followed by apoptotic cell 
death and to understand whether galectin-9 could also plays intracellular anti-apoptotic role as 
some other members of the galectin family (for example galectin-3).
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3. MATERIALS AND METHODS 
3.1 Materials 
Tissue culture medium and supplements were purchased from Sigma-Aldrich (Sufflock, UK). 
Mouse monoclonal antibodies directed against mTOR and β-actin, and rabbit polyclonal 
antibodies against phospho-S2448 mTOR, RAGE, galectin-9, HRP-labelled rabbit anti-mouse 
secondary antibody were purchased from Abcam (Cambridge, UK). Rabbit polyclonal 
antibodies against LPHN1 (PAL1 and RL1) as well as rabbit polyclonal antibody against 
LPHN2 (PAL2) were previously described (Davydov et al., 2009; Volynski et al., 2000). Other 
two anti-LPHN1 antibodies, rabbit antibody against native form and mouse monoclonal 
antibody, were purchased respectively from Abcam and Santa Cruz Biotechnology (Dallas, 
Texas, USA). Another rabbit antibody against LPHN2 was obtained from Abcam. Human 
recombinant FLRT3 and mouse monoclonal anti-FLRT3 antibody were purchased from Santa 
Cruz Biotechnology. Antibodies against phospho-S65 and total eukaryotic initiation factor 4E 
binding protein 1 (eIF4E-BP1) were obtained from Cell Signalling Technology (Danvers, MA, 
USA). Goat anti-mouse and goat anti-rabbit fluorescence dye-labelled antibodies were 
purchased from LI-COR (Lincoln, Nebraska USA).  
Anti-Tim-3 mouse monoclonal antibody, its single chain variant, human Ig-like V-type domain 
of Tim-3 (amino acid residues 22–124), human HMGB1 and human SCF were a kind gift of 
Dr Luca Varani (Gonçalves Silva et al., 2017; Prokhorov et al., 2015; Yasinska, et al., 2018). 
A soluble extracellular fragment of LPHN1, LPH-51, was produced and purified as previously 
described (Volynski et al., 2000). 
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DOPAT transfection reagent, primers and galectin-9 silencing RNA (siRNA) were obtained 
from Sigma-Aldrich. Tim-3 silencing RNA (siRNA) was purchased from Santa Cruz 
Biotecnology. 
Maxisorp™ microtitre plates were provided either by Nunc (Roskilde, Denmark) an Oxley 
Hughes Ltd. (London, UK). ELISA-based assay kits for the detection of galectin-9, Tim-3, IL-
2, TNF-α, IL-1β, SCF and VEGF were purchased from Bio-Techne (R&D Systems, Abingdon, 
UK).  
Secondary antibodies for confocal laser microscopy, TRITC labelled antibody (goat anti-
mouse IgG) and t FITC labelled antibody (goat anti-rabbit IgG), were obtained from Abcam. 
Imaging flow cytometry (goat anti-mouse and goat anti-rabbit Alexa 488, Alexa 555 and Alexa 
647) were purchased from Invitrogen (Carlsbad, USA).  
All other chemicals purchased were of highest grade of purity and obtained from Fischer 
Scientific (Loughborough, UK) or Sigma (Sufflock, UK). 
3.2 Tissue culture 
3.2.1 Cells lines 
THP-1 human myeloid leukaemia monocytes, K562 chronic myelogenous leukaemia cells, 
Jurkat T cells, MCF-7 human epithelial breast cancer cells, Colo-205 human colorectal 
adenocarcinoma cells of epithelial origin, HEP G2 human hepatocarcinoma cells were obtained 
from the European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK). RC-
124 non-malignant human kidney cells of epithelial origin and renal clear cell carcinoma RCC-
FG1 cells were obtained from CLS Cell Lines Service GmbH (Eppelheim, Germany). Cells 
were cultured in RPMI 1640 medium (R8758 – Sigma-Aldrich) with L-glutamine and sodium 
bicarbonate and supplemented with 10% foetal bovine serum (FBS), penicillin (50 IU/ml) and 
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streptomycin sulphate (50 µg/ml). LAD2 mast cells were kindly provided by A. Kirshenbaum 
and D. Metcalfe (NIH, USA). Cells were cultured in StemPro-34 serum-free media in the 
presence of 100 ng/ml SCF (Kirshenbaum et al., 2003). Untransfected mouse neuroblastoma 
cells (NB2A) and those overexpressing the full-size LPHN1 (LPH-42) were cultured as 
previously described (Volynski et al., 2000). TALL-104 cytotoxic T lymphocytes derived from 
human acute lymphoblastic leukaemia were obtained from the American Tissue Culture 
Collection (ATCC). TALL-104 were cultured in ATCC-formulated Iscove’s Modified 
Dulbecco’s Medium supplemented with 100 units/ml recombinant IL-2, 2.5 µg/ml human 
albumin, 0.5 µg/ml D-mannitol and FBS to a final concentration of 20%. LN401 human 
glioblastoma cells, BC-8701 human breast cancer cells, MDA-MB-231 human breast 
adenocarcinoma cells, PC3 prostate adenocarcinoma cells, Calu 6 human pulmonary non-small 
cell carcinoma cells, BEAS-2B human bronchial epithelium cells, D10 human malignant 
melanoma and HaCaT human keratinocytes were obtained from ECACC, ATCC or CLS Cell 
Lines Service GmbH. All the cells were cultured at 37 ºC and 5% CO2. 
Cell lines were accompanied by identification test certificates and were cultured according to 
specific tissue culture protocols. The cells were cultured for maximum 25-30 passages. 
3.2.2 Primary human cells 
Primary human AML mononuclear blasts (AML-PB001F, newly diagnosed/untreated) were 
purchased from AllCells (Alameda, CA, USA) and handled in accordance with the 
manufacturer's instructions following ethical approval (REC reference: 16-SS-033). Other 
primary human AML cells were obtained from the sample bank of the University Medical 
Centre Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer Hamburg, reference: 
PV3469). Cells were incubated in IMDM medium containing 15% BIT 9500 serum substitute, 
 51 
 
100 μM mercaptoethanol, 100 ng/ml stem cell factor (SCF), 50 ng/ml FLT3, 20 ng/ml G-CSF, 
20 ng/ml IL-3, 1 μM UM729 and 500 nM stemregenin 1 (SR1). 
Primary human NK cells and primary human healthy leukocytes were purified from buffy coat 
blood (prepared from healthy donors) obtained from the National Health Blood and 
Transfusion Service (NHSBT, UK) following ethical approval (REC reference: 16-SS-033).  
Primary CD34-positive HSCs were obtained from Lonza (Basel, Switzerland).  
Primary cells were cultured for maximum 2-3 passages before being used for the experiments. 
3.2.3 Primary human blood plasma samples 
Blood plasma from healthy donors was provided by the National Health Blood and Transfusion 
Service (NHSBT, UK) following ethical approval (REC reference: 16-SS-033).  
Primary human AML plasma samples were obtained from the sample bank of University 
Medical Centre Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer Hamburg, 
reference: PV3469). 
3.2.4 Bone marrow extracts 
Femur bones of six-week-old C57 BL16 mice (25 ± 2.5 g, kindly provided by Dr. Gurprit Lall, 
School of Pharmacy, University of Kent) were used for the experiments following approval by 
the Institutional Animal Welfare and Ethics Review Body. Animals were handled by 
authorized personnel in accordance with the Declaration of Helsinki protocols. Bone marrow 
was isolated from femur bone heads as described before (Swamydas & Lionakis, 2013). Cells 
were kept in RPMI 1640 medium supplemented with 10% FBS, penicillin (50 IU/ml) and 
streptomycin sulphate (50 µg/ml). In addition, whole extracts were obtained from isolated bone 
marrow with final protein concentration 1 mg/ml. 
 52 
 
3.2.5 Human breast tissue samples 
Primary human tumour tissue samples paired together with peripheral tissues (also called 
“normal” or “healthy” of the same patients) were collected surgically from breast cancer 
patients treated at the Colchester General Hospital, following written consent taken before 
surgery. Paired normal (healthy) peripheral tissues were removed during macroscopic 
examination of a tumour by pathologists. Blood samples were collected before breast surgery 
from patients with primary breast cancer and before treatment from patients with metastatic 
breast cancer. Samples were also collected from healthy donors (individuals with no diagnosed 
pathology), which were used as control samples. Blood separation was performed using 
buoyancy density method employing Histopaque 1119-1 (Sigma, St. Louis, MO) according to 
the manufacturer’s protocol. Ethical approval documentation for these studies was obtained 
from the NRES Essex Research Ethics Committee and the Research & Innovation Department 
of the Colchester Hospitals University, NHS Foundation Trust [MH 363 (AM03) and 
09/H0301/37]. 
3.3 Cell lysis 
Cell pellets obtained after the centrifugation were re-suspended in lysis buffer (50 mM Tris-
HCl, 5 mM Ethylenediaminetetraacetic acid (EDTA), 150 mM NaCl, 0.5% Nonidet-40, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), pH 8.0) and kept on the ice for 60-90 minutes. After 
the incubation on the ice, the samples were centrifuged. The supernatants containing protein 




3.4 Tissue lysis 
The lysates were prepared using 100 mg of each frozen tissue, which was initially grounded 
into a powder and then, homogenised with 100 µL of the tissue lysis buffer (20mM Tris/HEPES 
pH 8.0, 2 mm EDTA, 0.5 M NaCl, 0.5% sodium deoxycholate, 0.5% Triton X-100, 0.25 M 
Sucrose, supplemented with 50 mM 2-mercaptoethanol, 50 µM PMSF, 1 µM pepstatin 
supplied just before use). Tissues were homogenised using Polytron Homogenizer (Capitol 
Scientific, USA) and a syringe was used to obtain homogeneous cell suspension. These tissue 
suspension were then filtered through medical gauzes and centrifuged at +4ºC at 10,000 g for 
15 minutes. After the centrifugation, proteins present in supernatants were precipitated by 
incubation of the samples on ice for 30 minutes with equal volumes of ice-cold acetone. Protein 
pellets were obtained by centrifugation (4ºC, 10,000 g, 15 minutes) followed by air drying at 
room temperature and then suspended in the SDS-lysis buffer described in the section 3.3 
(D’Arcy et al., 2008). 
3.5 Protein quantification 
Protein concentration in the samples was measured using Bradford assay, which involves the 
addition of an acidic dye (Coomassie Brilliant Blue G-250) to the protein solutions.  
At the assay pH (under acidic conditions) the dye molecules are protonated and present the 
maximum of absorption at 465 nm (brownish colour) [Figure 18A]. When added to protein 
solutions, the Coomassie Brilliant Blue G-250 (CBB) can bind proteins via π-interactions 
(aromatic ring of CBB with aromatic aa residues of the protein) and via electrostatic attraction 
(negatively charged sulfonate groups of CBB with protonated basic aa residues of the protein).  
Protein-CBB complex formation leads to the shift of the dye maximum absorption from 465 




Figure 18: Maximum of absorption of CBB alone and in complex with the protein. Protonated CBB 
has maximum of absorption at 465 nm (A). Deprotonation of CBB by basic amino acids leads to the 
formation of negatively charged sulfonate groups which can bind the protein through electrostatic 
interactions. In addition, aromatic residues, such as Trp, Tyr and Phe, can bind CBB through π-
interactions. Stabilisation of CBB-protein complex results in the shift of maximum of absorption of the 
dye from 465 nm to 595 nm (Adapted from Gregoriu, et al., 2008). 
For protein quantification, 5 µl of cell lysate were mixed with 150 µl of Bradford reagent 
(0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (w/v) ethanol and 8.5% (w/v) phosphoric 
acid) in a microwell plate. Following 5 minutes of incubation, the optical density at 620 nm 
was read in the plate reader. 
3.6 Western Blot analysis1 
Tissue o cell lysates were mixed with 2X or 4X sample buffer (125 mM Tris-HCL, 2% sodium 
dodecyl sulphate (SDS), 10% glycine, 1 mM dithiothreitol (DTT), 0.002% bromophenol blue, 
pH6.9) and boiled 5 min at 95°C. 
The mixture of proteins was then separated according to their MW using sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS is an anionic detergent that 
denatures (together with DTT) the proteins and “wraps” the obtained polypeptide chains. This 
binding results in the formation of negatively charged complexes with equal charge densities 
per unit length of protein, thereby eliminating the ionic charges of individual amino acids. In 
 
1 Buffers and other solutions used in this paragraph are reported in section 7.1 and 7.2 in Appendix 
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this way the proteins can be resolved on the SDS-PAGE gel according to their MW and not to 
their three-dimensional size or their individual charges. 
After loading the protein mixtures in the wells of the gel kept in the running buffer (described 
in Appendix), an electric field was applied to force negatively charged polypeptides to migrate 
from cathode (negative pole) to anode (positive pole) leading to the separation of proteins 
according to their MW. Constant voltage of 150-200 V was applied until the dye front was 
about 1 cm from the bottom of the gel. Proteins were resolved on 7.5%, 10% or 12% SDS-
polyacrylamide gels, prepared as described in section 7.1 in Appendix. Polyacrylamide gel 
percentage was chosen according to the molecular weight of the target protein: 
Protein target, (KDa) >250 90-250 50-90 20-50 <20 
Gel% 5 7.5 10 12 15 
After performing SDS-PAGE, the separated proteins in the gel were transferred to a 
nitrocellulose membrane using semi-dry (BioRad system) or wet (Invitrogen system) blotting. 
Filter paper and/or filter pads, together with nitrocellulose membrane were soaked in blotting 
buffer and assembled with obtained gel in the transfer cassette as illustrated in Figure 19. 
 
Figure 19: Schematic representation of gel/membrane/filter papers/filter pads assembly in semi-dry 
(A) and wet (B) transfers. 
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The blotting was performed in a semi-dry (BioRad system) or wet (Invitrogen system) 
environment at constant voltage and 0.07 Amp (semi-dry transfer) or 0.1 Amp (wet transfer), 
one to two hours, according to the gel and system used. 
After the blotting, the membranes were blocked with blocking buffer (tris-buffered saline, 0.1% 
Tween 20 (TBST), 2% bovine serum albumin (BSA)) for at least 1 h under constant agitation 
at room temperature to minimise unspecific binding of the antibodies on the membrane. 
Blocked membranes were then incubated with the antibodies for target proteins for at least two 
hours at room temperature. For all primary antibodies a 1:1000 dilution in blocking buffer was 
used, except those against LPHNs, FLRT3 (where a 1:500 dilution was used) and CD3 (where 
a 1:100 dilution was used). 
Following the incubation with primary antibodies, the membranes were washed with TBST 
buffer for at least 15 min, under constant agitation at room temperature and then incubated with 
Li-Cor goat secondary antibodies, conjugated with fluorescent dyes, diluted in TBST buffer 
(1: 2000 dilution). After the incubation with secondary antibodies (1h, room temperature), the 
membranes were washed with TBST buffer as described above and visualised using a Li-Cor 
Odyssey imaging system. The detection of the bands corresponding to target proteins is 
possible because of the fluorescent tags bound to the secondary antibodies. These fluorescent 
dyes, when excited with specific wavelengths of light in the near infrared spectrum, emit at 
different wavelengths, which can be detected by Odyssey Imaging System. In particular, this 
imaging system has two channels which can be employed for the detection of fluorescence 
corresponding to one of two specific monochromatic wave lengths (680 nm and 800 nm). 
Western blot data were qualitatively and quantitatively analysed using Odyssey software and 
values obtained were normalised against those of β-actin, employed to ascertain equal protein 
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loading into the wells of the gel. Molecular weights of target proteins were calibrated in 
proportion to the running distance of protein standard markers. 
Western blot analysis was employed to detect the components of the Tim-3, galectin-9, FLRT3, 
LPHNs 1-3, Gαq, CD3, Hif-1α and RAGE in cell or tissue lysates. 
In order to quantitatively analyse mTOR-dependent phosphorylation of eIF4E-BP using 
Western Blot analysis, levels of phospho-S65-eIF4E-BP and total eIF4E-BP were detected on 
different membranes to avoid the overlap of protein bands due to possible incomplete 
membrane stripping. Values obtained after densitometry analysis of the bands corresponding 
to phospho-S65-eIF4E-BP and total eIF4E-BP were normalised against those of β-actin for 
respective membranes. The levels of eIF4E-BP phosphorylation were then calculated using the 
ratio between normalised phospho-S65-eIF4E-BP and total eIF4E-BP as described in the 
following equation: 
𝐩𝐒𝟔𝟓 − 𝐞𝐈𝐅𝟒𝐄 − 𝐁𝐏 𝐥𝐞𝐯𝐞𝐥 =  
[𝐩𝐒𝟔𝟓 − 𝐞𝐈𝐅𝟒𝐄 − 𝐁𝐏]
[𝐀𝐜𝐭𝐢𝐧]
÷
[𝐞𝐈𝐅𝟒𝐄 − 𝐁𝐏 𝐭𝐨𝐭𝐚𝐥]
[𝐀𝐜𝐭𝐢𝐧]
 
This ratio in control samples was considered as 100%.  
3.7 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was used for the detection and quantification of target proteins in the cell culture media, 
human plasma, and cell and tissue lysates. 
3.7.1 Determination of galectin-9, soluble Tim-3 (sTim-3), TNF-α, IL-1β, SCF, VEGF 
and IL-2 concentrations released by the cells 
Levels of galectin-9, soluble Tim-3 (sTim-3), TNF-α, IL-1β, SCF, VEGF and IL-2 in cell 
culture media or in human blood plasma were determined by solid phase sandwich ELISA 
(R&D Systems assay kits) according to the manufacturer’s protocol. Briefly, 100 µL of capture 
 58 
 
antibody for specific target protein were added to each well of 96-well microplate coated with 
poly-D-lysine (PDL), which was then incubated overnight at room temperature. Prior to the 
well-loading, capture antibody was diluted in phosphate-buffered saline (PBS) solution 
obtaining an optimal concentration for ELISA performance as recommended in the 
manufacturer’s protocol. After the incubation with the capture antibody, the wells were blocked 
with ELISA blocking buffer (PBS/BSA 1%) for at least one hour under constant agitation at 
room temperature. 100 µL of sample (culture media or human blood plasma) were then added 
to each well and left for at least two hours under constant agitation at room temperature. 
Following the incubation with the samples, the wells were washed with TBST buffer and 
incubated with 100 µL of specific biotinylated detection antibody diluted in PBS/BSA 1% for 
at least two hours under constant agitation at room temperature. After the incubation with the 
detection antibody, the wells were washed with TBST buffer and incubated with 100 µL of 
streptavidin labelled with horse radish peroxidase (HRP) diluted in PBS/BSA 1% for at least 
30 minutes under constant agitation at room temperature. The wells were then washed with 
TBST buffer and then incubated with 100 µL of substrate solution (0.2% H2O2, 56 Mm orto-
phenylenediamine (OPD)) for maximum 10 minutes at room temperature protecting from light. 
The reaction was stopped by adding 100 µL of 1.8 M H2SO4 in each well when change colour 
was observed. Indeed, HRP catalyses the oxidation of OPD in presence of H2O2 leading to the 
formation of 2,3-diaminophenazine (DAP), which maximum absorbance wavelength depends 
on the pH of the solution. The pH lowering after the addition of H2SO4 leads to irreversible 
inactivation of HRP and to the formation of protonated form of DAP which absorbance can be 
measured between 450 nm and 500 nm [Figure 20] (Bovaird, Ngo, & Lenhoff, 1982; Fornera 




Figure 20: OPD oxidation catalysed by HRP leads to the formation of DAP, which absorbs wavelengths 
in the range 400 – 450 nm (corresponding to the violet colour) of visible light spectrum and reflects 
wavelengths in the range 560 – 590 nm donating the typical yellow colour to the solution. DAP 
protonation leads to the formation of the compound absorbing the wavelengths from 450 nm to 500 nm 
and reflecting wavelengths which together donate bright orange colour to the solution [structures were 
drawn using ChemSpace].  
Since DAP concentrations are directly proportional to the levels of HRP-labelled streptavidin 
in the well, obtained absorbance values are directly proportional to the concentration of the 
protein of interest contained in the sample. 
3.7.2 Determination of phospho-S2448 mTOR in cell lysates 
ELISA plate was initially coated with mouse anti-mTOR antibody and then blocked with 
PBS/BSA 2%. Subsequently, the wells were incubated with the cell lysates at room temperature 
for at least two hours. After washing the plate with TBST buffer, the wells were incubated with 
anti-phospho-S2448 mTOR antibody at room temperature for at least 2 h. The plate was then 
washed with TBST again and HRP-labelled goat anti-rabbit IgG (Abcam) was added to the 




TBST, bound secondary antibodies were detected by the peroxidase reaction (OPD/H2O2) as 
described above. 
3.7.3 Detection of Tim-3-galectin-9 complex in cell and tissue lysates 
Mouse single-chain antibody against Tim-3 was employed as capture antibody, instead of using 
the full-length anti-Tim3 antibody from R&D ELISA kit. The wells were then incubated with 
cell or tissue lysates at room temperature for at least two hours. After washing the plate with 
TBST, biotinylated goat antibody against galectin-9 (detection antibody of R&D Systems 
ELISA kit) was added to the wells and kept for at least two hours at room temperature. The 
plate was then washed and incubated with HRP-labelled streptavidin for at least 30 minutes. 
This step was followed by the development of peroxidase reaction and its visualization as 
described above. 
3.7.4 Detection of cortisol in human blood plasma 
Plasma cortisol was measured by ELISA using the Salimetrics assay kit according to the 
manufacturer’s protocols (Salimetrics, Suffolk, UK). Briefly, plasma samples were added to 
microtitre plate coated with monoclonal anti-cortisol antibodies. Cortisol enzyme conjugates 
(cortisol bound to HRP) were then added to the samples and incubated for at least one hour at 
room temperature. After the incubation the plate was washed and the chromogenic substrate 
3,3′,5,5′-tetramethylbenzidine (TMB) is added. The oxidation of TMB by HRP causes the 
development of the blue colour in the wells of microtiter plate. The reaction is stopped by 
adding an acidic solution, which leads to the yellow colour formation. The optical density can 
be then read at 450 nm. 
In this competitive immunoassay, plasma cortisol competes with cortisol conjugated to HRP 
for the antibody binding sites on a microtitre plate. Therefore, the levels of cortisol HRP 
conjugates are inversely proportional to the amount of cortisol present in the sample. 
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3.8 Determination of LPHN1 fragments in human blood plasma 
ELISA plates were initially coated with mouse monoclonal LPHN1 antibody and blocked with 
TBST/BSA 2%. Human plasma samples were then added to the wells of the microtitre plate 
and kept under constant agitation for 4 hour at room temperature. After the incubation the plate 
was washed with TBST. Bound proteins were then extracted using glycine-HCl pH lowering 
buffer (pH 2.0) and mixed with lysis buffer (pH 7.5) at ratio 1:1 and with 4x sample buffer 
(described previously). Following Western Blot analysis of the samples obtained, LPHN1 
fragments were detected using rabbit PAL1 anti-LPHN1 antibody. 
In addition to protein immunoprecipitation followed by Western Blot detection, LPHN1 in 
human plasma was determined by ELISA. Mouse monoclonal LPHN1 antibody was used as 
capture antibody, while PAL1 antibody was employed as detection antibody. After the 
incubation with PAL1 antibody, the plate was incubated with HRP-labelled anti-rabbit 
secondary antibody. LPHN1 fragments were then visualised through the development of the 
peroxidase reaction as previously described. 
3.9 Detection of Tim-3-galectin-9 complex in tissue culture medium 
ELISA plates were coated with mouse single-chain antibody against Tim-3and blocked with 
PBS/BSA 2%. RPMI-1640 medium, in which THP-1 cells were cultured, was then added to 
the wells of the plate. After 4 hour of incubation with the samples, the plate was washed with 
TBST and the proteins were extracted employing 0.2 M glycine-buffer. Obtained extracts were 
then neutralised with lysis buffer, mixed with lysis buffer and subjected to Western Blot 
analysis, as described above. The bands corresponding to Tim-3-galectin-9 complex were 
visualised using mouse anti-Tim-3 antibody and galectin-9 antibodies-. 
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3.10 Cell viability assay 
Promega (Southampton, UK) MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay kit was used to evaluate cell 
viability. In this assay, MTS tetrazolium compound is converted to a coloured formazan 
product by dehydrogenases in metabolically active cells. This conversion is proportional to the 
amount of living cells and can be assessed by measuring the maximum absorbance of the 
reaction product at 490 nm (Riss et al., 2013) [Figure 21].      
 
Figure 21: Viable cells contain active dehydrogenases able to reduce NAD+ in NADH; then, 
electron coupling reagent phenazine ethosulfate (PES) transfers electrons from NADH in the 
cytoplasm to reduce MTS in the culture medium into an aqueous soluble formazan (Adapted 
from Riss et al., 2013).  
To assess cell viability, 20 µl of “One Solution Reagent” containing MTS and an electron 
coupling reagent (phenazine ethosulfate (PES)) were added to 100 µl of cell suspension into a 
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microwell of 96-well plate. After mixing, the plate was placed in the incubator at 37°C for 1-4 
hours, and the absorbance at 490 nm was then measured in accordance to the manufacturer’s 
protocol. 
3.11 Caspase 3 activity 
Caspase 3 activity was determined employing colorimetric assay kit (R&D Systems). This 
assay is based on the ability of the activated caspase 3 to cleave molecules that contain the 
amino acid motif DEVD such as poly ADP ribose polymerase (PARP).  
Indeed, in this colorimetric assay, caspase-specific peptide (containing DEVD motif) 
conjugated to the colour reporter molecule p-nitroaniline (pNA) is added to sample to verify 
caspase 3 activity. The cleavage of the peptide by the caspase leads to the release of the 
chromophore pNA, which can be quantitated spectrophotometrically at a wavelength of 405 
nm. The intensity of colour reaction is directly proportional to the level of caspase enzymatic 
activity in the cell lysate. 
Once added caspase lysis buffer to the cell pellets, the samples are incubated on the ice for 10 
minutes. After the incubation on the ice, the samples are centrifuged (10,000 x g for 1 minute) 
and the supernatants are transferred in the new tubes and kept on the ice. To 50 µL of sample 
are added 0.5 µL of 1 M solution of dithiothreitol (DTT), 50 µL of Reaction Buffer and 5 μL 
of Caspase-3 colorimetric substrate (DEVD-pNA) into a microwell of the 96-well plate. The 
plate is then incubated at 37 °C for 1-2 hours. After the incubation, the absorbance at 405 is 
measured in accordance to the manufacturer’s protocol. 
3.12 Granzyme B activity 
Granzyme B activity was determined using a fluorimetric assay kit (BioVision). This assay is 
based on the employment of synthetic substrate, containing the Granzyme B recognition 
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sequence along with a fluorescent label 7-Amino-4-trifluoromethylcoumarin (AFC). The 
cleavage of this specific recognition sequence by Granzyme B leads to the release of AFC, 
which then can be fluorometrically determined (Excitation wavelength = 380 nm; Emission 
wavelength = 500 nm). 
After homogenising the cells in specific assay buffer, the samples were kept on the ice for 10 
minutes and then centrifuged. Obtained supernatants were then transferred in the new tubes 
and placed on the ice. To 1 – 50 µL of sample supernatants were added 50 µL of the mixture 
Granzyme B substrate/Granzyme B Assay Buffer (1:10) into each well of 96-well plate. After 
the incubation for 30-60 min at 37⁰C (protected from light), the fluorescence was measured at 
Ex/Em = 380/500 nm. 
3.13 Mitochondria isolation 
Cellular mitochondria were isolated employing differential centrifugation (Nicholas, 
Coughlan, et al., 2011). The cells were initially homogenised in an isolation buffer containing 
0.32 M sucrose, 1 mM EDTA (K+ salt), and 10 mm Tris-HCl (pH 7.4). Homogenates were 
then centrifugated (1330 x g, 3 minutes) and obtained supernatants were further subjected to 
centrifugation (21,200 x g, 10 minutes). After the centrifugation, pellets (isolated 
mitochondria) were lysed in the cell lysis buffer. Protein content of the samples were then 
analysed using Bradford assay. 
3.14 Uptake of BH3I-1 by the cells 
Cells treated and untreated with 5-[(4-bromophenyl)methylene]-a-(1-methylethyl)-4-oxo-2-
thioxo-3-thiazolidineacetic acid (BH3I-1), a synthetic apoptosis inducer, were harvested and 
then centrifuged. After applying harsh reaction conditions (high temperature and low pH) to 
the obtained pellet, 125 µL of RPMI 1640 medium were added to Eppendorf tubes containing 
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the sample. Dibromine (Br2) resulting from the molecular disruption of BH3I-1, as a 
consequence of harsh conditions applied to the sample, can react with phenol red (λmac=428 
nm) contained in RPMI 1640 medium leading to the formation of bromophenol, which has the 
maximum of absorbance at 585 nm (Sollo, et al., 1971; Wever, et al., 2018). Therefore, it is 
possible to estimate amount of BH3I-1 molecules which entered the cell by measuring the 
absorbance of the sample containing bromophenol at 585 nm [Figure 22]. Indeed, quantity of 
bromophenol molecules resulting from bromination of phenol red are directly proportional to 
BH3I-1 molecules present inside the cell after the incubation with this apoptosis inducer. 
 
Figure 22: Dibromine (obtained after breaking BH3I-1 compound) reacts with phenol red 
(λmac=428 nm) leading to the formation of bromophenol blue (λmac=585-590 nm). (Adapted 
from Wever et al., 2018). 
3.15 Galectin-9 and Tim-3 knockdown 
For galectin-9 gene expression silencing, a specific siRNA target sequence (uga ggu gga cga 
ugu ggu ucc c) was employed. For Tim-3 knockdown, a commercially available siRNA 
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obtained from Santa Cruz Biotechnology, CA, USA, was used. Corresponding random siRNA 
(uac acc guu agc aga cac c dtd) was employed as a negative control. 
The cells were transfected with specific siRNAs using cationic liposome-forming compound 
DOTAP as recommended in manufacturer’s instructions. Briefly, the liposomes were prepared 
using 7 μg of siRNA, 20 μL of DOTAP and 74 μL of HEPES. After incubating these reagents 
for 30-60 minutes on the ice (to allow the formation of the liposomes), 15 μl of the mixture 
obtained were added to 3 ml of the culture media containing Colo-205 cells. 
3.16 Quantitative real-time PCR (qRT-PCR) 
Quantitative real-time PCR (qRT-PCR) was employed to monitor mRNA levels corresponding 
to target proteins. 
Total RNA was isolated from the cells using a GenEluteTM mammalian total RNA preparation 
kit (Sigma-Aldrich). Target mRNAs was then converted into DNA sequences and amplified 
through reverse transcriptase-polymerase chain reaction (RT-PCR) in accordance with 
manufacturer’s protocol. This was followed by quantitative real-time PCR. For Galectin-9 
following primers were employed: 5’-CTTTCATCACCACCATTCTG-3’ and 5’-
ATGTGGAACCTCTGAGCACTG-3’. For Tim-3 was used 5’-CATGTTTTCAC-
ATCTTCCC-3’ primer and for actin were employed 5’-TGACGGGGTCACCCACACTG-
TGCCCATCTA-3’ and 5’-CTAGAAGCATTTGCGGTCGACGATGGAGGG-3’ primers. 
For LPHN1 following primers were exploited: 5′-AGCCGCCCCGAGGCCGGAACCTA-3′ 
and 5′-AGGTTGGCCCCGCTGGCATAGAGGGAGTC-3′. Reactions were performed using 
a LightCycler® 480 real-time PCR system and respective SYBR Green I Master kit (Roche, 
Burgess Hill, UK). Analysis was performed according to the manufacturer’s protocol. Values 
representing galectin-9, Tim-3 and LPHN1 mRNA levels were normalised against β-actin. 
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3.17 Determination of PKC-α activity 
The catalytic activity of PKC-α was measured based on its ability to phosphorylate specific 
substrate (such as Histone IIIS) (Micol, et al., 1999). Briefly, ELISA plates were initially coated 
with 0.2 mg/ml Histone IIIS. Then the samples mixed with reaction buffer (20 mM Tris-HCl 
(pH 7.5), 200 µM CaCl2, 5 mM MgCl2 and 20 µM ATP) at ratio 1:5 were added to the wells 
and the plate was incubated for 30 minutes at 37°C. After washing with TBST, Histone IIIS 
phosphorylation was determined spectrophotometrically employing molybdenum blue reaction 
(Nagul, 2015). The values obtained from this colorimetric assay were then normalised against 
total protein present in each sample. 
3.18 Measurement of phospholipase C (PLC) activity 
The activity of PLC was determined based on the ability of this enzyme to catalyse hydrolysis 
of the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) with consequent formation 
of diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). 
30 µL of cell or tissue lysates were mixed with 70 µL of assay buffer containing PIP2 (20 mM 
Tris-HCl buffer (pH 7.2), 0.1% sodium deoxycholate, 300 µM CaCl2, 100 µM EDTA, 100 mM 
NaCl) and incubated for 60 minutes at 37°C. After the incubation, to 100 µL of the sample 
obtained were added 100 µL of organic phase (heptane/isopropanol in ratio 13:7). The mixtures 
obtained were then left to reform the biphasic system. Extracted organic phase was then 
combined with lysis buffer and sample buffer and subjected to gel electrophoresis on 33% 
PAGE. PIP2 and its cleaved components were the visualised on PAGE employing blue 
toluidine staining. 
3.19 In-cell assay (also known as on-cell assay) 
The in-cell assay (ICA) was employed to characterise surface presence of Tim-3, galectin-9 
and CD8. Briefly, the cells were suspended in the culturing medium containing primary 
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antibodies against one of the target proteins and left to react for at least 3 h under constant 
agitation at room temperature. After washing with PBS or tissue culture medium, the cells were 
re-suspended in the fresh media containing Li-Cor goat secondary antibodies and incubated for 
at least 2 hours under constant agitation at room temperature. The cells were then washed and 
placed in a microtitre plate, which was scanned using Li-Cor Odyssey imaging system. Cells 
incubated only in presence of specific secondary antibody were employed as negative control. 
Li-COR on cell assay was also used to characterise the interaction of RL-1 antibody with the 
surface of THP-1 cells. 
3.20 Confocal microscopy and imaging flow cytometry 
THP-1 cells were grown on 12 mm cover slips in 24-well plates. Cells were treated overnight 
with PMA and then fixed/permeabilised for 20 min with ice-cold methanol (MeOH) or 
MeOH/acetone (purissimus). Alternatively, cells were fixed in a freshly prepared 2% 
paraformaldehyde, washed 3 times with PBS and then permeabilised with 0.1% triton X-100. 
Cover slips were then blocked for 1h at RT with 10% goat serum in PBS. 1 µg/ml anti-Tim-3 
antibody and anti-galectin-9 antibody were used as primary antibodies and incubated overnight 
at 4°C. Goat-anti-mouse Alexa Fluor 488 and goat-anti-rabbit Alexa Fluor 555 were used as 
secondary antibodies. Cells were incubated with secondary antibodies for 45 min at RT. The 
preparations were examined on Olympus laser scanning confocal microscope as described 
(Prokhorov et al., 2015; Fasler-Kan et al., 2010). Images were then collected and analysed 
using proprietary image acquisition software. Imaging flow cytometry was performed in 
accordance with a previously described protocol (Fasler-Kan et al., 2016). Briefly, 
permeabilised cells were stained with mouse anti-Tim-3 and rabbit anti-galectin-9 antibodies 
for 1 hour at room temperature. Goat anti-mouse Alexa Fluor 647 and goat-anti-rabbit Alexa 
Fluor 488 were used as secondary antibodies. Images were collected and analysed using 
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IDEAS analytical software on ImageStream X mark II (Amnis-EMD-Millipore, USA). This 
method described in Gonçalves Silva et al., 2017. 
For Tim-3-galectin-9 co-localisation assay in breast tissue slices, image acquisition, a Nikon 
A1si laser scanning confocal microscope was allied with a Plan Fluor DIC 40x magnifying, 
1.3-numerical aperture (N.A.) oil-immersion objective. NIS Elements software (version 
3.21.03, Nikon, Tokyo, Japan) was used to analyse the data. Cell images were acquired in three 
channels for DAPI (excitation at 399 nm with laser power 10 arbitrary units [AU], emission 
collection at 450 nm; nuclei labelling), Alexa Fluor 488 (excitation wavelength 488 nm with 
laser power 10 AU and, emission wavelength at 525 nm (corresponds to a green channel, 
galectin-9), Alexa Fluor 555 (excitation 561 nm with laser power 10 AU, emission collection 
at 595nm, red channel, Tim-3), with a photomultiplier tube gain of 100 AU. No offset was 
used, and pinhole size was set between 1.2 and 2 times the Airy disk size of the used objective, 
depending on the strength of a signal. This method is described in Yasinska et al., 2019. 
3.20.1 Tim-3 and galectin-9 characterisation in THP-1 cells 
THP-1 cells were cultivated in 12 mm cover glasses in 24-well plates. Cells were treated with 
phorbol 12-myristate 13-acetate (PMA) and fixed/permeabilised for 20 min with ice-cold 
methanol or a mixture methanol/acetone. Alternatively, cells were fixed in a freshly prepared 
2% paraformaldehyde, washed 3 times with PBS and permeabilised with 0.1%TX-100.   
Cover glasses were blocked for 1 hour at room temperature with 10% goat serum in PBS. The 
plates were then incubated overnight at 4°C with 1 µg/ml of anti-Tim-3 and anti-galectin-9 
antibodies. After washing, the cells were incubated for 45 min at room temperature with goat-
anti-mouse Alexa Fluor 488 and goat-anti-rabbit Alexa Fluor 555 secondary antibodies. 
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The preparations were examined using the Olympus laser scanning confocal microscope as 
described previously (Prokhorov et al., 2015). Obtained images analysed using the proprietary 
image acquisition software. 
3.20.2 Tim-3 and galectin-9 characterisation in primary human breast tissues 
Tissue sections were obtained using a freezing microtome with the cutting thickness of 5-6 µm. 
Each tissue section was sliced onto a poly-D-lysine-coated microscope slide (BDH). Acquired 
slides were then incubated in 3% H2O2 for 15 minutes to block endogenous peroxidase activity. 
Subsequently, the slides were permeabilised using PBS containing 0.26% Triton for 20 minutes 
at room temperature and blocked for at least 30 minutes in the blocking buffer (PBS, 0.05% 
Tween, 2% serum, 1% BSA). After blocking, the slides were incubated with anti-Tim-3 and 
anti-galectin-9 antibodies diluted in the blocking buffer (1:2000 dilution) for 2 h at room 
temperature. Then, the slides were washed three times with PBS and incubated in the dark for 
1 h with anti-IgG-FITC-labelled secondary antibody (1:400 dilution). Slide washing was then 
followed by Fluoro-Gel mounting media containing DAPI nuclei-staining reagent. Negative 
controls were prepared by incubating the slides with secondary antibody alone. Images were 
obtained employing Confocal Laser Scanning Microscopy (BioRad Hercules). 
For image acquisition, a Nikon A1si laser scanning confocal microscope was used with a Plan 
Fluor DIC 40x magnifying, 1.3-numerical aperture (N.A.) oil-immersion objective. NIS 
Elements software (version 3.21.03, Nikon, Tokyo, Japan) was employed for data analysis. 
Cell images were acquired in three channels for DAPI (excitation at 399 nm with laser power 
10 arbitrary units [AU], emission collection at 450 nm; nuclei labelling), Alexa Fluor 488 
(excitation wavelength 488 nm with laser power 10 AU and, emission wavelength at 525 nm 
(corresponds to a green channel, galectin-9), Alexa Fluor 555 (excitation 561 nm with laser 
power 10 AU, emission collection at 595nm, red channel, Tim-3), with a photomultiplier tube 
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gain of 100 AU. No offset was used, and pinhole size was set between 1.2 and 2 times the Airy 
disk size of the used objective, depending on signal strength. 
3.21 Fluorescence-activated cell sorting (FACS) 
Surface presence and total cellular levels of Tim-3 and galectin-9 were characterised using 
FACS. The cells were initially fixed with freshly prepared 2% paraformaldehyde, washed 3 
times with PBS and permeabilised with 0.1% TX-100. The cells were then incubated with 
mouse anti-Tim-3 and rabbit anti-galectin-9 antibodies overnight at 4ºC. Goat anti-mouse 
Alexa Fluor 647 and goat-anti-rabbit Alexa Fluor 488 were employed as secondary antibodies. 
Target protein characterisation was then analysed using FACS Calibur cytometer with 
CellQuestPro software (Becton Dickinson, USA). 
3.22 Synchrotron radiation circular dichroism spectroscopy (SRCDS) 
The interactions of Tim-3 with galectin-9 as well as the binding of LPHN1 and LPHN2 with 
FLRT3 were characterised employing SRCD spectroscopy at beamline B23, Diamond Light 
Source (Didcot, UK) [Figure 23]. 
SRCD measurements of human recombinant Tim-3 and human recombinant galectin-9 were 
performed using 0.2 μg/ml of samples in 10 cm path length cell, 3 mm aperture diameter and 
800 μl capacity using Module B with 1 nm increment, 1 s integration time, 1.2 nm bandwidth 
at 23 °C (Hussain, et al., 2012; Siligardi & Hussain, 2015). These macromolecules were 
analysed alone and as a mixture (with stoichiometry of 1:1 molar ratio). 
SRCD measurements of soluble extracellular fragment of LPHN1, LPH-51, alone or in 
combination with human recombinant FLRT3 (equimolar ratio) were carried out using 0.01 
µM sample of soluble LPH-51 in a 1 cm path length cell of 3 mm aperture diameter and 60 μl 
capacity using a Module B instrument with 1 nm increment, 1 s integration time and 1.2 nm 
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bandwidth at 23 ºC. Similarly, human recombinant LPHN2 (olfactomedin-like domain, 
MyBioSource, San Diego, Ca, USA) was analysed alone or mixed with FLRT3 by SRCD 
spectroscopy. In this case SRCD measurements were performed using 0.7 µM samples.  
The results obtained were processed using CDApps (Hussain et al., 2015) and OriginLab™. 
 
Figure 23: Beam light 23 at Diamond Light Source Synchrotron and scheme of Synchrotron 




3.23 Leukaemia cell protection assay 
K562 (chronic myeloid leukaemia cells not releasing galectin-9) and NK cells were cultivated 
separately or as a 1:2 co-culture (K562: NK) for 16 h, at 37°C, in the presence or absence of 
0.5 - 5 ng/ml of galectin-9. The unfixed cell cultures were then imaged under an inverted 
microscope (TE200, Nikon), using phase-contrast lighting, a digital camera and the WinFluor 
image acquisition software (J. Dempster, University of Strathclyde). 
Images were acquired at different focal planes and analysed using the ImageJ software. Since 
K562 cells are significantly larger than NK cells, it was possible to identify each cell type both 
in mono-cultures and in co-cultures, by optimising the ranges of particle sizes during automatic 
particle counting. Additionally, illumination correction, background substraction, overlapping 
cell separation, and particle size optimization were applied using ImageJ software. 
3.24 Statistical Analysis 
Each experiment was performed at least three times. Statistical analysis of the results obtained 
was performed using two-tailed Student’s t-test, when comparing two events at a time. One-
way ANOVA test was employed instead for multiple comparisons. Where applicable, a post-
hoc Bonferroni correction was used. Statistical probabilities (p) reflecting significant 
differences between individual events were expressed as * where p<0.05, ** where p<0.01 and 





4. Tim-3-galectin-9 immunosuppressive pathway and its 
pathophysiological role 
Recently it has been discovered that Tim-3-galectin-9 pathway is involved in the immune 
system suppression (Golden-Mason et al., 2013; Gonçalves Silva, Rüegg, Gibbs, Bardelli, 
Fruewirth, et al., 2016; Kikushige et al., 2015; F. Wang et al., 2007). However, the mechanisms 
implicated in the activation of biosynthesis of the components of the Tim-3-galectin-9 pathway, 
galectin-9 secretion and its effects on cytotoxic lymphocytes (NK cells and T cells) remain 
unclear. 
4.1 Free and galectin-9-bound Tim-3 are shed differentially from the cell surface  
It has been previously reported that Tim-3 can be shed from the cell surface by proteolytic 
enzymes, such as a disintegrin and metalloproteinase domain-containing proteins (ADAM) 
10/17 (Clayton et al., 2015; Möller-Hackbarth et al., 2013).  Therefore, proteolytic shedding 
was proposed as possible mechanism of secretion of both Tim-3 and Tim-3-galectin-9 complex 
by AML cells.  
For this reason, THP-1 cells were cultured for 16 h in presence or in absence of 100 nM phorbol 
12-myristate 13-acetate (PMA), compound known to induce proteolytical shedding of Tim-3 
from the cell surface and galectin-9 release (possibly consequent to the proteolysis of Tim-3-
galectin-9 complex expressed on the membrane) (Chabot et al., 2002; Möller-Hackbarth et al., 
2013). After the incubation, immunoprecipitation from the culture media was performed 
employing 96-well plates coated with mouse single-chain antibody against Tim-3 and the 
precipitate was extracted as described in Materials and Methods. Obtained extracts were then 
subjected to Western blot analysis. Following the incubation with anti- galectin-9 antibody, 
specific bands were detected at ~32 kDa (the molecular weight of galectin-9) and ~52 kDa 
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[Figure 24 A]. Following the incubation with anti-Tim-3 antibody, specific bands appeared at 
~33 kDa (the molecular weight of soluble Tim-3 – sTim-3), ~20 kDa and ~52 kDa [Figure 24 
A]. The fact that the band at 52 kDa is detectable by both antibodies suggests that it corresponds 
to the unbroken Tim-3-galectin-9 complex. Moreover, Tim-3 fragment of 20 kDa is likely to 
be shed in complex with galectin-9 (~32 kDa) from the cell surface and then disassociated from 
its ligand during the Western blot procedure. Therefore, Tim-3 is probably shed at different 
cleavage sites when bound to galectin-9 (Tim-3 band at 20 kDa) and when expressed on the 
cell surface in absence of its natural ligand (Tim-3 band at 33 kDa). Consequently, different 
enzymes should be involved in its surface shedding. 
To verify this hypothesis, ADAM 10/17 were investigated. The aim was to find out whether 
these proteases are involved in the release of free Tim-3 fragment and/or galectin-9-Tim-3 
complex. Thus, THP-1 cells were cultured for 16 h with or without 100 nM PMA, a compound 
known to upregulate the expression of proteolytic enzymes and other proteins. After 16 h of 
incubation, PMA-containing medium was removed and replaced with the fresh medium 
containing 100 µM GI254023X (ADAM 10 and 17 inhibitor) or 100 µM BB-94 (a matrix 
metalloproteinase inhibitor) and the cells were incubated for further 4 h. The levels of galectin-
9 and Tim-3 released in the media were then determined by ELISA kits as described in 
manufacturer’s protocol, while the concentration of soluble Tim-3-galectin-9 complex was 
measured using a single-chain anti-Tim-3 antibody for capturing and biotinylated anti-galectin-
9 antibody for detecting as outlined in Materials and Methods. Obtained data showed that PMA 
treatment significantly increased the release of Tim-3, galectin-9 and Tim-3-galectin-9 
complex [Figure 24 B]. However, subsequent treatment with protease inhibitors, GI254023X 
and BB-94, reduced the levels of soluble Tim-3 in the media but did not influence the release 
of galectin-9 and Tim-3-galectin-9 complex [Figure 24 B]. This suggests that different 




Figure 24: Tim-3 is shed differentially from the cell surface depending if expressed in complex with galectin-9 or as a free transmembrane protein. Following 
the treatment of THP-1 cells with 100 nM PMA for 16 h, the media was exchanged with the fresh one containing 100 µM GI254023X (ADAM10/17 inhibitor) 
or 100 µM BB-94 (matrix metalloproteinase inhibitor) and incubated for 4 h. (A) The media collected after 16 h of incubation was subjected to 
immunoprecipitation and Western blot analysis for galectin-9 and Tim-3 detection (as outlined in Material and Methods). (B) The media collected after 20 h of 
incubation (all the samples) was subjected to ELISA for galectin-9, Tim-3 and galectin-9-Tim-3 complex detection. Images are from one experiment 
representative of six which gave similar results. Quantitative data are mean values ±SEM (n=6) *p < 0.05; **p < 0.01 vs. control.
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Intracellular levels of Tim-3 and galectin-9 in THP-1 cells untreated and treated with PMA 
were also characterised employing Western blot analysis. The data obtained showed that 
despite the increase in the release of sTim-3, galectin-9 and Tim-3-galectin-9 complex by THP-
1 cells, the intracellular levels of these proteins decreased [Figure 25]. In addition, a specific 
band detectable by both anti-Tim-3 and anti-galectin-9 antibodies appeared at ~70 kDa 
(molecular weight corresponding to the sum of uncleaved Tim-3 and galectin-9) [Figure 25]. 
These results suggest that the complex between full Tim-3 and galectin-9 (~70 kDa) is first 
formed intracellularly and undergoes proteolytical shedding only after being expressed on the 





Figure 25. PMA induces generation and/or release of Tim-3, galectin-9 and Tim-3-galectin-9 complex. Following the treatment of THP-1 cell 
with 100 nM PMA (16 h incubation), secreted and intracellular levels of galectin-9, Tim-3 and Tim-3-galectin-9 complex were characterised by 
ELISA and Western blot. Comparative analysis (expressed in % control) of galectin-9 and Tim-3-galectin-9 complex levels secreted by PMA-
treated and untreated THP-1 cells are illustrated in the bar diagram on the top. Images are from one experiment representative of three which gave 
similar results. Quantitative data are mean values ±SEM (n=3) *p < 0.05; **p < 0.01; ***p < 0.001 vs. control.
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The presence of Tim-3-galectin-9 complex in THP-1 cells was also verified by co-localization 
assays using confocal microscopy [Figure 26]. Following PMA treatment and 
paraformaldehyde fixation, non-permeabilised and methanol-permeabilised THP-1 cells were 
analysed.  Areas full of either Tim-3 or galectin-9 were detected on non-permeabilised cells. 
However, no substantial co-localisation of these two proteins was observed on THP-1 cell 
surface. On the other hand, clear evidence of Tim-3 and galectin-9 co-localization was found 
in permeabilised cells [Figure 26]. 
 
Figure 26: Co-localization of Tim-3 and galectin-9 in THP-1 cells. PMA-activated and 
paraformaldehyde-fixed cells were analysed using confocal microscopy for the detection of Tim-3 
and/or galectin-9. Images are from one experiment representative of six which gave similar results. 
The results obtained by confocal microscopy were also confirmed using imaging flow 
cytometry: Tim-3 and galectin-9 were found co-localised in PMA-treated and permeabilised 





Figure 27: Co-localization of galectin-9 and Tim-3 in THP-1 cells upon PMA activation. THP-1 cells 
stimulated with PMA were permeabilized and subjected to imaging flow cytometry as described in 
Materials and Methods. Images represent six selected single cells.  
The fact that the Tim-3-galectin-9 complex is detectable intracellularly, but not on the cell 
surface can be explained by the incapacity of the antibody to interact with the extracellular part 
of Tim-3 when it is bound to galectin-9 due to steric hindrance. Indeed, since galectin-9 is 
soluble, it is reasonable to assume that it must be bound to a transmembrane protein (such as 
Tim-3) in order to remain on the cell surface. 
Taken together these results indicate that Tim-3 can be externalised on its own or can act as a 
trafficker for galectin-9, which does not have the signal domain necessary for secretion and 
thus requires a trafficker for its surface expression. 
Tim-3 and galectin-9 were then analysed in plasma samples obtained from 98 AML patients 
and from 12 healthy donors. It was found that the levels of galectin-9 and Tim-3 were 
significantly higher in AML patients’ blood plasma compared to healthy donors’ ones [Figure 




Figure 28: Levels of galectin-9, sTim-3 and soluble Tim-3-galectin-9 complex are significantly higher in blood plasma of AML patients compared to that 
of healthy donors.  Galectin-9 and Tim-3 concentrations in blood plasma of 98 AML patients and of 12 healthy donors were analysed by ELISA (A, B, E and 
F). Five randomly chosen plasma samples of each group were used for Tim-3-galectin-9 ELISA-based detection (C and G). Five randomly selected blood 
plasma obtained from AML patients and healthy donors were sonicated, boiled for 5 minutes at 95⁰ C and subjected to Western blot analysis (D). Correlations 
between the levels of Tim-3 and galectin-9 as well as Tim-3-galectin-9 complex and galectin-9 in blood plasma were determined for both healthy donors (H 
and J) and AML patients (I and K). Images are from one experiment representative of five which gave similar results. Quantitative data are mean values ±SEM 
(n=3) *p < 0.05; **p < 0.01; ***p < 0.001 vs. control.
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Tim-3-galectin-9 complex was also characterised employing ELISA (as previously described) 
using five randomly selected plasma samples from the group of studied AML patients and five 
from the group of healthy donors. It was found that the levels of Tim-3-galectin-9 complex 
were significantly greater in AML patients and the grade of this elevation was similar to that 
of galectin-9 [Figure 28 C and G]. In addition to ELISA-based detection, Tim-3 and galectin-
9 were characterised by Western blot analysis using five randomly chosen plasma samples 
from each group. The bands corresponding to galectin-9 (32 kDa), Tim-3 fragment (20 kDa) 
and sTim-3 (33 kDa) appeared following the incubation with anti-Tim-3 or anti-galectin-9 
antibodies. A clear band at ~52 kDa was detected by both anti-Tim-3 and anti-galectin-9 
antibody. These results match those obtained with THP-1 cells and reinforce the theory 
according to which soluble Tim-3 and Tim-3 complexed with galectin-9 are differentially shed 
from plasma membranes of AML cells. Additionally, the correlations obtained between Tim-
3 and galectin-9 concentrations as well as Tim-3-galectin-9 complex and galectin-9 levels in 
blood plasma of both healthy donors and AML patients suggest a co-release of both proteins 
in both cohorts [Figure 28 H, I, J and K]. 
Recently, it has been shown by surface plasmon resonance (SPR) analysis that galectin-9 can 
bind non-glycosylated Tim-3 with nanomolar affinity (Kd= 2.8x108 M). However, this 
interaction is even greater if Tim-3 is glycosylated (Prokhorov et al., 2015). This is in line with 
the fact that galectin-9 is a β-galactoside binding protein and thus interacts strongly with 
glycosylated proteins, such as Tim-3. Schematic representation of Tim-3 and galectin-9 
structures is illustrated in Figure 29A. 
Galectin-9-Tim-3 interaction was also analysed by synchrotron radiation circular dichroism 
(SRCD) spectroscopy at Diamond Light Source. Galectin-9 and Tim-3 were mixed to a 




Figure 29: Interaction of Tim-3 with galectin-9 leads to major conformational changes increasing 
solubility of the protein complex. Galectin-9 (right) and extracellular domain of Tim-3 (left) are 
schematically represented in panel A. In Tim-3 structure, amino acid residues involved in galectin-9-
independent binding are highlighted in green., while those which can be potentially glycosylated are 
shown in red. In galectin-9 structure, sugar molecules possibly involved in the binding with the 
glycoprotein and located close to the close to the carbohydrate binding sites are illustrated in green (A). 
The SRCD spectroscopy of Tim-3, galectin-9 and Tim-3-galectin-9 interaction (both simulated and real 
curves are presented) (B). 
CD spectrum obtained after mixing galectin-9 with Tim-3 was significantly different from the 
simulated spectrum. This indicates that significant conformational changes occur in these 
proteins upon the binding. In particular, a clear increase in β-strand component was observed. 
These results suggest that Tim-3 may alter the conformation of galectin-9 leading to its 
increased ability to interact with other receptors in target cells. Indeed, galectin-9 is tandem 
protein containing two carbohydrate recognition domains (CRDs) and thus one sugar-binding 
domain could bind Tim-3 (or other proteins) leaving the other CRD free to interact with another 
transmembrane receptor of a target cell. 
4.2 Latrophilin 1, PKC-α and mTOR-dependent translation are crucial for Tim-3 
and galectin-9 production and secretion 
Recently it was discovered that the neuronal receptor LPHN1 is expressed in AML cells, but 
is absent in healthy leukocytes (Sumbayev et al., 2016). 
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To investigate whether LPHN1 triggering is involved in Tim-3 and galectin-9 expression, THP-
1 cells were exposed to 250 pM α-latrotoxin (α-LTX), a highly specific and potent ligand of 
LPHN1, for 16 hours. Obtained lysates were then subjected to Western blot and the media was 
analysed by ELISA. It was found that the levels of intracellular galectin-9 and Tim-3 were 
downregulated (though not significantly), while the secretion of these proteins was drastically 
increased [Figure 30 B and D]. 
Similar results were also obtained when THP-1 cells were exposed to 100 nM PMA, specific 
PKC-α activator [Figure 30 A and D]. Therefore, one-hour pre-treatment with 70 nM Gö6983 
(PKC-α inhibitor) before the exposure to PMA or LTX was performed. It was found that 70 
nM Gö6983 treatment following the exposure to PMA or LTX downregulated both secreted 
and intracellular levels of Tim-3 and galectin-9 [Figure 30 A, B and D]. However, basic release 
of galectin-9 and Tim-3 wasn’t affected by Gö6983 suggesting that it is PKCα independent 
[Figure 30 D]. 
It has been also shown that PMA promotes the activation of mTOR, a kinase essential for AML 
cell survival and proliferation (Gonçalves Silva et al., 2016; Prokhorov et al., 2015; Roux, et 
al., 2004). Therefore, the phosphorylation rate of mTOR in position Ser2448 (active form) was 
also investigated in these cell lysates. It was found that both PMA and LTX significantly 
increased the phosphorylation of mTOR at 2448. This stimulus-induced mTOR activation was 
attenuated when THP-1 cells were pre-treated with Gö6983 following the exposure to PMA or 
LTX. Interestingly, the level of phosphor-S2448-mTOR after the incubation with just Gö6983 





Figure 30: LPHN1, PKCαand mTOR pathways are involved in Tim-3 and galectin-9 production and secretion in AML cells. THP-1 cells were exposed to 
100 nM PMA or 250 pM LTX for 16 h with or without 1 h pre-treatment with the PKCα inhibitor Gö6983 (A, B, D) or the mTOR inhibitor AZD2014 (C, D). 
Cellular levels of Tim-3 and galectin-9 were characterised by Western blot. The p-S2448 mTOR was measured by ELISA. Secreted Tim-3 and galectin-9 were 
detected by ELISA. Images are from one experiment representative of three which gave similar results. Quantitative data are the mean values ± SEM of three 
independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate differences vs. PMA and LTX-






To prove mTOR involvement in galectin-9 and Tim-3 production, THP-1 cells were pre-treated 
with 10 μM AZD2014 (a highly selective mTOR inhibitor), before the exposure to 100 nM 
PMA or to 250 µM α-LTX. It was found that 1 h pre-treatment of THP-1 cells with mTOR 
inhibitor followed by the exposure to PMA or LTX, reduced intracellular Tim-3 and galectin-
9 levels as well as release of both proteins [Figure 30 C and D]. This suggests that PMA or 
LTX-induced translation of galectin-9 and Tim-3 depends on the mTOR pathway. Importantly, 
the solvents employed to dissolve pharmacological inhibitors had no effect on any of the 
studied protein levels or their secretion (data not shown). 
To validate obtained results, primary human AML mononuclear blasts AML-PB001F were 
exposed for 24 h to 250 pM LTX. Western blot analysis showed that AML-PB0011F expressed 
LPHN1, which production wasn’t changing upon the incubation with LTX [Figure 31 B]. 
Secreted levels of galectin-9 and Tim-3 were significantly increased in LTX-treated AML cells 
[Figure 31 A] confirming the findings obtained in THP-1 cells. 
 
Figure 31: LTX induces Tim-3 and galectin-9 release in primary human AML cells. Primary human 
AML blasts (AML-PB001F) were incubated for 24 h with 250 pM LTX. The media was then subjected 
to ELISA for galectin-9 and Tim-3 detection (A). Harvested cells after the incubation were lysed and 
subjected to Western blot analysis and LPHN1 expression was characterised (B). Images are from one 
experiment representative of six which gave similar results. Quantitative data are mean values ± SEM 
of six independent experiments; **p < 0.01 vs. control. 
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Recently it was found that FLRT3 is one of the physiological ligands of LPHN1 (Boucard, 
2014). Thus, THP-1 cells were incubated with 10 nM FLRT3 for 16 h. It was found that FLRT3 
induced significant upregulation of galectin-9 and sTim-3 release [Figure 32 A]. To confirm 
that this effect was physiologically relevant, THP-1 cells were also exposed for 16 h to mouse 
bone marrow (mBM) extracts (containing FLRT3) [Fig. 32 B] with or without 1h pre-treatment 
with 5 μg/ml FLRT3 neutralizing mouse antibody. It was found that galectin-9 and sTim-3 
secretion by THP-1 cells was significantly increased after the exposure to mBM extract. 
However, this upregulation was attenuated, but not completely blocked, by FLRT3 neutralising 
antibody [Figure 32 B]. This suggests that BM contains, in addition to FLRT3, other inducers 
of galectin-9 secretion by AML cells. 
THP-1 cells were also co-cultured with FLRT3-expressing RCC-FG1 renal carcinoma cells in 
the ratio 1 : 2, respectively [Figure 32 C]. The cells were incubated for 16 h in the absence or 
presence of 5 μg/ml FLRT3 neutralizing antibody. The levels of galectin-9 and sTim-3 secreted 
in the media were measured by ELISA. It was found that the presence of RCC-FG1 cells 
significantly increased galectin-9 and sTim-3 release and FLRT3 neutralization attenuated 
these effects [Figure 32 C]. Since RCC-FG1 cells release almost undetectable amounts of 
galectin-9 and Tim3, the concentrations of these proteins in the media can be attributed quite 
exclusively to their secretion by THP-1 cells. These results confirm that FLRT3 stimulates the 





Figure 32: FLRT3 induces galectin-9 and Tim-3 secretion in THP-1 cells. (A) THP-1 cells were treated for 16 h with 10 nM extracellular domain of human 
recombinant FLRT3. The concentrations of galectin-9 and Tim-3 in the media obtained were determined by ELISA. (B) THP-1 cells were incubated with mouse 
bone marrow (mBM) extracts (10 µg protein/ml) for 16 h with or without 1 h pre-treatment with 5 μg/ml anti-FLRT3 antibody. The presence of FLRT3 in 
mBM extracts was confirmed by Western blot analysis. The levels of Tim-3 and galectin-9 released in the media were measured by ELISA. (C) The presence 
of FLRT3 was also confirmed in RCC-FG1 cells by Western blot analysis. RCC-FG1 cells were co-cultured with THP-1 cells at a ratio of 1 THP-1:2 RCC-
FG1 with or without 1 h pre-treatment with 5 μg/ml FLRT3 neutralizing antibody. The levels of Tim-3 and galectin-9 released in the media were measured by 
ELISA. Images are from one experiment representative of three which gave similar results. Quantitative data depict mean values ± SEM of three independent 
experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate differences vs. cells treated with mBM 




In addition, PKCα activity was determined (as outlined in materials and methods) in THP-1 
cells treated as described above. It was found that PMA, LTX and FLRT3 significantly 
upregulated PKCα activity [Figure 33 A]. Similarly, PKCα activity was increased in THP-1 
cells when co-cultured with RCC-FG1 cells; this effect was attenuated in presence of anti-
FLRT3 neutralising antibody [Figure 33 B]. These results indicate that FLRT3 induces 
galectin-9 secretion in THP-1 cells in PKCα-dependent manner. 
 
Figure 33: PMA, LTX and FLRT3 upregulate PKCα activity in THP-1 cells. (A) PKCα activity was 
analysed in resting THP-1 cells as well as those exposed for 16 h to 100 nM PMA, 250 pM LTX and 
10 nM FLRT-3. (B) PKCα activity was analysed in resting THP-1 cells and those co-cultured with 
RCC-FG1 cells (ratio 1 THP-1: 2 RCC-FG1) in the absence or presence of 5 µg/ml FLRT-3 neutralising 
antibody. Images are from one experiment representative of three which gave similar results. 
Quantitative data are mean values ± SEM of three independent experiments; *p < 0.05; **p < 0.01 vs. 
control. Symbol “bb” indicates p<0.01 vs. THP-1/RCC-FG1 co-culture. 
4.3 Galectin-9 protects AML cells from NK cell killing activity 
Recently, Tim-3 was found to be expressed in NK cells. In addition, it was shown that the 
exposure to galectin-9 (soluble or cell-surface associated) in presence or absence of anti-Tim-
3 antibody influences IFN-γ release by NK cells (Gleason et al., 2012). Thus, it has been 
speculated that Tim-3-galectin-9 interaction might be involved in the creation of 
immunological synapses between target cells and cytotoxic lymphoid cells. 
To investigate this hypothesis, LAD2 human mast cell sarcoma cells (expressing both Tim-3 
and galectin-9) and primary human NK cells were employed.  
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Comparative analysis of total and cell-surface levels of Tim-3 and galectin-9 suggest that these 
proteins are predominantly expressed on the membrane rather than inside LAD2 cells [Figure 
34]. In addition, it was found that resting LAD2 cells don’t secrete detectable amounts of 
galectin-9 but its release can be induced by IgE. Contrarily, intracellular levels of galectin-9 
and Tim-3 don’t change considerably when LAD2 cells are exposed to IgE [Figure 34].   
 
Figure 34. LAD2 cells express and externalize Tim-3 and galectin-9. Left panel: the levels of cell 
surface and total Tim-3 and galectin-9 in LAD2 cells were measured using LICOR in cell assay (ICA, 
non-permeabilized cells) and in cell Western (ICW, permeabilized cells). Right panel: LAD2 cells were 
cultured in presence or absence of 0.1 μg IgE; Tim-3 and galectin-9 intracellular levels were measured 
by Western blot analysis, while the amount of secreted galectin-9 was characterised by ELISA. Images 
are from one experiment representative of three which gave similar results. Quantitative data show 
mean values ± SEM of three independent experiments; ***p b 0.001 vs. control. 
Primary human NK cells instead express Tim-3 (several glycosylation variants) but do not 




Figure 35: Primary human NK cells express Tim-3 but don’t produce detectable amounts of galectin-
9 in primary human NK cells. Expressions of both proteins were analysed in whole cell extracts by 
Western blot. Human recombinant galectin-9 was used as a positive control (PC). Images are from one 
experiment representative (two donors in each) of three which gave similar results. 
Primary human NK cells were immobilised on ELISA plates and co-cultured in presence or 
absence of IgE-sensitized LAD2 cells (Sumbayev, et al., 2012) at a ratio of 1:1 with or without 
15 min pre-incubation with galectin-9 neutralizing antibody. To exclude IgG involvement in 
synapsis formation, LAD2 and NK cells were also incubated with isotype control antibody 
instead of anti-galectin-9 one [Figure 35].  
Since LAD2 cells, express high affinity IgE receptors (FcεRI), which are not present in NK 
cells, specific detection of LAD2 cells was possible by incubating the plate with IgE, and 
following incubations with mouse IgM anti-IgE and then anti-mouse LI-COR secondary 
antibody (the scheme of the experiment is illustrated in Figure 36). 
It was found that LAD2 cells bind NK cells and the presence of galectin-9 neutralizing antibody 
(but not isotype control antibody) abolished this effect [Figure 36]. These results confirm that 




Figure 36: Galectin-9 participates in the formation of an “immunological synapse” between NK 
cells and LAD2 cells. Primary human NK cells were immobilized on the surface of Maxisorp plates. 
Cells were then co-cultured for 30 min with LAD2 cells with or without 30 min pre-treatment of LAD2 
cells with 5 μg/ml galectin-9 neutralizing antibody (or the same amount of isotype control antibody). 
LAD2 cells were then visualized using LI-COR assay as outlined in Materials and Methods. Images are 
from one experiment representative of five which gave similar results. Quantitative data represent mean 
values ± SEM of five independent experiments; *p < 0.05; **p < 0.01. 
To attest whether these immunological synapses participate or not in the prevention of AML 
cell killing by cytotoxic immune cells, the co-culture of K562 (chronic myeloid leukaemia 
cells, not secreting galectin-9) with NK cells was analysed.  
K562 cells were grown for 24 h in RPMI media containing 100 nM PMA. After the treatment 
of K562 cells with PMA (24 h), the media was replaced with the fresh one containing primary 
human NK cells at ratio of 1 K562:2 NK in the absence or presence of 5 ng/ml human 
recombinant galectin-9. Following 16 h of co-incubation, MTS test was performed to 
determine the cell viability of both cell lines. It was found that K562 viability was significantly 
decreased when co-cultured with NK cells in absence of galectin-9. This reduction was 
attenuated in presence of galectin-9 [Figure 37 A]. On the other hand, NK cells viability wasn’t 




Figure 37: Galectin-9 protects myeloid leukaemia K562 cells from being killed by primary human 
NK cells. K562 cells were incubated for 24 h with PMA in 96-well Maxisorp plates. (A) After 24 h, 
PMA-containing media was replaced with the media containing primary human NK cells. K562 and 
NK cells were then co-cultured (at ratio 1:2) for 16 h in the absence or presence of 5 ng/ml galectin-9. 
Viability of K562 and NK cells was measured using MTS test. Images are from one experiment 
representative of three which gave similar results. Quantitative data represent mean values ± SEM (n=3) 
independent experiments; ***p < 0.001 vs. control. (B) K562 cells co-incubated for 16 h with primary 
human NK cells, at a 1:2 ratio, in presence or absence of galectin-9 5 ng/ml. Cells were imaged using 
phase-contrast microscopy. The images are from one representative experiment of six (n = 6), which 
gave similar results. Scale bar (the same for all images), 50 μm. (C) NK cells induced aggregation of 
K562 cells was quantified as a function of galectin-9 concentration. Left, the per cent of cells found in 
aggregates in individual cultures and in the co-culture. Right, the size of cell aggregates in individual 
cultures and in the co-culture. The data represent the mean values ± SD of six independent experiments; 
*, p < 0.05; **, p < 0.01; ****, p < 0.0001 
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In addition, the cells (grown alone and in co-culture) with or without 5 ng/ml galectin-9 were 
visualised using phase contrast microscopy. Images obtained showed that NK cells induce the 
formation of massive K562 aggregates in absence of galectin-9. Indeed, none of the cell lines 
formed visible aggregates if cultured alone with or without galectin-9 [Figure 37 B]. Also, NK 
cell-induced aggregation of K562 cells was abrogated when the cells were co-cultured in 
presence of 5 ng/ml galectin-9 [Figure 37 B]. This effect was quantified using increasing 
concentrations of galectin-9 (in the range 0 – 5 ng/ml) in the co-culture. The data obtained 
showed that K562 aggregation induced by NK cells decreased in presence of galectin-9 in dose-
dependent manner until no K562 cell aggregation was detectable when galectin-9 concentration 
reached 5 ng/ml [Figure 37 C]. Thus, galectin-9 clearly protects myeloid leukaemia cells from 
being killed by NK cells.  
The interactions between AML THP-1 cells and NK cells were then investigated. THP-1 cells 
were treated with 100 nM PMA for 16 h. After the pre-treatment of THP-1 cells, their culture 
medium was replaced with PMA-free medium containing NK cells (ratio of 2 NK cells:1 THP-
1 cells) and the cells were co-incubated for 6 h with or without 5 μg/ml galectin-9-neutralising 
antibody. After the incubation, granzyme B and caspase-3 activities as well as the cell viability 
of THP-1 cells were characterised as described in Materials and Methods. It was found that the 
viability of THP-1 cells was significantly reduced when co-cultured with NK cells in presence 
of anti-galectin-9 neutralising antibody. The stimulation of AML cell death by NK cells was 
also confirmed by increased granzyme B and caspase-3 activities in THP-1 cells when co-
incubated in presence of anti-galectin-9 neutralising antibody [Figure 38]. However, the levels 
of galectin-9 secreted by THP-1 cells (measured by ELISA) didn’t change considerably in any 
of described conditions (galectin-9 bound to neutralising antibody was also detectable by 
ELISA) [Figure 38]. 
 95 
 
In addition, cell lysates of isolated NK cells were subjected to Western blot analysis for specific 
detection of Tim-3 and galectin-9. It was confirmed that resting NK cells don’t produce 
detectable amounts of galectin-9. However, this protein on its own, and in the form of unbroken 
Tim-3-galectin-9 complex, was detectable in NK cells co-cultured with THP-1 cells. 
Furthermore, the levels of both, galectin-9 alone and in complex with Tim-3, were significantly 
reduced when the cells were co-incubated in the presence of galectin-9 neutralising antibody 
[Figure 38]. These results suggest that galectin-9 detected in NK cell lysates is most likely to 
derive from THP-1 cells, which release high amounts of this protein in the culture media. Once 
secreted, galectin-9 is able to bind to Tim-3 present on NK cell surface preventing granzyme 




Figure 38: Cell-derived galectin-9 attenuates AML cell killing activity of primary human NK cells. 
PMA pre-treated THP-1 cells were co-cultured with primary human NK cells at 1:2 ratio for 6 h. After 
the incubation, MTS test was performed on isolated THP-1 cells. Granzyme B and caspase 3 activity 
was also characterised in THP-1 cell lysates as described in Materials and Methods (left panel). Galetin-
9 levels in the media were measured using ELISA (left panel). NK cells were subjected to Western blot 
analysis for specific detection of galectin-9 and Tim-3 (right panel). Images are from one experiment 
representative of three which gave similar results. Quantitative data show mean values ± SEM of three 
independent experiments; *p < 0.05; **p < 0.01; ***p < 0.001 vs control. 
In addition to galectin-9 function in inhibition of cytotoxic activity of NK cells (as described 
above), sTim-3 has been suggested to participate in the attenuation of cell-mediated immune 
response (Geng et al., 2006). Indeed, it was found that sTim-3 is able to attenuate immune cells 
proliferation and to reduce the secretion of IL-2, a cytokine, which activates cytotoxic activity 
of NK cells and T cells (Geng et al., 2006). 
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Since the levels of sTim-3 are considerably higher in the plasma AML patients compared to 
healthy donors [Figure 28 B], comparative analysis of IL-2 concentration between two groups 
was also performed. It was found that IL-2 levels are significantly lower in AML patients 
compared to healthy donors [Figure 39 A and B]. To confirm Tim-3 involvement in the 
reduction of IL-2 secretion by the immune cells, Jurkat T cells (producing detectable amounts 
of IL-2) were treated with increasing concentrations of sTim-3 for 24h. It was found significant 
downregulation of IL-2 secretion by Jurkat T cells in presence of increasing concentrations of 
sTim-3. These results suggest that sTim-3 is also involved in the immune escape of AML cells. 
 
Figure 39: Soluble Tim-3 attenuates IL-2 release. (A and B) The levels of IL-2 in blood plasma 
obtained from AML patients and healthy donors were measured by ELISA. (C) Jurkat T cells were 
treated with increasing concentration of Tim-3 for 24 h. After the treatment the media was subjected to 
ELISA for IL-2 detection. Data show mean values ± SEM of three independent experiments; *p < 0.05; 
**p < 0.01. 
4.4 Discussion 
AML cells are able to suppress anti-tumour immunity, but the biochemical mechanisms 
involved in this immune escape remain unclear. Recent evidences suggest that Tim-3 and 
galectin-9, two proteins highly secreted by AML cells, may participate in attenuation of NK 
and T cell cytotoxic activities (Golden-Mason et al., 2013; Gonçalves Silva, et al., 2016; 
Kikushige et al., 2015). However, stimuli required for Tim-3 and galectin-9 expression by 
AML cells as well as their release from the cell surface are poorly understood.  
It is known that galectin-9 lacks the signalling sequence necessary for its secretion and thus 
requires a trafficker in order to be expressed on the membrane or released by the cell (Delacour, 
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et al., 2009).Tim-3 has been proposed as a possible trafficker of galectin-9 (Gonçalves Silva, 
et al., 2016). 
Our results reinforced the assumption according to which Tim-3 is a galectin-9 trafficker. Tim-
3-galectin-9 complex was detected inside the cell (70 kDa) and in the culture media (52 kDa) 
[Figure 24 and 25]. Indeed, the bands at 70 kDa (cell lysates) and at 52 kDa (media) were 
recognised by both anti-Tim-3 and anti-galectin-9 antibodies. However, when the same blot 
was incubated sequentially with both antibodies, the second antibody failed to detect the 
respective protein in the same band (unless the first antibody is stripped off) due to steric 
hinderance. Moreover, confocal microscopy co-localisation analysis confirmed the presence of 
Tim-3-galectin-9 complex inside permeabilised THP-1 cells. Contrarily, surface presence of 
the complex wasn’t detectable by both antibodies using confocal microscopy co-localisation 
analysis [Figure 26]. This is in line with the previous observation (impossibility to detect the 
same band by sequential incubation with anti-Tim-3 and anti-galectin-9 antibodies and vice 
versa). In fact, when the complex is expressed on the cell surface, Tim-3 is covered by galectin-
9 and thus can’t bind anti-Tim-3 antibody (steric hinderance).  
The interaction of Tim-3 with galectin-9 was also characterised by SRCD spectroscopy. We 
found that the interaction between Tim-3 and galectin-9 leads to major conformational changes 
in these proteins [Figure 29]. In particular, a clear increase in β-strand has been observed. This 
suggests that Tim-3 binding alters galectin-9 conformation, possibly increasing its ability to 
interact with the target proteins. Since galectin-9 is a tandem protein containing two sugar-
binding domains, one of them could bind Tim-3 expressed on the membrane of AML cell, 
leaving the other sugar-binding domain free to interact with Tim-3 (or another receptor) present 
on the membrane of the target cell (e.g., NK cell).  
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Previously it was also reported that PKC-α is involved in the secretion of both Tim-3 and 
galectin-9 (Chabot et al., 2002). We confirmed these findings. PKC-α activation led to mTOR-
dependent synthesis of galectin-9 and Tim-3 as well as their increased release by THP-1 cells 
[Figure 24, 25 and 30].  The release of Tim-3-galectin-9 complex was also found to be 
considerably augmented following PKC-α activation in THP-1 cells [Figure 34, 25 and 30]. 
Tim-3 has been reported to be shed from the cell surface by ADAM 10/17 (Möller-Hackbarth 
et al., 2013). Therefore, we investigated whether these proteolytic enzymes are involved in the 
shedding of Tim-3 in its free form and/or in complex with galectin-9.  We found that ADAM 
10/17 contribute to considerably increased secretion of free Tim-3 (sTim-3), but don’t induce 
any significant changes in Tim-3-galectin-9 release from THP-1 cell surface [Figure 24]. 
Therefore, different proteolytic enzymes are involved in the shedding of Tim-3 depending 
whether it is bound or not to galectin-9. This deduction was also confirmed by the fact that two 
distinct bands were specifically detected by anti-Tim-3 antibody at 20 kDa and at 33 kDa in 
the blot containing immunoprecipitated media used for THP-1 cell culture. Since the band at 
~52 kDa was recognised by both anti-Tim-3 and anti-galectin-9 antibodies and the molecular 
weight of galectin-9 is ~32 kDa, the band at 20 kDa is likely to represent the fragment of Tim-
3 that is shed from the cell surface when this Ig is associated with galectin-9. Diversely, when 
Tim-3 is expressed on the membrane without galectin-9, it is shed at a different site and thus 
has a different molecular weight (~33 kDa) when compared to the fragment (frTim-3) partially 
dissociated from the complex during gel electrophoresis [Figure 24]. 
Recently it was discovered that LPHN1, a G-protein coupled neuronal receptor, is expressed 
in AML cells but is absent in healthy leukocytes. Moreover, triggering of LPHN1 in myeloid 
leukaemia cells was found to induce the secretion of IL-6, cytokine promoting survival and 
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proliferation of AML cells (Sumbayev et al., 2016). Therefore, the involvement of LPHN1 in 
galectin-9 and Tim-3 exocytosis was investigated.  
We found that both natural (FLRT3) and exogenous (LTX-α) ligands of LPHN1 induced 
mTOR-dependent synthesis of Tim-3 and galectin-9 as well as their exocytosis in AML cells 
[Figure 30, 31 and 32]. Moreover, LPHN1 triggering increased also PKC-α activity in AML 
cells [Figure 33]. PKC-α has been reported to induce the formation of SNARE complex 
responsible for exocytosis (Morgan et al., 2005; Stöckli, et al., 2011). Therefore, our results 
suggest that FLRT3, found to be physiologically expressed in the bone marrow [Figure 32], 
can interact with LPHN1 expressed by AML cells inducing galectin-9 and Tim-3 synthesis and 
their abundant secretion consequent to PKC-α activation. Thus, the presence of LPHN1 in 
AML cells, but not in healthy leukocytes, may explain considerably higher levels of Tim-3, 
galectin-9 and of the complex formed by these proteins in the blood plasma of AML patients 
when compared to healthy donors’ ones [Figure 28]. Importantly, high galectin-9 plasma levels 
have been correlated with lower overall survival rates in patients affected by myelodysplastic 
syndromes (MDS), a group of blood disorders frequently progressing to AML (Asayama et al., 
2017). In addition, AML cells expressing constitutively active PKC-α were also associated 
with poor prognosis and high mortality rate (Kurinna et al., 2006).  
Interestingly, increased PKC-α activation in THP-1 co-cultured with RCC-FG1 cells 
(expressing FLRT3) was abolished by FLRT3 neutralising antibody [Figure 33]. This is in line 
with the fact that FLRT3-induced increase of secreted galectin-9 and Tim-3 by THP-1 cells 
when co-incubated with RCC-FG1 cells was also abolished by FLRT3 neutralising antibody 
[Figure 32 C]. Diversely, FLRT3 neutralising antibody significantly reduced, but not 
abolished, PKC-α-induced increase of secreted galectin-9 and Tim-3 by THP-1 cells incubated 
with bone marrow [Figure 32 B]. This suggests that bone marrow may contain, in addition to 
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FLRT3, other PKC-α activating proteins, which can bind AML membrane receptors (LPHN1 
or others) and induce synthesis and exocytosis of Tim-3 and galectin-9.  
Once expressed on the cell surface or released in the culture media, galectin-9 protects AML 
cells from the immune attack. Indeed, the cell viability of K562 cells (chronic myeloid 
leukaemia cells not releasing detectable amounts of galectin-9) was significantly reduced by 
NK cells. On the other hand, cytotoxic activity of NK cells was abolished when the co-culture 
was performed in the presence of human recombinant galectin-9 [Figure 37].  
Galectin-9 involvement in the protection of AML cells from the immune attack was then 
confirmed using THP-1 cells co-cultured with NK cells in presence or absence of neutralising 
anti-galectin-9 antibody [Figure 38]. Indeed, the cell viability of THP-1 cells (expressing on 
their surface and releasing high amounts of galectin-9) was significantly decreased in presence 
of anti-galectin-9 neutralising antibody. 
It is known that NK cell cytotoxic activity consists mainly in the release of the granules 
containing granzyme B, which leads to the activation of caspase 3 inside the target cell and 
thus provokes apoptosis of malignant cells (as described in the Introduction). We found that 
the activities of both enzymes were significantly augmented in THP-1 cells when the co-culture 
was performed in presence of anti-galectin-9 neutralising antibody. This confirms that NK cells 
kill AML cells through the delivery of granzyme B inside the malignant cells. Our results 
suggest also that galectin-9 interacts with Tim-3 exposed on the membrane of NK cells (which 
don’t express galectin-9) preventing granzyme B delivery into AML cells.  
Possible mechanism through which galectin-9 binding to Tim-3 expressed on NK cell surface 
prevents the release of cytotoxic granules containing Granzyme B is illustrated in Figure 40. It 
is based on the recent finding regarding the capability of galectin-9 to induce NK cells to release 
IFN-γ (Gleason et al., 2012). The binding of IFN-γ with its respective receptor expressed on 
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the surface of AML cells leads to the activation of indoleamine 2,3-dioxegenase (IDO1), an 
enzyme which converts L-tryptophan into formyl-L-kynurenine, which is then converted into 
L-kynurenine (Corm et al., 2009; Folgiero et al., 2015; Mabuchi et al., 2016). This intermediate 
of tryptophan catabolism is then converted to L-kynurenine, which attenuates cytotoxic NK 
cell activity through the prevention of granzyme B delivery into AML cells. 
 
Figure 40: Possible biochemical interactions between AML and NK cells. Triggering of LPHN1 leads 
to the surface expression and release of galectin-9 by AML cells. Cell surface-associated or secreted 
galectin-9 binds then to the NK cell receptor (likely – Tim-3). This interaction induces NK cells to 
release of IFN-γ, which stimulates IDO1 to convert tryptophan (Trp) into formyl-kynurenine (FKU) 
inside AML cells. FKU is then further degraded into L-kynurenine (KU), which can be released by 
AML cells. KU attenuates the ability of NK cells to deliver granzyme B into AML cells in 
perforin/mannose-6-phosphate receptor (MPR)-dependent manner. If successfully delivered, granzyme 
B catalyses the cleavage of the protein Bid into tBid, which leads to mitochondrial disfunction with 
consequent release of cytochrome c from the mitochondria into the cytosol of malignant cells. Once 
liberated in the cytosol, cytochrome c induces apoptosome formation leading to the activation of 
caspase-3. Furthermore, granzyme B is capable of performing direct proteolytic activation of caspase-
3. These effects lead to AML cell apoptosis. However, this process is not taking place in presence of 
galectin-9, which impairs NK cell cytotoxic activity as described above. 
In addition to galectin-9-associated immune escape, we found that AML cells protect 
themselves from cytotoxic attack through the secretion of Tim-3. Our results suggest that 
soluble Tim-3 is capable of binding a target protein (or a group of target proteins) expressed 
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by T cells leading to their decreased secretion of IL-2, a cytokine required for activation of NK 
cells and cytotoxic T lymphocytes. This is in line with the results obtained from comparative 
analysis of sTim-3 and IL-2 levels in blood plasma of AML patients and healthy donors (HD). 
Indeed, we found considerably higher levels of sTim-3 and significantly lower concentration 
of IL-2 in the blood plasma of AML patients when compared to HD [Figure 28 and 39]. 
Schematic representation of the pathway derived from previously described findings is 







Figure 41: Pathobiochemical pathway allowing AML cells to escape host anti-cancer immunity. The 
interaction of FLRT3, expressed on the surface of endothelial cells (EC), with AML surface receptor, 
LPHN1, leads to the activation of Gq which then stimulates PLC. Activated PLC catalyses the 
hydrolysis of phosphatidyl-inositol-bisphosphate (PIP2) into inositol-trisphospate (IP3) and 
diacylglycerol (DAG). IP-3 is then able to bind ER-associated IP3 receptor (IP3R) leading to Ca2 + 
mobilization. Released IP3 and DAG activate PKC-α, which triggers mTOR translational pathway 
through downregulation of TSC1/TSC2. This leads to increased synthesis of galectin-9 and Tim-3. In 
addition, PKCα phosphorylates protein Munc18 leading to the formation of SNARE complexes, which 
tether cytosolic vesicles to the plasma membrane. This pre-activates the release machinery, and elevated 
cytosolic Ca2 + lead to exocytosis of free and galectin-9-associated Tim-3. Once expressed on the 
membrane of AML cells, both types of Tim-3 are differentially shed from the cell surface by proteolytic 
enzymes. Galectin-9 impairs the ability of NK cells to kill AML cells, while sTim-3 attenuates the 
release of IL-2, cytokine required for the activation of immune cells. 
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5. AML cells recruit normal physiological systems to progress 
the disease by preserving expression of stem cell proteins 
As previously described (Section 4.2), triggering of LPHN1, expressed in AML cells but not 
in healthy leukocytes, upregulates the expression and the secretion of Tim-3 and galectin-9 in 
AML cells allowing these malignant cells to escape host immune attack. However, the 
mechanisms underlying the regulation of LPHN1 expression in AML cells remain unclear. In 
addition, the presence of LPHN1 natural ligand (FLRT3) in blood hasn’t been investigated yet. 
5.1 Hematopoietic stem cells (HSCs) produce LPHN1, expression of which is 
preserved in malignant AML cells but not in healthy leukocytes 
Recently, LPHN1 mRNA was detected in primary human CD34-positive stem cells (Maiga et 
al., 2016). Thus, LPHN1 protein expression was also investigated in them. Western blot 
analysis confirmed the presence of LPHN1 in hematopoietic stem cells (HSCs) [Figure 42]. 
Interestingly, the molecular weight of LPHN1 found in HSCs was slightly higher (~140 kDa) 
compared to the one detected in THP-1 cells (~130 kDa) [Figure 42] or in primary AML cells 
(~130 kDa) (Sumbayev et al., 2016).  
Since triggering of LPHN1 induces Tim-3 and galectin-9 synthesis in AML cells, the 
expression of these proteins was also investigated in HSCs. Contrarily to THP-1, neither Tim-






Figure 42: Characterisation of expression of LPHN1, Tim-3 and galectin-9 proteins in CD34-
positive human stem cells (HSCs) and THP-1 AML cells (positive control). Western blot analysis was 
employed for the detection of LPHN1, Tim-3 and galectin-9 proteins in CD34-positive HSCs and THP-
1 cells. Images are from one experiment representative of three which gave similar results. 
Comparative analysis of LPHN1 protein expression was then characterised in primary human 
AML cells, THP-1 cells and primary human leukocytes by Western blot analysis. As previously 
reported, LPHN1 wasn’t detectable by Western blot analysis in primary healthy leukocytes 
(Sumbayev et al., 2016). Clear bands were instead observed in the other two cell types and it 
was found that LPHN1 levels are considerably higher in primary human AML cells than in 




Figure 43: Comparative analysis of LPHN1 protein expression in primary human AML, THP-1 cells 
and PHL. Lysates of each cell type were subjected to Western blot analysis. Images are from one 
experiment representative of three which gave similar results. Data are the mean values ± SEM of three 
independent experiments; **p < 0.01 vs. AML cells. 
5.2 Cortisol induces LPHN1 expression in AML cells and HSCs, but not in healthy 
leukocytes 
Since AML cells and HSCs are typically present in the blood vessels or in bone marrow, the 
components normally circulating in the blood were taken under consideration as potential 
LPHN1 expression inducers. Cortisol, steroid hormone secreted in the bloodstream by adrenal 
glands, was proposed to stimulate LPHN1 expression in these cells. 
To investigate the effects of cortisol on LPHN1 transcription and translation, primary and THP-
1 human AML cells, primary human HSCs and primary healthy human leukocytes were 
incubated with 1 µM cortisol for 24 h. RNA extracts were then subjected to quantitative real-
time PCR (qRT-PCR) to characterise any changes in LPHN1 gene expression in the cells upon 
the exposure to 1 µM cortisol. Detectable amounts of LPHN1 mRNA were found in all the 
tested cell types, except primary healthy leukocytes, and in all these cases the levels were 




Figure 44: LPHN1 expression in human AML cells and haematopoietic stem cells, but not in primary 
healthy human leukocytes, is upregulated by cortisol. Primary human AML, THP-1 and 
haematopoietic stem cells as well as primary healthy leukocytes (PHL) were treated with 1 µM cortisol 
for 24 h. The levels of LPHN1 mRNA were measured by quantitative real-time PCR (A). LPHN1 
protein levels were characterised by Western blot analysis (B – primary AML cells, C – THP-1 cells 
and D – PHL). For PHL, lysates of LPHN1 overexpressing NB2A cells were used as a positive control. 
The concentrations of secreted galectin-9 were measured by ELISA (B, C, D). Images are from one 
experiment representative of four which gave similar results. Data represent mean values ± SEM for 
four independent experiments. *p < 0.05; **p < 0.01 vs. control. 
In addition, cell lysates of primary and THP-1 human AML cells, PHLs incubated for 24 h in 
presence or absence of 1 µM cortisol were subjected to Western blot analysis. It was found that 
LPHN1 protein levels were also upregulated by cortisol in primary and THP-1 human AML 
cells [Figure 44 B and C]. Contrarily, LPHN1 wasn’t detectable in PHLs by Western blot 




The influence of cortisol in galectin-9 release by these three cell types was also investigated. 
ELISA analysis showed that cortisol treatment didn’t provoke any changes in galectin-9 
secretion by any of these cell types [Figure 44 B, C and D]. This suggests that LPHN1 needs 
to be activated by a ligand to induce galectin-9 release by AML cells.  
Cortisol and galectin-9 concentrations were then measured in blood plasma of AML patients 
and healthy donors. It was found that both, cortisol and galectin-9, were significantly higher in 
blood plasma of AML patients compared to healthy donors one [Figure 45]. 
  
Figure 45: The levels of cortisol and galectin-9 are significantly higher in blood plasma of AML 
patients compared to healthy donors one. Blood plasma of ten healthy donors and ten AML patients 
was collected at the same time of the day to avoid the influence of circadian dynamics ensuring 
comparability of cortisol levels. The levels of cortisol (left panel) and galectin-9 (right panel) were 
measured by ELISA, and the correlation between these two proteins was analysed. Data are the mean 
values ± SEM of ten independent experiments.; *p < 0.05; **p < 0.01; ***p < 0.01  vs control. 
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In addition, no correlation between cortisol and galectin-9 levels was observed in the blood 
plasma of healthy donors. Contrarily, a clear correlation between the levels of these two 
proteins was found in the blood plasma of AML patients suggesting that galectin-9 secretion 
might be linked to LPHN1 expression in this circumstance. 
5.3 Soluble LPHN1 fragments are detectable in AML blood plasma 
Since LPHN1 is expressed on the membrane of blood cells, it can possibly undergo 
proteolytical shedding and be released in the bloodstream. To investigate this, blood plasma of 
AML patients was subjected to immunoprecipitation followed by Western blot analysis using 
several LPHN1 antibodies. A clear band at ~67-68 kDa was detectable by anti-LPHN1 
antibody [Figure 46 A]. Also, the bands having lower molecular weight were observed after 
the incubation with these antibodies. Thus, once expressed on AML cell membrane, LPHN1 
(~120 kDa) can be subjected to proteolytical shedding, which leads to the release of LPHN1 
fragments (of ~67-68 kDa and of lower molecular weight) in the bloodstream. None of these 
bands was, instead, detectable by Western blot analysis in the immunoprecipitated extracts 
obtained from the blood plasma of healthy donors [Figure 46 A].  
The presence of soluble LPHN1 fragments in the blood of AML patients, but not in the one of 






Figure 46: Soluble LPHN1 fragments are elevated in blood plasma of AML patients. Blood plasma 
of ten healthy donors and ten AML patients was subjected to immunoprecipitation employing Santa 
Cruz mouse monoclonal antibody as capture antibody. Obtained extracts were then subjected to 
Western blot analysis using rabbit anti-LPHN1 antibody (PAL-1 or Abcam anti-LPHN1 antibody) for 
detection (A). Specific detection of soluble LPHN1 fragments (in the same blood samples) was 
performed using ELISA as outlined in Material and Methods (B). Images are from one experiment 
representative of six which gave similar results. Data are the mean values ± SEM of ten independent 
experiments; *p < 0.05; **p < 0.01; ***p < 0.01 vs control. 
5.4 FLRT3 upregulates galectin-9 secretion in AML cells in a LPHN1-dependent 
manner 
As reported in Figure 32, FLRT3 induces galectin-9 secretion in THP-1 AML cells. To 
investigate whether this effect is LPHN1-associated or not, specific anti-LPHN1 neutralising 
antibody (clone name RL1) was employed.  
The specificity of this antibody was determined using THP-1 cells (expressing high amounts 
of LPHN1 on their surfaces) and NB2A cells, which don’t express LPHN1, as a negative 
control. The interaction of the antibody with THP-1 cell surface receptors, but with NB2A 
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ones, was characterised by Li-Cor on-cell assay (as described in Materials and Methods) 
[Figure 47].  
 
Figure 47: On cell detection of cell surface presence of rabbit polyclonal antibody recognising 
LPHN1 (clone name RL1). LPHN1 negative NB2A cells (negative control) and THP-1 cells were 
subjected to on cell assay using anti-rabbit Li-Cor secondary antibody. Images are from one experiment 
representative of three which gave similar results. 
To confirm neutralising properties of RL1, THP-1 cells were incubated in presence and absence 
of 1 µg/ml RL1 antibody for 16 h. After the incubation, the levels of secreted galectin-9 were 
measured by ELISA. It was found that galectin-9 secretion levels weren’t affected by RL-1 
antibody (data not shown), suggesting that this antibody doesn’t exert an LPHN1 agonistic 
effect. 
After assessing the specificity and neutralising properties of RL1 antibody, the involvement of 
LPHN1 in galectin-9 secretion by THP-1 AML cells was explored. THP-1 cells were incubated 
for 16 h with or without 10 nM FLRT3. This treatment was performed with or without 1 h pre-
exposure to 1 µg/ml RL1 antibody. After the incubation the levels of galectin-9 released in the 
culture media were measured by ELISA. It was found that RL1 antibody attenuated FLRT3-
induced galectin-9 release in THP-1 cells [Figure 48 A], confirming the involvement of LPHN1 
in this process. In addition, this assumption was further reinforced by the fact that FLRT3 
treatment didn’t upregulate galectin-9 release in primary healthy leukocytes (cells not 







Figure 48: FLRT3, component normally circulating in blood plasma, induces galectin-9 secretion in 
AML cells in a LPHN1-dependent manner. THP-1 cells and PHL were exposed to 10 nM human 
recombinant FLRT3 for 16 h followed by detection of secreted galectin-9 levels by ELISA. In THP-1 
cells, the treatment was performed with or without 1 h pre-exposure to 1 µg/ml RL1 anti-LPHN1 
polyclonal antibody (A). The levels of secreted FLRT3 and its fragments were analysed in the blood 
plasma of healthy donors and AML patients using Western blot (B). THP-1 cells were exposed for 16 
h to 10% blood plasma either from healthy donors or AML patients with or without pre-treatment with 
FLRT3 neutralising antibody. Levels of secreted galectin-9 were analysed using ELISA (C). Data are 
shown as mean values ± SEM from four independent experiments; *p < 0.05; **p < 0.01 vs. control. 
Blood plasma obtained from both, AML patients and healthy donors, was then subjected to 
Western blot analysis for specific detection of FLRT3. The bands at ~55 kDa and ~27-28 kDa 
were specifically detected by anti-FLRT3 antibody in both groups [Figure 48 B]. These bands 
correspond to soluble fragments of FLRT3, which are likely to be shed from the cell surface 
by proteolytic enzymes. Interestingly, the blood plasma from both, AML patients and healthy 
donors, contained approximately equal amounts of both FLRT3 fragments [Figure 48 B]. 
To investigate whether these blood-associated FLRT3 fragments are able to stimulate galectin-
9 secretion by AML cells in a LPHN1-dependent manner, THP-1 cells were cultured in RPMI 
1640 media containing antibiotics (as outlined in Materials and Methods) and 10 % blood 
plasma from either AML patients or healthy donors (instead of 10% FBS). THP-1 cells were 
incubated for 16 h with or without a 30 min pre-exposure to anti-FLRT3 neutralising antibody. 
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The concentration of galectin-9 released in culture media was then measured by ELISA. It was 
found that the levels of galectin-9 secreted by THP-1 cells were significantly higher when the 
cells were cultured with 10 % blood plasma than in presence of 10 % FBS (negative control). 
In addition, anti-FLRT3 neutralising antibody attenuated galectin-9 secretion [Figure 48 C]. 
FLRT3-LPHN1 interaction was also characterised using SRCD spectroscopy. CD spectrum 
obtained after mixing FLRT3 with LPHN1 was significantly different from the simulated 
spectrum suggesting that considerable conformational changes occur in these proteins upon the 
binding [Figure 49]. 
 
Figure 49: Interaction of FLRT3 with LPHN1 leads to significant conformational changes. SRCD 
spectroscopy of FLRT3, LPHN1 FLRT3-LPHN1 interaction (both simulated and real curves are 
presented). 
5.5 Discussion 
Taken together, our results demonstrate that cortisol upregulates LPHN1 expression in AML 
cells. Cortisol is a glucocorticoid hormone produced by the adrenal gland in response to 
numerous stimuli such as stress and energetic deficiency (Torpy & Chrousos, 1996). 
In AML, rapid progression of this malignancy leads to decreased glucose levels (Gonçalves 
Silva, Rüegg, Gibbs, Bardelli, Fruewirth, et al., 2016) and thus the HPA axis is continuously 
stimulated to release high amounts of cortisol in the bloodstream. This is in line with the fact 
that significantly higher cortisol levels were found in the blood of AML patients compared to 
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healthy donors one [Figure 45]. After being released, cortisol is employed by AML cells to 
upregulate their surface expression of LPHN1, which can then interact with FLRT3, an 
endogenous ligand of LPHN1 widely available in blood plasma, leading to the upregulation of 
galectin-9 release. The latter protects AML cells from cytotoxic immune cells (as outlined in 
Chapter 4) [Figure 50]. Thus, AML cells use crucial components of functional systems within 
the body to support their survival and attenuate anti-cancer activities of cytotoxic lymphoid 
cells. 
Interestingly, hematopoietic stem cells contain detectable amounts of LPHN1 mRNA and its 
transcription is also upregulated by cortisol [Figure 44]. Protein expression of LPHN1 was also 
detected in HSCs [Figure 42]. However, HSCs-associated LPHN1 has a higher MW (~140 
kDa) than AML-associated one (~120 kDa). Moreover, contrarily to AML cells, HSCs don’t 
express detectable amounts of galectin-9 and Tim-3 [Figure 42]. Thus, in HSCs, LPHN1 should 
be involved in different biochemical mechanisms. 
PHLs, instead, are able to synthesise and release detectable amounts of galectin-9, but this 
process occurs in a LPHN1-independent manner. Indeed, neither mRNA nor protein expression 
of LPHN1 were detectable in PHLs. In addition, cortisol didn’t induce LPHN1 
transcription/translation, possibly because of gene repression. 
Importantly, LPHN1 fragments were clearly detectable by both, Western blot and ELISA, in 
the blood plasma of AML patients but not in healthy donors. This difference in the composition 
of blood plasma can be exploited in the future for a faster AML diagnosis, although differential 






Figure 50: Physiological cross-links leading to cortisol-induced upregulation of LPHN1 expression 
in AML cells followed by facilitation of galectin-9 secretion in a FLRT3-dependent manner. AML is 
associated with a decreased blood plasma glucose levels, which normally leads to upregulation of 
secretion of corticotropin-releasing hormone (CTRH) by hypothalamus. CTRH induces secretion of 
adrenocorticotropic hormone (ACTH) by pituitary gland. Secreted ACTH upregulates cortisol 
production by the adrenal cortex, thus leading to cortisol-induced upregulation of LPHN1 levels in 
AML cells. Galectin-9, secreted in FLRT3-LPHN1-dependent manner attenuates anti-cancer activity 






6. AML cells employ stress and danger signals to support 
overall malignant cell survival and proliferation 
Recently, it was found that the blood of AML patients contains significantly higher HMGB1 
concentration when compared to healthy donors. Moreover, AML cells were shown to express 
high levels of HMGB1, possibly because of the conditions associated with AML progression, 
which support its secretion (such as hypoxia and death of the cells in the tumour 
microenvironment) (Tang et al., 2017; Yu et al., 2012; Zhang, et al., 2017).  
As previously described (in the introduction), released HMGB1 can interact with several 
surface receptors, including TLR2, TLR4, RAGE and Tim-3 (highly expressed in AML cells). 
However, the role of HMGB1 in AML progression remains unclear. 
6.1 The effects induced in human AML cells by HMGB1 stimulation 
It has been reported that triggering of TLR2, TLR4, RAGE and Tim-3 induces the activation 
of several pathways including PI-3K/mTOR pathway in AML cells. Moreover, activation of 
this pathway has been shown (1) to upregulate production and secretion of a variety of 
cytokines including TNF-α and (2) to induce HIF-1α accumulation, which leads to increased 
glycolysis and angiogenesis (Nicholas, et al., 2011; Prokhorov et al., 2015; Silva, et al., 2015; 
Sumbayev & Nicholas, 2010; Yasinska, et al., 2014). However, the involvement of HMGB1 
on signalling events above described remains hypothetic and it hasn’t been investigated yet in 
AML cells. 
To explore this, THP-1 cells, expressing Tim-3 mostly at intracellular level rather than on the 
membrane [Figure 51, left panel], and primary human AML cells (AML-PB001F), expressing 




Figure 51: Differential receptors are involved in HMGB1-induced biological responses of human 
AML cells. Total levels of the immune receptor Tim-3 and its surface presence were characterised in 
THP-1 and primary human AML-PB001F cells by in-cell Western (ICW) and in-cell (on-cell) assay 
(ICA) respectively. Both cell types were exposed to 1 µg/ml HMGB1 for 4 h with or without 1 h pre-
treatment with single chain anti-Tim-3 antibody (aTim-3 (-)) followed by Western blot analysis of 
phospho-S65 vs total eIF4E-BP1, HIF-1α and RAGE expression as well as by detection of phospho-
S2448 mTOR, release of TNF-α and VEGF using ELISA. PI-3 K activity was monitored by 
colorimetric assay. Images are from one experiment representative of five which gave similar results. 
Data is shown as mean values ± SEM of five independent experiments. * p < 0.05; **, p < 0.01 and *** 
when p < 0.001 vs control; a p< 0.05; aa, p < 0.01 vs HMGB1. 
To investigate specifically Tim-3-associated effects, the cells were exposed for 4 h to 1 µg/ml 
HMGB1 with or without 1 h pre-treatment with single-chain anti-Tim-3 neutralising antibody. 
Increased activation of PI-3K was found in both, THP-1 and primary human AML cells, upon 
HMGB1 stimulation and this effect was non-significantly downregulated by anti-Tim-3 
neutralising antibody [Figure 51]. Moderate activation of mTOR (phosphorylation at S2448) 
 119 
 
and increased phosphorylation of mTOR substrate eukaryotic initiation factor 4 E binding 
protein 1 (eIF4E-BP1) were observed in both cell types following the incubation with HMGB1. 
Pre-treatment with anti-Tim-3 neutralising antibody didn’t provoke any changes in these 
processes.  
A moderate increase in mTOR phosphorylation in Ser2448 residue (active form) was also 
observed in both cell types after the treatment with HMGB1. In line with this finding, 
augmented phosphorylation of eIF4E-BP (one of mTOR substrates) was found in AML cells 
after the incubation with HMGB1. Moreover, significant increase in TNF-α secretion by both 
cell types was induced by HMGB1. The pre-treatment with anti-Tim-3 neutralising antibody 
didn’t affect any of these HMGB1-induced processes, suggesting that these effects are Tim-3-
independent [Figure 51]. 
In addition, HMGB1 induced the upregulation of Hif-1α accumulation in THP-1 cells but not 
in primary human AML cells [Figure 51]. This difference in Hif-1α accumulation can be 
explained by the fact that primary human AML cells possess high background levels of this 
transcription factor subunit and thus are incapable to respond to HMGB1. Despite this, a 
significant upregulation in VEGF secretion was observed in both cell types after HMGB1 
treatment. Interestingly, anti-Tim-3 neutralising antibody significantly attenuated HMGB1-
induced VEGF secretion, but did not reduce Hif-1α accumulation in AML cells. The level of 
downregulation in VEGF secretion was proportional to the amount of Tim-3 present on the 
surface of each cell type [Figure 51]. Intracellular levels of VEGF weren’t affected by anti-
Tim-3 neutralising antibody as confirmed by ELISA performed on the cell lysates (data not 
shown). These results suggest that HMGB1 induces VEGF release in AML cells by triggering 
Tim-3 receptor expressed on their surface. 
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Highly sensitive spectroscopic analysis of HMGB1-Tim-3 interactions confirmed that these 
two proteins interact with each other specifically. The SRCD spectrum of Tim-3/HMGB1 
mixture (at ratio 1 : 1) was significantly different from the simulated spectrum (obtained by 
summing SRCD spectra of the individual components), suggesting that complex formation 
causes considerable conformational change of the proteins with a clear increase in α-helical 
content [Figure 52 B]. SRCD spectroscopy was also employed to determine its binding affinity. 
200 nM HMGB1 was titrated with increasing amounts of Tim-3 and the changes in CD signal 
were monitored at 222 nm. The values of obtained CD signals were plotted against increasing 
Tim-3 concentrations and it was found that HMGB1 binds Tim-3 with high affinity (Kd is 
coming at nanomolar level 10−7 M) [Figure 52 A]. 
 
Figure 52: HMGB1 binds Tim-3 with a high binding affinity. Recombinant, purified Ig-like V-type 
domain of human Tim-3 (residues 22–124) and human HMGB1 were employed for these experiments. 
Interaction of HMGB1 protein with Tim-3 was analysed using SRCD spectroscopy-based titration 
which was conducted in the far UV region using 0.2 µM HMGB1 and increasing stoichiometric 
concentrations of Tim-3 (A). Changes in CD signal monitored at 222 nm were plotted against Tim 3 
concentration using Hill function. Qualitative binding was verified by analysis of interactions of 
equimolar concentrations of Tim-3 and HMGB1 using SRCD spectroscopy (B). 
As shown above, HMGB1-induced TNF-α secretion by AML cells doesn’t occur via Tim-3 
receptor [Figure 51]. Thus, other AML receptors binding HMGB1 were explored as possible 
inducers of TNF-α secretion. As previously described, AML cells express TLR2 and TLR4. 
 121 
 
RAGE expression in AML cells was confirmed by Western blot analysis. Thus, THP-1 cells 
were exposed for 4 h to 1 µg/ml HMGB1 with or without 1 h pre-treatment with 2 µg/ml 
neutralising antibodies directed against TLR2, TLR4 and RAGE. It was found that TLR2 and 
TLR4, but not RAGE, are involved in HMGB1-induced TNF-α secretion [Figure 53]. 
However, it does not rule out the fact that during long-term exposure RAGE might contribute 
to HMGB1-induced intracellular TNF-α expression which can be upregulated by RAGE 
ligands (Rashid, et al., 2004). 
 
Figure 53: TLRs 2 and 4, but not RAGE, are involved in HMGB1-induced TNF-α secretion. THP-1 
cells were pre-treated for 1 h with the indicated concentrations of TLR2/4 and RAGE-neutralising 
antibodies followed by 4 h exposure to 1 µ/ml HMGB1. TNF-α concentrations were then measured in 
the culture medium by ELISA. Data are shown as mean values ± SEM for three independent 
experiments. * p<0.05; **, p<0.01 vs control; a p<0.05; aa, p<0.01 vs HMGB1. 
6.2 HMGB1 stimulates TNF-α secretion by human AML leading to upregulation 
of SCF production 
The effects of HMGB1-induced TNF-α were studied in primary healthy human leukocytes 
(PHLs). Cell culture medium containing TNF-α (obtained after the stimulation of THP-1 cells 
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with 1 µg/ml HMGB1) was employed to treat PHLs for 4 h with or without 1 h pre-treatment 
with 2 µg/ml TNF-α-neutralising antibody. After the incubation, IL-1β concentration was 
measured in the media by ELISA. It was found that in the absence of TNF-α-neutralising 
antibody, PHL released IL-1β, while in the presence of TNF-α-neutralising antibody PHL did 
not release detectable amounts of IL-1β [Figure 54 A]. 
Recently, it was reported that MCF-7 breast cancer epithelial cells express IL-1 receptor type 
1 and its triggering induces these cells to release stem cell factor (SCF) (Wyszynski, et al., 
2016). Therefore, MCF-7 cells were cultured for 24 h in the media containing IL-1β (obtained 
after culturing PHL in presence of TNF-α) with or without 2 µg/ml of IL-1β-neutralising 
antibody. After the incubation, collected media was subjected to ELISA for SCF detection. It 
was found that, in the presence of IL-1β-neutralising antibody, MCF-7 did not release 
detectable amounts of SCF, while in the absence of it SCF release was clearly detectable 
[Figure 54 A].  
Taken together, these results suggest HMGB1 induces the release of TNF-α by AML cells. 
TNF-α stimulates IL-1β secretion by PHL. Released IL-1β binds IL-1 receptor expressed by 
endothelial/epithelial cells and induces the release of SCF is required for proliferation of AML 
cells and thus supports leukaemia progression. 
To confirm that this effect was physiologically relevant, mouse bone marrow cells (ex vivo) 
were culture for 24 h in presence or absence of 1 µg/ml HMGB1. It was found that HMGB1 





Figure 54:HMGB1 triggers an intercellular signalling cascade leading to SCF secretion. (A) Primary human AML cells (AML-PB-001F) were incubated  
for 4 h  with 1 µg/ml HMGB1 followed by collection of the culture medium (detection of TNF-α was performed in this medium using ELISA), which was used 
to culture primary human healthy leukocytes for 4 h in the absence or presence of TNF-α-neutralising antibody. Medium was collected (levels of IL-1β were 
measured by ELISA) and used to culture MCF-7 breast cancer epithelial cells for 4 h in the absence or presence of IL-1β-neutralising antibody. Following this 
exposure, medium was collected and SCF was measured in it by ELISA. (B) Primary mouse bone marrow cells (106 cells per 3 ml medium) were exposed for 
24 h to 1 µg/ml HMGB1 followed by detection of TNF-α, IL-1β and SCF by ELISA. (C – I). Levels of TNF-α, IL-1β and SCF were measured in the blood 
plasma of healthy donors and AML patients by ELISA. Mean values ± SEM are presented as well as levels of each protein in blood plasma of each analysed 
donor/patient. *p < 0.05; **p< 0.01 vs control. 
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The concentrations of TNF-α, IL-1β and SCF were then also measured in blood plasma of 10 
healthy human donors and 45 AML patients. It was found the levels of all three factors were 
significantly higher in the blood plasma of AML patients compared to healthy donors [Figure 
54 C – I]. In addition, a clear evidence of correlation between IL-1β vs TNF-α, SCF vs IL-1β 
and SCF vs TNF-α was observed in the blood plasma of both healthy donors and AML patients 
which contained detectable amounts of all the studied cytokines/SCF [Figure 54 C and 55].  
 
Figure 55: Correlation between TNF-α, IL-1β and SCF levels in the blood plasma of healthy donors 
and AML patients. Data were obtained from the blood plasma of healthy donors (n=10) and AML 
patients (n=30). Correlation analysis was performed using GraphPad Prism (R2 values are presented in 
Figure 54 C). 
6.3 Discussion 
Our results show that HMGB1 stimulates the activity of the PI-3 K/mTOR pathway in both, a 
human AML cell line (THP-1 cells) and primary AML cells (AML-PB001F). This HMGB1-
induced activation leads to increased TNF-α secretion and accumulation of HIF-1α as well as 
VEGF release. However, except VEGF secretion, these effects are Tim-3-independent. Also, 
upregulation of VEGF secretion via Tim-3 receptor is HIF-1α-independent. Indeed, HMGB1-
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induced HIF-1α accumulation wasn’t attenuated by anti-Tim-3 neutralising antibody in AML 
cells. 
SRCD spectroscopic analysis showed that HMGB1 binds Tim-3 with nanomolar affinity (Kd = 
10−7 M). However, this affinity can be potentially increased by glycosides which normally bind 
to Tim-3 (the protein used in the studies was sugar-free). Interestingly, the formation of the 
HMGB1-Tim-3 complex was accompanied by an increase in α-helical content and consequent 
reduction in β-strand component. This considerable loss in β-strand structures is likely to occur 
in the Tim-3 protein. 
Our results showed also that TNF-α released from HMGB1-stimulated AML cells induce PHL 
to secrete IL-1β, which in turn stimulated epithelial/endothelial cells to produce/secrete SCF, 
factor able to bind Kit receptor and induce the survival/proliferation of AML cells [Figure 56]. 
 
Figure 56: HMGB1 induces SCF and VEGF production via interaction with differential signalling 
receptors. The scheme shows that secreted HMGB1 is capable of inducing TNF-α secretion by living 
AML cells (and possibly healthy leukocytes, based on results obtained in the experiments with mouse 
bone marrow samples). Secreted TNF-α induces IL-1β production by healthy leukocytes which then 
induces SCF release in endothelial cells. These processes are Tim-3-independent. HMGB1 also induces 
VEGF secretion by AML cells in Tim-3-dependent manner. 
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In addition, a clear evidence of correlation between TNF-α, IL-1β and SCF levels was observed 
in the blood plasma of AML patients and healthy donors, but the concentrations of these 
signalling proteins were significantly higher in the blood plasma of AML patients than in 
healthy donors. This in line with the fact that HMGB1 concentration in the blood plasma of 
AML patients is significantly higher than in healthy donors (Fucikova et al., 2016). However, 
since the levels of circulating HMGB1 in healthy donors are usually close to zero or anyway 
very low (Fucikova et al., 2016; Vicentino et al., 2018), other mechanisms (HMGB-1-
independent) could be involved in this intercellular signalling cascade. In addition, healthy 
bone marrow is unlikely to contain HMGB1, an “alarmin” secreted by stressed/dying or injured 
cells. Indeed, trypan blue exclusion assay showed that 95% of the cells in mouse bone marrow 
(sample used for our experiments) were viable (data not shown). Contrarily, in leukemic bone 
marrow (or in AML blood) stressing conditions, such as lack of oxygen, contribute to 
continuous release of HMGB1, that is able to activate this intercellular cascade (illustrated in 
Figure 56), which leads to increased levels of SCF, and thus supports leukaemia progression.  
HMGB1 has already been proposed as a possible therapeutic target for leukaemia treatment 
(Yu et al., 2012). In addition, inhibition of  HMGB1 has recently been shown to increase drug 
sensitivity in AML (Lu et al., 2014). Our findings demonstrate additional insights that HMGB1 
could be considered as a possible therapeutic target in AML and further confirm the efficiency 








7. Activity of Tim-3-galectin-9 pathway in solid tumours 
7.1 Biochemistry and functions of Tim-3-galectin-9 secretory pathway in human 
breast cancer cells 
Recently, breast cancer tissues were shown to be capable of expressing some of the key 
components of above described immunosuppressive pathway. In particular, LPHN2, one of 
LPHN isoforms, was found to be upregulated in breast tissues (White, et al., 1998). In addition, 
it was found that breast cancer cells express galectin-9, which was shown to be involved in cell 
aggregation, thus preventing metastasis (Yamauchi et al., 2006). 
Therefore, we decided to investigate whether the Tim-3-galectin-9 immunosuppressive 
pathway was specific solely to AML or was operating also in breast cancer, and possibly other 
solid tumours. 
7.1.1 Expression and activity of the FLRT3/LPHN/Tim3/galectin-9 pathway in breast 
tumours 
Breast cancer tissues lysates were subjected to Western blot analysis for specific detection of 
galectin-9, Tim-3, LPHN2, LPHN3 and FLRT3. It was found that all these proteins were 
expressed in breast cancer tissues [Figure 57 A&B, and 61 C]. Two bands were detected by 
anti-FLRT3 at ~75 kDa (full protein) and ~55 kDa (highlighted by a question mark). The latter 
may represent FLRT3 which underwent proteolytical processing. A clear band specifically 
detectable by anti-galectin-9 antibody appeared at ~55 kDa [Figure 57 A], when gel 
electrophoresis for protein separation was performed using 12% PAGE (concentration 
normally used to detect proteins having molecular weight of 20-50 kDa). Since the molecular 
weight of galectin-9 is ~31-32 kDa, we hypothesized that the band at ~55 kDa could correspond 
to Tim-3-galectin-9 complex. However, since this band wasn’t detectable by anti-Tim-3 
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antibody, it doesn’t represent Tim-3-galectin-9 complex, but probably a galectin-9 isoform 
bound to carbohydrates. Indeed, when the same sample was subjected to Western blot analysis 
using 10% PAGE, a specific band detectable by anti-galectin-9 antibody appeared slightly 
above 31 kDa [Figure 58]. This suggests that, in a 12 % gel, protein running was “delayed” 
possibly due to the presence of traces of glycosides or other post-translational modifications 




Figure 57: Expression of FLRT3/LPHN/Tim-3/galectin-9 pathway components and activities of PLC/PKCα and mTOR pathways in primary human breast 
tumours. Expression levels of Tim-3, galectin-9 (A), FLRT3 and LPHN2 (B) were analysed in primary breast malignant tumours and healthy breast tissues 
(HT) of five patients (n=5) by Western blot. Activities of PLC, PKCα and the levels of phospho-S2448 mTOR were detected as outlined in the Materials and 
Methods (C). The amounts of phospho-S65 and total eIF4E-BP (mTOR substrate) were analysed using Western blot (D). The levels of CD3 (biomarker of T 
cells) were also measured using lysate of Jurkat T cells as a positive control (E). Molecular weight markers (MW) are expressed in kDa. Images are from one 





Figure 58: Expression of galectin-9 in primary human breast tumours and healthy breast tissues. 
Lysates of primary breast malignant tumours and healthy breast tissues (HT) of five patients (n=5) were 
subjected to Western blot using 10 % PAGE. Specific detection of galectin-9 was performed employing 
Abcam rabbit anti-galectin-9 antibody. Images are from one experiment representative of five which 
gave similar results. Other results are shown as mean values ± SEM. *** p<0.001 vs HT. 
The levels of Tim-3, galectin-9, LPHN2 and FLRT3 found in primary breast malignant tumours 
were then compared to heathy tissues isolated from the same patients. Western blot analysis 
showed that the amounts of these components, except FLRT3, were significantly higher in 
malignant tissues compared to healthy ones [Figure 57 A, B and Figure 58]. 
The activities of PLC, PKC-α and mTOR were also measured in tumour and healthy breast 
homogenates. It was found that the activities of PLC and PKC-α were significantly higher in 
breast cancer tissues compared to healthy ones. The amounts of active mTOR form (mTOR 
phosphorylated at S2448) were similar in these tissue types [Figure 57 C]. The ratio between 
phospho-S65 eIF4E-BP and its total amount was also similar in both tissue types, although the 
amount of both phospho-S65 and total eIF4E-BP was higher in tumour tissues [Figure 57 D]. 
To confirm that all the protein characterised above are expressed by breast tumour cells and 
not by tumour-infiltrating lymphocytes, the samples were subjected to Western blot analysis 
for specific detection of CD3 (a marker of T cells). It was found that CD3 was undetectable in 
healthy and barely detectable in tumour tissue lysates, proving that the proteins characterised 
are associated with breast cells [Figure 58 E]. 
 131 
 
The presence of Tim-3-galectin-9 complex was also verified in both tissue types (as described 
in material and methods). It was found that the complex was barely detectable in healthy tissue 
homogenates but was clearly detectable in malignant tissue extracts [Figure 59 A]. The 
presence of Tim-3-galectin-9 complex was also confirmed by confocal microscopy co-
localization analysis [Figure 59 B]. 
 
Figure 59: Expression, interaction and co-localisation of Tim-3 and galectin-9 in primary human 
breast tumours. (A) Presence of the Tim-3-galectin-9 complex in primary normal and tumour tissue 
extracts was analysed using ELISA as outlined in the Materials and Methods. (B) Expression and co-
localisation of galectin-9 and Tim-3 were analysed in primary human breast tumours and healthy tissues 
of the same patients using confocal microscopy (see Materials and Methods for further details). Images 
are from one experiment representative of five which gave similar results. Scale bars correspond to 20 
µm. 
Next, the levels of galectin-9, Tim-3 and IL-2 were measured in blood plasma of healthy donors 
(HD), primary (PBC) and metastatic breast cancer (MBC) patients. It was found that the levels 
of Tim-3 and galectin-9 were significantly lower in both, PBC and MBC, than in HD. The 





Figure 60: Levels of galectin-9, Tim-3 and IL-2 in blood plasma of human healthy donors and 
patients suffering from primary and metastatic breast tumours. (A) Concentrations of galectin-9, 
soluble Tim-3 and IL-2 were analysed in blood plasma of healthy donors and breast cancer patients by 
ELISA. Data are shown as mean values ± SEM of 20 for healthy donors (HD), 42 for primary breast 
cancer (PBC) patients and 20 for metastatic breast cancer (MBC) patients. * - p<0.05; **, p<0.01 and 
vs HD. 
To explore whether the immunosuppressive mechanism described for AML cells can be also 
activated in breast tumour tissues, MCF-7 breast cancer cells were selected for the further 
investigations. Among the other breast cancer cell lines analysed [Table 7 and 8], MCF-7 cells 
were the only ones to express detectable amounts of both LPHNs 2 and 3 and the levels of 
these proteins were similar to their amounts found in primary breast tumours [Figure 57 B, 61 
A and C]. We also confirmed that MCF-7 cells, as primary breast tumours, express detectable 
amounts of Tim-3, galectin-9 and the complex formed by these proteins [Figure 61 A]. 
Comparative analysis of galectin-9 mRNA levels between healthy and tumour breast tissues, 
and MCF-7 cells was performed using qRT-PCR. It was found that the levels of galectin-9 
mRNA were significantly higher in both, MCF-7 cells and primary breast tumours, when 
compared to primary healthy breast tissues [Figure 61 B]. Importantly, the ratio of galectin-9 
mRNA in tumour and normal tissues was similar to the respective levels of protein detected 
[Figure 57 A and 61 B]. Taken together, these results suggest that MCF-7 cells as well as 
primary healthy and malignant cells express identical galectin-9, thus re-confirming that the 




Figure 61: Expression of crucial components of FLRT3/LPHN/Tim-3/galectin-9 pathway in MCF-
7 cells and primary human breast tumours. (A) Expression of a key components of this pathway was 
characterised in MCF-7 cells and primary breast tumour tissue lysates using Western blot analysis. 
Beta-actin was used as a housekeeping protein. (B) Levels of galectin-9 mRNA were compared in 
normal and healthy breast tissues as well as in MCF-7 cells and normalised against those of β-actin. (C) 
Expression of LPHN3 was detected in primary human breast tumour tissue lysates and MCF-7 cells. 
(D) Expression of GαQ was detected in primary human breast tumour tissue lysates and MCF-7 cells. 
Images are from one experiment representative of at least three which gave similar results. Data are the 
mean values ± SEM of five independent experiments; **, p<0.01 and *** when p<0.001 vs control 
(HT). 
Since LPHN is a G-coupled receptor and thus requires an adaptor protein for the transduction 
of the signal, cells and tissue lysates were subjected to Western blot analysis for GαQ detection. 
It was confirmed that both, MCF cells and primary breast tumours, express GαQ [Figure 61 
B]. 
Once assessed that all the key components of FLRT3/LPHN/Tim-3/galectin-9 pathway are 
present in MCF-7 cells, the activation of this signalling system was investigated by exposing 
these cells to FLRT3, protein able to bind olfactomedin-like domain expressed by all three 
LPHN isoforms (as described in the Introduction). 
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MCF-7 cells were cultured in presence or absence of 10 nM human recombinant FLRT3 for 4 
h. After the incubation, PLC and PKC-α activities were measured as described in Materials 
and Methods. Cell lysates were also subjected to Western blot analysis for the detection of 
phospho-S2448 mTOR and phospho-S65/total eIF4E-BP. It was found that FLRT3 
significantly upregulated PLC and PKC-α activities but did not provoke any changes in the 
intracellular concentration of phosphor-S2440 mTOR and thus didn’t affect the 
phosphorylation eIF4E-BP (mTOR substrate) [Figure 62 A].  
 
Figure 62: FLRT3 induces translocation of galectin-9 onto the surface of MCF-7 breast cancer cells. 
(A) MCF-7 cells were exposed for 4 h to 10 nM FLRT3 and activities of PLC, PKCα, the levels of 
phospho-S2448 mTOR and the amounts of phospho-S65 and total eIF4E-BP (an mTOR substrate) were 
analysed as described in the Materials and Methods. (B) MCF-7 cells were exposed for 4 h to 10 nM 
FLRT3 with or without 1 h pre-treatment with 30 µM U73122 (PLC inhibitor) or 70 nM Gö6983 (PKCα 
inhibitor). Surface presence of galectin-9 was characterised by on-cell assay. (C) Secondary structure 
and conformational changes of LPHN2 olfacomedin-like domain, FLRT3, and the complex of the two 
proteins mixed at the equimolar ratio were characterised using SRCD spectroscopy as outlined in the 
Materials and Methods. An interaction between olfactomedin-like domain of LPHN3 and FLRT3 
generated by Swiss PDB viewer (5cmn.pdb file downloaded through PubMed database was used 
(Prokhorov et al., 2015)) is presented to illustrate the structural basis of this interaction. Images are 
from one experiment representative of four which gave similar results. Other results are shown as mean 
values ± SEM of at least three independent experiments. * p<0.05; **, p<0.01 vs control. 
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Since MCF-7 cells don’t release detectable amounts of galectin-9 to the culture media and its 
secretion is not induced by FLRT3 (data not shown), surface presence of this protein was 
characterised as illustrated in Figure 39 B. It was found that the levels of surface-based galectin-
9 were significantly upregulated by FLRT3 and this effect was considerably attenuated by 
U73122 (PLC inhibitor) or Gö6983 (PKCα inhibitor) [Figure 62 B]. This indicates that FLRT3-
induced translocation of galectin-9 onto the cell surface of MCF-7 cells is controlled by 
PLC/PKCα pathway. 
To confirm FLRT3-LPHN2 interaction, SRCD spectroscopy analysis of the olfactomedin-like 
domain of LPHN2 and FLRT3 alone and in their equimolar combination was performed. It 
was found that conformational changes occurring during FLRT3-LPHN2 interaction are 
similar to the ones taking place during FLRT3-LPHN1 complex formation [Figure 62 C]. This 
is in line with the fact that FLRT3 binds specifically olfactomedin-like domain, highly 
conserved extracellular domain common to all LPHNs. A 3D interaction of LPHN3 
olfactomedin-like domain with FLRT3 leucine-rich repeat (LRR) domain is illustrated in 
Figure 62 C. 
7.1.2 Galectin-9 protects breast cancer cells against cytotoxic immune attack 
We found that galectin-9 (both secreted and surface-based) was able to attenuate AML cell 
killing by cytotoxic NK cells [Figure 37 and 38]. Thus, we decided to assess this effect also in 
breast cancer cell lines. Since solid tumours are mainly infiltrated by T cells rather than NK 
cells, cytotoxic ALL-derived TALL-104 CD8 lymphocytes were employed to verify this effect. 
Indeed, MCF-7 cells (adherent) were co-cultured with TALL-104 cells (expressing Tim-3 but 
not galectin-9) for 16 h at ratio of 4 : 1 in presence or absence of 5 μg/ml galectin-9 neutralising 
antibody. After the incubation, TALL-104 cells were collected, lysed and subjected to Western 
blot analysis for the detection of full-length and cleaved PARP (marker of apoptosis).  
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It was found that PARP cleavage in TALL-104 cells was significantly increased when co-
cultured with MCF-7 cells and this effect was attenuated by anti-galectin-9 neutralising 
antibody [Figure 63 B]. Increased level of PARP cleavage indicates a higher number of 
apoptotic cells.  
 
Figure 63: Galectin-9 protects MCF-7 cells against T cell-dependent cytotoxic immune attack. (A) 
MCF-7 cells were co-cultured with TALL-104 cytotoxic T lymphocytes at a ratio of 4 : 1 for 16 h (the 
ratio was determined by the aggressive behaviour of TALL-104 cells) in the absence or presence of 5 
µg/ml galectin-9 neutralising antibody or 5 µg/ml isotype control antibody. (B) After the experiment 
TALL-104 cells were lysed and PARP cleavage, as an indicator of the rate of apoptotic cells, was 
measured using Western blot analysis.  (C) CD8 expressions (reflecting the infiltration of TALL-104 
into the MCF-7 layer) were measured by on-cell assay. (D) Galectin-9 surface presence was measured 
using on-cell assay in resting MCF-7 cells and those co-cultured with TALL-104 cells. (E) Viability of 
MCF-7 cells was measured by MTS test. Images are from one experiment representative of five which 
gave similar results. Other results are presented as mean values ± SEM of five independent experiments. 
* p<0.05 vs control. 
To investigate the effect of galectin-9 on the ability of cytotoxic lymphocytes to bind breast 
malignant cell (and thus kill them), on-cell assay of MCF-7 cells co-cultured with TALL-104 
in presence or absence of galectin-9 neutralising antibody was performed. It was confirmed 
that MCF-7 cells don’t express CD8, since it wasn’t detectable when these cells were cultured 
on their own. CD8 was instead detectable when MCF-7 were co-incubated with TALL-104 
and the levels of CD8 were significantly increased when the co-culture was performed in 
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presence of anti-galectin-9 neutralising antibody [Figure 63 C]. This suggests that the ability 
of cytotoxic T lymphocytes to bind breast malignant cells increases when galectin-9 activity is 
disabled, and thus their potential to kill cancer cells augments. Indeed, cell viability of MCF-7 
cells was significantly decreased when the co-culture was performed in presence of anti-
galectin-9 neutralising antibody (as measured by MTS test) [Figure 63 D]. Importantly, neither 
binding ability of TALL-104 cells neither cell viability of MCF-7 cells was affected by isotype 
control antibody [Figures 63 C and D], confirming that these effects are galectin-9 -specific. 
Interestingly, galectin-9 surface expression was significantly upregulated in MCF-7 cells when 
co-cultured with TALL-104 cells. 
Previously described results represent a strong indication that galectin-9 is capable of 
protecting breast tumour cells against cytotoxic cell-dependent killing. 
7.1.3 Discussion 
Our results demonstrate that FLRT3/LPHN/Tim-3/galectin-9 immunosuppressive pathway is 
activated in breast cancer tissues and protects malignant cells from cytotoxic immune attack. 
We found that FLRT3 binds LPHN (2 or 3) expressed on the surface of MCF-7 cells and 
upregulates PLC and PKCα activities, which induce a significant increase in galectin-9 surface 
expression. We confirmed that, as in AML, also in breast cancer cells, galectin-9 attenuates 
cytotoxic activity of immune cells. In addition, we found that galectin-9 surface expression was 
significantly increased by the presence of TALL-104 cells, suggesting that there are other 
pathways employed by MCF-7 cells to escape cytotoxic attack. Indeed, the biochemical 
pathway underlying this phenomenon remains to be identified.  
We found also that, contrarily to AML, mTOR activity wasn’t upregulated by FLRT3 4 h 
treatment. This can be explained by the fact that breast cancer cells don’t secrete galectin-9 in 
contrast to AML cells. Indeed, since AML is blood/bone marrow cancer, its malignant cells 
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are in constant contact with cytotoxic immune cells and thus require high amounts of galectin-
9 to be released and express on the surface in order to escape host immune attack, survive and 
proliferate. For this reason, mTOR activity is upregulated in AML cells and is continuously 
stimulated by blood-available endogenous ligand FLRT3. Contrarily, breast cancer is a solid 
tumour and thus needs “to fight” only with tissue-infiltrating T cells (significantly lower 
number than in the blood). Therefore, FLRT3-induced moderate PLC and PKC-α activation, 
which result in the translocation of Tim-3-galectin-9 complex on the surface of breast cancer 
cells is sufficient to attenuate anti-cancer immunity of cytotoxic lymphocytes.  
These results are in line with those obtained in breast tumours compared with healthy breast 
tissues obtained from the same patients. Indeed, LPHN2, Tim-3 and galectin-9 expression was 
significantly higher in breast tumours compared to healthy tissues. Tim-3-galectin-9 complex 
was also detectable by Western blot analysis and co-localisation confocal microscopy in breast 
tissues. Importantly, its levels were significantly higher in breast cancer tissues than in healthy 
ones. We found also that PLC and PKCα activities were significantly increased in breast cancer 
tissues, while mTOR phosphorylation levels were comparable in both tissue types. Also, in line 
with the results obtained in MCF-7 cells, galectin-9 levels were significantly lower in patients 
affected by breast cancer than in healthy donors. This confirms that galectin-9 is not released 
by breast cancer cells but is kept on the cell surface to protect themselves from host immune 
attack. Tim-3 blood plasma levels were also significantly lower in breast cancer patients 
compared to healthy donors. The levels of IL-2 were instead non-significantly upregulated in 
cancer patients compared to healthy donors. Indeed, lower levels of Tim-3 allow higher 
production of IL-2, which has been shown to be downregulated by sTim-3. This suggests that 
induction of the cytotoxic activity of NK cells and cytotoxic T cells can still take place. 
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The presence of active cytotoxic cells could explain also the anti-metastatic potential of 
galectin-9 previously reported (Yamauchi et al., 2006). Indeed, galectin-9, expressed on the 
breast cancer cells may induce NK cells to release IFN-γ, which could activate cytotoxic 
lymphoid cells located in the area of the tumour microenvironment. Activated cytotoxic 
lymphocytes could then attack and kill malignant cells breaking off from the tumour thus 
preventing their circulation and metastasis. Overall, it appears that galectin-9 could protect the 
tumour which produces it in order to evade host immune attack, but this may not promote 
metastasis. 
Schematic representation of Tim-3-galectin-9 pathway operating in breast cancer cells is 




Figure 64: Breast cancer cell-based pathobiochemical pathways showing LPHN-induced activation 
of PKCα, which triggers the translocation of Tim-3 and galectin-9 onto the cell surface which is 
required for immune escape. The interaction of FLRT3 with LPHN isoform leads to the activation of 
PKCα, most likely through the classic Gq/PLC/Ca2+pathway. Ligand-bound LPHN activates Gq, which 
in turn stimulates PLC. This leads to phosphatidyl-inositol-bisphosphate (PIP2) degradation and 
production of inositol-trisphospate (IP3) and diacylglycerol (DAG). PKCα is then activated by DAG 
and cytosolic Ca2+. PKCα provokes the formation of SNARE complexes that tether vesicles to the 
plasma membrane. Galectin-9 impairs the cancer cell killing activity of cytotoxic T cells (and other 
cytotoxic lymphocytes). Possible (not directly confirmed) interactions of galectin-9 with glycoside 
component and T cell receptor (TCR)/CD8, with MHC I and antigen are highlighted with question mark 
“?” to indicate the fact that it is a hypothetic interaction, since TALL-104 cells used in the study kill 
tumour cells in MHC-independent manner. 
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7.2 Expression of key components of the FLRT3/LPHN/Tim-3/galectin-9 pathway 
in solid and liquid tumours 
In addition to AML and breast cancer, Tim-3-galectin-9 pathway was shown to suppress anti-
cancer immunity in solid tumours, such as colon cancer (Kang et al., 2015). Therefore, we 
decided to investigate the expression of FLRT3, LPHNs, Tim-3 and galectin-9 (both cell-based 
and secreted) in various human cancer cell lines (derived from brain, colorectal, kidney, 
blood/mast cell, liver, breast, prostate, lung and skin tumours) and various non-malignant cell 
lines and primary cells.  
Cell lysates of various cell lines were subjected to Western blot analysis for specific detection 
of Tim-3, galectin-9, LPHNs 1, 2 and 3 as well as FLRT3 proteins, while galectin-9 released 
by these cells in the media was measured using ELISA. We found that most of the key 
components of this immunosuppressive pathway were present in cancer cell lines [Table 7 and 
Table 8].  The majority of the studied cells expressed at least one LPHN isoform. In some of 
the cells, in which was present at least on LPHN isoform, FLRT3 wasn’t detectable by Western 
blot analysis. We hypothesised that in this case LPHN-expressing cells can use blood-based 
soluble FLRT3 to trigger Tim-3-galectin-9 pathway. Indeed, Tim-3 and galectin-9 were found 
to be expressed in all the studied cancer cell lines, except for the chronic myeloid leukaemia 
(CML) cell line, K562, which expressed Tim-3 but only traces of cell-associated galectin-9. 
This could be one of the reasons why CML cells entering the circulation are rapidly eliminated 
by cytotoxic immune cells. 
Additional clarification regarding molecular weight, isoforms and glycosylation level of 





Table 7:  Expression of Tim-3, galectin-9, LPHNs 1, 2 and 3 as well as FLRT3 proteins in brain, 
colorectal, kidney, blood/bone marrow cell lines. Cell lysates were subjected to Western blot analysis 
for specific detection of the proteins. The concentration of galectin-9 in the media used to culture these 




Table 8: Expression of Tim-3, galectin-9, LPHNs 1, 2 and 3 as well as FLRT3 proteins in liver, 
breast, prostate, lung and skin cell lines. Cell lysates were subjected to Western blot analysis for 
specific detection of the proteins. The concentration of galectin-9 in the media used to culture these 







Figure 65: Molecular weight, isoforms and glycosylation level of the proteins reported in Table 1 
and 2. Tim-3: lower band represents non-glycosylated protein, upper band(s), protein with differential 
levels of glycosylation; Galectin-9: multiple bands represent different isoforms of the same protein; 
FLRT3 – detectable between 80 and 95 kDa (upper band where applicable or the only visible band); 
another band (lower band; possibly extracellular domain) often appears at around 60 most likely 
reflecting levels of glycosylation in first two cases and proteolytic processing in the third. Traces – 
detectable expression which requires loading of >100 µg protein per well. 
Comparative analysis of the studied proteins in different cell lines shown in Table 1 and 2 were 
performed by measuring infrared fluorescence of the bands divided by the total quantity of the 
loaded proteins. All the results of this quantitative analysis are illustrated in Figure 66. 
Importantly, this comparative analysis evidenced that non-malignant cells expressed lower 
amounts of galectin-9 and Tim-3 compared to cancerous cells of similar origins.  
Taken together, our results suggest that FLRT3/LPHN/Tim-3/galectin-9 pathway could be 
operating in other cancer cell types in order to avoid host immune attack. However, further 








Figure 66: Expression of Tim-3, galectin-9, LPHNs 1, 2 and 3 as well as FLRT3 proteins in various human cancer cell lines. Lysates of indicated cells 
were subjected to Western blot analysis as outlined in Materials and Methods (images are presented in Supplementary table 1). Detected infrared fluorescence 
of the bands divided by the total protein amounts loaded (measured using Bradford assay) was used as a measure of protein quantity. Levels of Tim-3 & total 
galectin-9 (A) and LPHNs 1, 2 & 3 (B) were expressed as a % of those levels present in THP-1 cells (expressed as 100%). Since THP-1 cells lack FLRT3 
expression, the levels of this protein were expressed as % RCC-FG1 (C), respectively considering FLRT3 level in these cells as 100%. Abbreviations used – 
Bn – brain, CR – colorectal, Ki – kidney, BBM – blood, bone marrow and mast cells, Li – liver, Br – breast, Pr – prostate, Lu – lung, Sk – skin. Data are 




8. Classic programmed cell death pathway downregulates Tim-
3-galectin-9 immunosuppressive pathway. 
Recently it was found some of the galectin family members, such as galectin-3, were able to 
protect AML and colorectal cancer cells against apoptosis through mitochondrial stabilisation 
in a B cell lymphoma protein (Bcl) 2-dependent manner (Lee, et al., 2013; Ruvolo, et al., 2016). 
Thus, we decided to investigate whether galectin-9 possesses this intracellular anti-apoptotic 
activity too. 
8.1 Pharmacologically induced mitochondrial defunctionalisation suppresses Tim-
3-galectin-9 secretory pathway in human colorectal cancer cells 
To conduct these studies, a pharmacological inhibitor 5-[(4-bromophenyl)methylene]-a-(1-
methylethyl)-4-oxo-2-thioxo-3-thiazolidineacetic acid (BH3I-1, Figure 67 A), a synthetic cell 
permeable Bcl-XL antagonist was employed as a pharmacological inducer of apoptosis. This 
compound induces apoptosis via inhibition of interactions between the BH3 domain and Bcl-
XL thus defunctionalysing mitochondria. 
Colorectal adenocarcinoma cells of epithelial origin, Colo-205, found to employ Tim-
3/galectin-9 to escape host immune attack, were incubated for 24 h with or without 100 μM 
BH3I-1. After the incubation, cell viability and caspase 3 activity were measured as described 
in material and methods. It was confirmed that BH3I-1 was capable of inducing apoptosis in 





Figure 67: Pro-apoptotic defunctionalisation of mitochondria reduces galectin-9 expression and 
leads to its redistribution in human Colo-205 colorectal adenocarcinoma cells. Colo-205 cells were 
exposed to 100 µM BH3I-1 for 24 h followed by (A) detection of cell viability using an MTS test and 
colorimetric assay of caspase 3 activity. Cell viability was also tested for normal and Tim-3 or galectin-
9 knockdown Colo-205 cells. (B) Following 24 h of exposure to BH3I-1 S65-phosphorylation levels of 
eIF4E-BP were analysed by Western blot. (C) Surface presence and total cellular levels of Tim-3 and 
galectin-9 were analysed in Colo-205 cells using FACS. (D) Secreted levels of galectin-9 were analysed 
in Colo-205 cells following 24 h of exposure to BH3I-1 by ELISA. (E) Surface levels of galectin-9 in 
non-treated and BH3I-1-stimulated Colo-205 cells were compared using an on-cell assay. (F) The 
presence of Tim-3-galectin-9 complex in Colo-205 cells was confirmed using Western blot analysis 
(bands were appearing at around 70 KDa). THP-1 cells were used as a positive and K562 as a negative 
control. (G) Levels of Tim-3 and galectin-9 were analysed in Colo-205 lysates following 24 h of 
exposure to BH3I-1 by Western blot. (H) Mitochondrial extracts were obtained from non-treated and 
BH3I-1-stimulated Colo-205 cells and subjected to Western blot analysis to detect Tim-3 and galectin-
9. Total protein levels were measured using a Bradford assay and equal protein amounts were loaded 
onto the gels. (I) Galectin-9 mRNA levels were analysed in non-treated Colo-205 cells and those 
exposed to BH3I-1 using qRT-PCR. Images are from one experiment representative of at least four 
which gave similar results. In the scheme galectin-9 is abbreviated as G9. Quantitative results are shown 
as mean values ± SEM of 3 - 6 independent experiments. * p<0.05; **, p<0.01 vs control. 
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To investigate whether galectin-9 (or possibly its receptor Tim-3) could protect the cells from 
apoptosis, knockdown either of galectin-9 either of Tim-3 was performed prior to BH3I-1 
exposure for 24 h. The efficiency of the knockdown was checked by qRT-PCR. It was found 
that silencing either galectin-9 or its receptor/trafficker Tim-3 did not affect the pro-apoptotic 
activity of BH3I-1 suggesting that galectin-9 is unlikely to be involved in cell protection in this 
case [Figure 67 A].  
Cell lysates from Colo-205 cultured in presence or absence of BH3I-1 were also subjected to 
Western blot analysis for specific detection of pS65-eIF4E-BP/ eIF4E-BP proteins. It was 
found that BH3I-1 didn’t affect the phosphorylation levels of eIF4E-BP [Figure 67 B]. Thus, 
BH3I-1 had no effect on the activity of mTOR, important for galectin-9/Tim-3 synthesis and 
secretion. Obviously, one could suggest that Colo-205 cells accumulate galectin-9 on their 
surface and inside the cells based on FACS analysis (Figure 67 C). Decreased levels of surface-
based Tim-3 might indicate its masking by galectin-9 (Yasinska et al., 2018). 
Next, galectin-9 release by Colo-205 with or without 24 h exposure to BH3I-1 was performed 
by ELISA. It was found that the BH3I-1 didn’t affect Colo-205 ability to secrete galectin-9 
[Figure 67 D]. Therefore, on-cell assay was performed to verify whether galectin-9 surface 
levels are affected by this compound. It was found that BH3I-1 significantly decreased 
galectin-9 surface expression in Colo-205 cells [Figure 67 E]. 
Then, we investigated whether Colo-205 cells are able to accumulate Tim-3-galectin-9 
complex at a level comparable to THP-1 AML cells. K562 were used as negative control. Thus, 
lysates of K562, Colo-205 and THP-1 cells were subjected to Western blot analysis. Bands 
detectable by both anti-Tim-3 and anti-galectin-9 antibodies confirmed that the presence of 
Tim-3-galectin-9 complex in Colo-205. In addition, we found that it was highly expressed in 
Colo-205 cells, at the level comparable to THP-1 AML cells [Figure 67 F].  
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Treatment with BH3I-1 significantly decreased galectin-9 intracellular level but didn’t affect 
Tim-3 concentration inside the cell (as confirmed by Western blot analysis) [Figure 67 G].  
Next, mitochondria of Colo-205 cells cultured in presence or in absence of BH3I-1 were 
isolated as described in material and methods. Isolated mitochondria lysates were then 
subjected to western blot analysis for Tim-3 and galectin-9 detection. Obtained results showed 
that the Tim-3-galectin-9 complex is accumulated in mitochondria upon stimulation with 
BH3I-1 [Figure 67 H].  
Quantitative real-time PCR on Colo-205 untreated and treated with BH3I-1 showed that 
galectin-9 mRNA levels were significantly reduced in presence of this compound [Figure 67 
I]. 
In addition, we observed that Colo-205 cells release lower amounts of galectin-9 in comparison 
to THP-1 cells. Importantly, these amounts are proportional to cellular Tim-3 levels [Figure 
68], supporting the conclusion regarding the involvement of Tim-3 in galectin-9 secretion. 
 
Figure 68: Total cellular levels of Tim-3 and galectin-9 and levels of secreted galectin-9 in THP-1 
human AML cells.  Total Tim-3 and galectin-9 levels were measured by FACS in permeabilised THP-
1 cells. The secreted levels of galectin-9 were also measured in culture medium, in which THP-1 cells 
were kept for 16 h and compared with those of Colo-205 cells cultured under the same conditions. 
Images are from one experiment representative of at least four which gave similar results. Other results 




The accumulation of Tim-3-galectin-9 complex upon mitochondrial defunctionalisation was 
then investigated in two other types of epithelial cells – non-malignant kidney RC-124 and 
malignant HepG2 hepatoma cells (both abundant in mitochondria levels). However, we found 
that apoptosis stimulation by BH3I-1 in non-malignant kidney RC-124 cells wasn’t as efficient 
as in Colo-205 cells (data not shown). Indeed, we found that RC-124 cells were less permeable 
to this inhibitor in comparison to Colo-205 (as confirmed by direct chemical measurement of 
drug-associated uptake of bromine, data not shown). Therefore, H2O2 was used to 
defunctionalize mitochondria in these cells. HepG2 and RC-124 cells were incubated for 6h in 
presence or absence of 1 mM H2O2. It was found that galectin-9 levels were significantly 
reduced in both cell types, but the Tim-3-galectin-9 complex was only accumulated in the 
mitochondria of HepG2 cells and not in RC-124 [Figure 69]. 
 
Figure 69: Mitochondrial defunctionalisation reduces intracellular galectin-9 levels in both healthy 
(RC-124) and malignant (HepG2) epithelial cells but induces galectin-9 translocation into 
mitochondria only in malignant (HepG2) cells.  Cells were exposed to 1 mM H2O2 for 6 h followed 
by Western blot analysis of cellular and mitochondrial levels of Tim-3 and galectin-9 in both RC-124 
(A) and HepG2 (B) cells. In mitochondria of RC-124 cells Tim-3, galectin-9 and the complex of both 
proteins (MW ~ 70 KDa) was not detectable, while in mitochondria isolated from HepG2 cells a 
complex was clearly detectable in H2O2-stimulated cells. Images are from one experiment 
representative of at least four which gave similar results. Quantitative results are shown as mean values 




Taken together, our results indicate pro-apoptotic mitochondrial dysfunction leads to a 
decreased transcription of galectin-9 mRNA leading to its reduced translation. In addition, this 
pharmacologically induced leads to a re-distribution of the Tim-3-galectin-9 complex into 
mitochondria where galectin-9 possibly interacts with mitochondrial glycoproteins.  The 
physiological relevance is still unclear. We proposed that   galectin-9 transfer in mitochondria 
and its decrease on the cell surface might be part of a regulated cell suicide program. Indeed, 
decrease in surface-associated galectin-9    would lead to a decreased protection of a dying cell 
thus allowing its smooth elimination. Importantly, this phenomenon was observed in both 
cancer cell line studied but not in non-malignant cells, suggesting that this mechanism could 
be cancer-specific. Therefore, targeted defunctionalisation of mitochondria in malignant cells 
may help cytotoxic lymphoid cells to eliminate more efficiently cancer cells since it would 
reduce cell surface presence of galectin-9 capable of suppressing anti-cancer activity of the 
immune system cells. 
Currently, several drugs targeting mitochondrial defunctionalisation have been shown to 
enhance conventional chemotherapy and radiotherapy treatment in haematological and solid 
tumours (Oltersdorf, et al., 2005; Konopleva, et al. 2006; Kang, et al., 2007; Hann, et al., 2008; 
Tse, et al., 2008; Lock, et al., 2008; Gandhi, et al., 2011; Liu, et al, 2009). We suggest that 
improved responses in patients undergoing this combinatorial treatment might be partly due to 








The following conclusions can be made from this research programme:  
1. Triggering of LPHN1, expressed in AML cells but absent in healthy leukocytes, 
activates Gαq/PLC/PKC and mTOR pathways leading to biosynthesis and exocytosis of Tim-
3 and galectin-9. Both proteins, Tim-3 and galectin-9 suppress anti-cancer immunity allowing 
AML cells to survive and proliferate. 
2. AML cells recruit crucial components of normal metabolism to escape surveillance and 
progress the disease. In particular: 
a) Human adrenal cortex hormone cortisol upregulates LPHN1 expression in AML cells; 
blood-available FLRT3 interacts with LPHN1 leading to galetin-9/Tim-3 synthesis and 
exocytosis in AML cells. 
b) HMGB1, released by dying or stressed cells, induces SCF and VEGF production via 
interaction with differential signalling receptors. Therefore, targeting HMGB1 in the 
treatment of AML may reduce SCF and VEGF, both factors pivotal for AML 
progression. 
3. Crucial components of FLRT3/LPHN/Tim-3/galectin-9 pathway are expressed in the 
majority of cancer cell lines and thus may be common for a variety of malignant tumours.  Tim-
3-galectin-9 pathway is active in breast cancer cells and is used to protect malignant cells from 
host immune attack. 
4. Galectin-9 doesn’t protect cancer cells against apoptosis via mitochondrial 
defunctionalisation. However, mitochondrial defunctionalisation reduces galectin-9 surface 
expression and leads to its accumulation in mitochondria in malignant cells but not in healthy 
ones. Therefore, targeted mitochondrial defunctionalisation may be a novel strategy for anti-
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cancer immunotherapy, since it would reduce galectin-9 surface expression allowing smooth 
elimination of cancer cells by immune system cells. 
5. Taken together our work demonstrates that Tim-3-galectin-9 immunosuppressive 
pathway plays a pivotal role in protection of AML and various solid tumour cells towards host 
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11.1 Electrophoresis solutions 
11.1.1 SDS-polyacrylamide gels 
Table 9: PAGEs preparation 
 4% 7.5% 10% 12% 
H2O 3.2 ml 5.525 ml 4.9 ml 4.4 ml 
1.5 M Tris-HCl (pH 8.8) 1.25 ml 2.5 ml 2.5 ml 2.5 ml 
40% Acrylamide/Bis-acrylamide 0.5 ml 1.875 ml 2.5 ml 3.0 ml 
10% (w/v) SDS 50 µl 100 µl 100 µl 100 µl 
10% (w/v) APS 100 µl 125 µl 125 µl 125 µl 
TEMED 20 µl 25 µl 25 µl 25 µl 
11.1.2 1.5 M Tris-HCL pH 8.8 
Tris 181.5 g  
H2O 1 l  
Adjust pH to 8.8 with HCl. 
11.1.3 0.5 M Tris-HCL pH 6.8 
Tris 60.5 g  
H2O 1 l  
Adjust pH to 6.8 with HCl. 
11.1.4 10X Running buffer (8.3) 
Tris 30 g  
Glycine 144 g  
SDS 10 g  
Add distilled water until 1 l and check the pH. 
11.1.5 Sample buffer 
Table 10: Sample Buffer preparation 
 2X 
0.5 M Tris-HCl pH 6.8 1.25 ml 
10% SDS 2 ml 
Glycerol 2.5 ml 




To this solution, DTT was added prior to use. For 4X sample buffer the quantity of chemical 
compounds was double. 
11.2 Western blot buffers 
11.2.1 10X Blotting Buffer (pH 8.3) 
Tris 30.3 g 
Glycine 144 g  
H2O 1 l  
Check if the pH is 8.3 but do not adjust it. 
11.2.2 1X Blotting Buffer (with 20% Methanol) 
10X Blotting buffer  
100 ml Methanol  
200 ml H2O 700 ml 
11.2.3 10X TBS buffer (9% NaCl, 100 mM Tris HCl, pH 7.4) 
Tris 12.11 g  
NaCl 90 g  
H2O 1 l  
Adjust the pH to 7.4, using HCl. 
11.2.4 1X TBST buffer (pH 7.4) 
10X TBS buffer  
100 ml Tween 20  
0.5 ml H2O 900 ml 
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Acutemyeloid leukemia (AML) is a severe and often fatal systemicmalignancy. Malignant cells are capable of es-
caping host immune surveillance by inactivating cytotoxic lymphoid cells. In this work we discovered a funda-
mental molecular pathway, which includes ligand-dependent activation of ectopically expressed latrophilin 1
and possibly other G-protein coupled receptors leading to increased translation and exocytosis of the immune
receptor Tim-3 and its ligand galectin-9. This occurs in a protein kinase C and mTOR (mammalian target of
rapamycin)-dependent manner. Tim-3 participates in galectin-9 secretion and is also released in a free soluble
form. Galectin-9 impairs the anti-cancer activity of cytotoxic lymphoid cells including natural killer (NK) cells.
Soluble Tim-3 prevents secretion of interleukin-2 (IL-2) required for the activation of cytotoxic lymphoid cells.
These results were validated in ex vivo experiments using primary samples from AML patients. This pathway
provides reliable targets for both highly speciﬁc diagnosis and immune therapy of AML.









Acutemyeloid leukemia (AML) is a blood/bonemarrow cancer orig-
inating from self-renewing malignant immature myeloid precursors,
which rapidly becomes a systemic malignancy. It is often a fatal disease
becausemalignant cells are capable of suppressing anti-cancer immuni-
ty by impairing the functional activity of natural killer (NK) cells and cy-
totoxic T cells (Golden-Mason et al., 2013;Wang et al., 2007; Khaznadar
et al., 2014). Recent evidence clearly demonstrated an involvement of
the T cell immunoglobulin and mucin domain 3 (Tim-3) - galectin-9
pathway in this immune escape mechanism (Golden-Mason et al.,
2013; Kikushige et al., 2015; Gonçalves Silva et al., 2016). Galectin-9 is
a β-galactoside-binding lectin, which has a tandem structure and
contains two carbohydrate recognition domains (CRDs) fused together
by a peptide (Delacour et al., 2009). Galectin-9 has a speciﬁc receptor
on AML cells known as Tim-3 which also could act as its possible traf-
ﬁcker (galectin-9 as all other galectins lacks a signal sequence required
for transport into the endoplasmic reticulum (ER) and thus requires a
trafﬁcking protein for its secretion (Hughes, 1999; Delacour et al.,
2009)). However, the mechanisms underlying the activation of biosyn-
thesis of the components of the Tim-3-galectin-9 autocrine loop,
galectin-9 secretion and its effects on cytotoxic lymphocytes (NK cells
and T cells) remain poorly understood.
Recently, we discovered that humanAML cells – but not healthy leu-
kocytes – express physiologically active latrophilin 1 (LPHN1;
Sumbayev et al., 2016). LPHN1, an adhesion G-protein-coupled recep-
tor, is highly expressed in neuronal axon terminals and in many secre-
tory cells (Davletov et al., 1998; Silva and Ushkaryov, 2010). In all cells
expressing this receptor, LPHN1 activation by its most potent agonist,
α-latrotoxin (LTX) from black widow spider venom (Ushkaryov,
2002), triggers intracellular Ca2+ signaling and exocytosis of neuro-
transmitters and hormones (Volynski et al., 2003). Similarly, ligand-
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induced activation of LPHN1 in AML cells facilitates exocytosis of cyto-
kines and growth factors (Sumbayev et al., 2016). Production of
LPHN1 in AML cells is controlled by themammalian target of rapamycin
(mTOR) (Sumbayev et al., 2016), a highly conserved serine/threonine
kinase that acts as a central regulator of growth and metabolism in
healthy and malignant human myeloid cells (Yasinska et al., 2014). To
function in cell-cell interactions and cell signaling, LPHN1 can interact
with at least two endogenous ligands, Lasso/teneurin-2 (Silva et al.,
2011) and ﬁbronectin leucine rich transmembrane protein 3 (FLRT3)
(Boucard et al., 2014), although only FLRT3 seems to be expressed in pe-
ripheral tissues. In addition to triggering exocytosis by increasing cyto-
solic Ca2+, LPHN1 can enhance the sensitivity of the release machinery
by activating protein kinase C (Liu et al., 2005), which is also thought to
be involved in galectin-9 secretion (Chabot et al., 2002). Based on these
observations, we hypothesized that activation of LPHN1 by its ligands
can induce secretion of galectin-9, thus protecting AML cells against
NK and cytotoxic T cells. This hypothesis has been studied experimen-
tally in the present study.
Here we report that the Tim-3-galectin-9 autocrine loop is
activated in AML cells through protein kinase C (PKC)/mTOR
pathways. These pathways trigger translation of both Tim-3 and
galectin-9 and induce high levels of galectin-9 secretion as well as
the release of soluble Tim-3. Importantly, this effect was also veriﬁed
in the AML patients studied. Galectin-9 was found to impair AML cell
killing by primary human NK cells. Soluble Tim-3 reduced the ability
of T cells to secrete IL-2, a cytokine, which is required for the
activation of both NK cells and cytotoxic T cells (Dhupkar and
Gordon, 2017). Blood plasmas of AML patients contained
signiﬁcantly lower amounts of IL-2 compared to those of healthy
donors. We conﬁrmed that PKC activation occurred in AML cells in
a LPHN1-dependent manner. The LPHN1 agonist LTX and natural
ligand FLRT3 upregulated the Tim-3-galectin-9 autocrine loop in a
PKC-dependent manner. Based on our ﬁndings, we conclude that
LPHN1/PKC/mTOR/Tim-3-galectin-9 is a biosynthetic and secretory
pathway which is operated by human AML cells resulting in a
decrease of immune surveillance and promotion of disease
progression.
2. Materials and Methods
2.1. Materials
RPMI-1640 medium, fetal bovine serum and supplements and basic
laboratory chemicals were purchased from Sigma (Suffolk, UK).
Maxisorp™microtitre plates were provided either by Nunc (Roskilde,
Denmark) and Oxley Hughes Ltd. (London, UK). Mousemonoclonal an-
tibodies directed against mTOR and β-actin, as well as rabbit polyclonal
antibodies against phospho-S2448 mTOR, galectin-9, HRP-labelled rab-
bit anti-mouse secondary antibody were purchased from Abcam (Cam-
bridge, UK). Mouse monoclonal antibody against FLRT3 was obtained
from Santa Cruz Biotechnology (Heidelberg, Germany). The polyclonal
rabbit anti-peptide antibody (PAL1) against LPHN1 was described pre-
viously (Davydov et al., 2009). LTXwas puriﬁed as previously described
(Ashton et al., 2000). Goat anti-mouse and goat anti-rabbit ﬂuorescence
dye-labelled antibodies were obtained from LI-COR (Lincoln, Nebraska
USA). ELISA-based assay kits for the detection of galectin-9, Tim-3 and
IL-2 were purchased from Bio-Techne (R&D Systems, Abingdon, UK).
Anti-Tim-3 mouse monoclonal antibody, its single chain variant as
well as human Ig-like V-type domain of Tim-3 (amino acid residues
22–124), expressed and puriﬁed from E. coli (Prokhorov et al., 2015)
were used in our work. Secondary antibodies for confocal laser
microscopy and imaging ﬂow cytometry (goat anti-mouse and goat
anti-rabbit Alexa 488, Alexa 555 and Alexa 647) were from Invitrogen
(Carlsbad, USA). All other chemicals purchased were of the highest
grade of purity.
2.2. Cell Lines and Primary Human Cells
THP-1 humanmyeloid leukemiamonocytes, K562 chronicmyeloge-
nous leukemia cells and Jurkat T cells were obtained from the European
Collection of Cell Cultures (Salisbury, UK). Renal clear cell carcinoma
RCC-FG1 cells were obtained from CLS Cell Lines Service (Eppelheim,
Germany). Cells were cultured in RPMI 1640 media supplemented
with 10% fetal bovine serum, penicillin (50 IU/ml) and streptomycin
sulfate (50 μg/ml). LAD2 mast cells were kindly provided by A.
Kirshenbaum and D. Metcalfe (NIH, USA). Cells were cultured in Stem-
Pro-34 serum-free media in the presence of 100 ng/ml SCF
(Kirshenbaum et al., 2003).
Primary human AMLmononuclear blasts (AML-PB001F, newly diag-
nosed/untreated)were purchased fromAllCells (Alameda, CA, USA) and
handled in accordance with the manufacturer's instructions. Primary
human NK cells were puriﬁed from buffy coat blood (prepared from
healthy donors) obtained from the National Health Blood and Transfu-
sion Service (NHSBT, UK) following ethical approval (REC reference:
16-SS-033). Primary CD34-positive HSCs were obtained from Lonza
(Basel, Switzerland).
Femur bones of six-week-old C57 BL16mice (25± 2.5 g, kindly pro-
vided by Dr. Gurprit Lall, School of Pharmacy, University of Kent) were
used for the experiments following approval by the Institutional Animal
Welfare and Ethics Review Body. Animals were handled by authorized
personnel in accordance with the Declaration of Helsinki protocols.
Bone marrow was isolated from femur bone heads as described before
(Swamydas and Lionakis, 2013) and whole extracts (1 mg protein/ml)
were then obtained.
2.3. Primary Human Plasma Samples
Blood plasma of healthy donors was obtained from buffy coat
blood (originated from healthy donors undergoing routine blood
donation) which was purchased from the National Health Blood
and Transfusion Service (NHSBT, UK) following ethical approval
(REC reference: 16-SS-033). Primary human AML plasma samples
were obtained from the sample bank of University Medical Centre
Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer
Hamburg, reference: PV3469).
2.4. Western Blot Analysis
Tim-3, galectin-9, FLRT3, LPHN1 and Gαq were analyzed by
Western blot and compared to β-actin in order to verify equal pro-
tein loading, as previously described (Yasinska et al., 2014). Brieﬂy,
cells were lysed using lysis buffer (50 mM Tris–HCl, 5 mM EDTA,
150 mM NaCl, 0.5% Nonidet-40, 1 mM PMSF, pH 8.0). After centrifu-
gation, the protein content in the supernatants was analyzed. Finally,
samples were added to the same volume of 2× sample buffer
(125 mM Tris–HCl, 2% sodium dodecyl sulfate (SDS), 10% glycerine,
1 mM dithiothreitol (DTT), 0.002% bromophenol blue, pH 6.9) and
boiled for 5 min. Proteins were resolved using SDS–polyacrylamide
gels followed by blotting onto nitrocellulose membranes. Molecular
weights were calibrated in proportion to the running distance of
rainbow markers. For all primary antibodies (see Materials section)
a 1:1000 dilution was used, except those against LPHN1 and FLRT3
(where a 1:500 dilution was used). β-actin staining was used to
conﬁrm equal protein loading as described previously (Yasinska et
al., 2014). LI-COR goat secondary antibodies (dilution 1:2000),
conjugated with ﬂuorescent dyes, were used in accordance with
manufacturer's protocol to visualize target proteins (using a LI-COR
Odyssey imaging system). Western blot data were quantitatively
analyzed using Odyssey software and values were subsequently
normalized against those of β-actin.
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2.5. Characterization of Tim-3 and Galectin-9 in Tissue Culture Medium
Secreted Tim-3 and galectin-9 were characterized in the RPMI-1640
mediumused to culture THP-1 cells. The proteinswere ﬁrst precipitated
onMaxisorp ELISA plates (seeMaterials section). For this purpose ELISA
plateswere coated overnight using single-chain antibody against Tim-3.
Plates were then blocked with 2% BSA. Tissue culture mediumwas then
applied and incubated for 4 h at room temperature, followed by exten-
sivewashingwith TBST buffer. Proteinswere then extracted using 0.2M
glycine-HCl buffer (pH 2.0). Extracts were neutralized using lysis buffer
and subjected toWestern blot analysis usingmouse anti-Tim-3 and rab-
bit anti-galectin-9 antibodies as described before (Gonçalves Silva et al.,
2016) and above.
2.6. Enzyme-linked Immunosorbent Assays (ELISAs)
Galectin-9, sTim-3 and IL-2 were measured by ELISA using R&D Sys-
tems kits according to manufacturer's protocols. In all cases the proce-
dure involves speciﬁc detection of captured target proteins using
biotinylated detection antibody. The interaction was then analyzed
using streptavidin conjugated with horseradish peroxidase (HRP) ac-
cording to the manufacturer's protocol. Tim-3-galectin-9 complex was
also analyzed by ELISA. Single-chain antibody (described above, dilution
1:100)was used to capture the complex and biotinylated goat R&D Sys-
tems antibody against galectin-9 (detection antibody) was used to de-
tect galectin-9 bound to Tim-3. HRP-labelled streptavidin was then
used to perform quantitative analysis according to the R&D Systems
protocol for the galectin-9 assay kit. Phosphorylation of mTORwas ana-
lyzed by ELISA as previously described (Yasinska et al., 2014).
2.7. In Cell Assays and in Cell Westerns
Weemployed a standard LI-COR in-cellWestern (ICW) assay (meth-
anol was used as permiabilization agent) to analyze total Tim-3 and
galectin-9 expressions in the studied cells. The in-cell (ICA, also called
on-cell) assay was employed to characterize Tim-3 and galectin-9 sur-
face presence in the studied cells. We also used this assay to visualize
binding of LAD2 cells toNK cells. IgE-sensitized LAD2 cellswere exposed
for 5 min to 1 μg/ml, carefully washed with sterile PBS and exposed to
LI-COR goat anti-mouse labelled secondary antibody. Following wash-
ing with PBS, cells were scanned using a LI-COR Odyssey imaging sys-
tem (Gonçalves Silva et al., 2016).
2.8. Confocal Microscopy and Imaging Flow Cytometry
THP-1 cells were grown on 12 mm cover glasses in 24-well plates.
Cells were treated (o/n) with PMA and then ﬁxed/permeabilized for
20 min with ice-cold MeOH or MeOH/acetone. Alternatively cells were
ﬁxed in a freshly prepared 2% paraformaldehyde, washed 3 times with
PBS and then permeabilized with 0.1%TX-100. Cover glasses were
blocked for 1 h at RTwith 10% goat serum in PBS. 1 μg/ml anti-Tim-3 an-
tibody and anti-galectin-9 antibody were used as primary antibodies
and incubated o/n at 4 °C. Goat-anti-mouse Alexa Fluor 488 and goat-
anti-rabbit Alexa Fluor 555 were used as secondary antibodies. Cells
were incubated with secondary antibodies for 45 min at RT. The prepa-
rations were examined on Olympus laser scanning confocal microscope
as described (Prokhorov et al., 2015; Fasler-Kan et al., 2010). Images
were collected and analyzed using proprietary image acquisition soft-
ware. Imaging ﬂow cytometry was performed in accordancewith a pre-
viously described protocol (Fasler-Kan et al., 2016). Brieﬂy,
permiabilized cells were stained with mouse anti-Tim-3 and rabbit
anti-galectin-9 antibodies for 1 h at room temperature. Goat anti-
mouse Alexa Fluor 647 and goat-anti-rabbit Alexa Fluor 488 were
used as secondary antibodies. Images were collected and analyzed
using IDEAS analytical software on ImageStream X mark II (Amnis-
EMD-Millipore, USA).
2.9. Synchrotron Radiation Circular Dichroism Spectroscopy
Human recombinant Tim-3, human recombinant galectin-9 and
Tim-3-galectin-9 complex were analyzed using SRCD spectroscopy at
beam line 23, Diamond Light Source (Didcot, UK). SRCD measurements
were performed using 0.2 μg/ml of samples in 10 cm path length cell,
3 mm aperture diameter and 800 μl capacity using Module B with
1 nm increment, 1 s integration time, 1.2 nm bandwidth at 23 °C
(Hussain et al., 2012a, 2012b; Siligardi and Hussain, 2015). The results
obtained were processed using CDApps (Hussain et al., 2015) and
OriginLab™.
2.10. PKCα Activity Assay
The catalytic activity of PKCα was measured as described before
based on its ability to phosphorylate speciﬁc substrate in a reaction buff-
er containing 20mMTris-HCl (pH 7.5), 20 μMATP, 5mMMgCl2 and 200
μM CaCl2 (Micol et al., 1999). Phosphate groups attached to the sub-
strate were detected using colorimetric assay (Abooali et al., 2014).
2.11. Cell Viability Assay
Cell viability was analyzed using the Promega UK Ltd. (Southamp-
ton, UK) assay kit. We used an MTS colorimetric assay for assessing
cell metabolic activity. NAD(P)H-dependent cellular oxidoreductase en-
zymes playing crucial role in human myeloid cell survival (Sumbayev
and Nicholas, 2010), reﬂect the number of viable cells present. Cells
were incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
and then absorbance was measured at 490 nm in accordance with the
manufacturer's protocol.
2.12. Leukemia Cell Protection Assay
K562 and NK cells were cultured separately or as a 1:2 co-culture
(K562:NK) for 16 h, at 37 °C, in the absence or presence of 0.5–
5 ng/ml of galectin-9. The unﬁxed cell cultures were then imaged
under an inverted microscope (TE200, Nikon), using phase-contrast
lighting, a digital camera and the WinFluor image acquisition software
(J. Dempster, University of Strathclyde). Raw images were analyzed
using the ImageJ software (Schindelin et al., 2015), including illumina-
tion correction, background subtraction, overlapping cells separation,
edge artefacts elimination, and particle size optimization (based on
the size difference between K562 and NK cells). The selected areas
were then applied to the raw images for automatic cell counting.
2.13. Statistical Analysis
Each experiment was performed at least three times and statistical
analysis when comparing two events at a time was conducted using a
two-tailed Student's t-test. Multiple comparisons were performed
using ANOVA test. Post-hoc Bonferroni correction was applied. Statisti-
cal probabilities (p) were expressed as * where p b 0.05; **, p b 0.01 and
*** when p b 0.001.
3. Results
3.1. Differential Proteolytic Enzymes are Involved in the Secretion of the
Tim-3 and Galectin-9 Complex in Human AML Cells
We investigated differential proteolytic shedding of free and
galectin-9-bound Tim-3 from the surface of human AML cells as a pos-
sible mechanism for the secretion of these proteins. Firstly, we exam-
ined the medium used to culture THP-1 human AML cells with or
without 16 h exposure to 100 nM phorbol 12-myristate 13-acetate
(PMA) known to activate proteolytic shedding of Tim-3 (Moller-
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Hackbarth et al., 2013). We then immunoprecipitated Tim-3 from the
medium and extracted the precipitate as outlined in the Materials and
Methods. Extracts were subjected to Western blot analysis followed
by speciﬁc detection of galectin-9 and Tim-3. Speciﬁc galectin-9 bands
appeared at around 32 kDa (molecular weight of galectin-9) as well as
52 kDa (Fig. 1A). Interestingly, the 52 kDa band was also detectable by
anti-Tim-3 antibody (Fig. 1A), suggesting that this band corresponds
to the unbroken Tim-3-galectin-9 complex. Furthermore, speciﬁc Tim-
3 bands appeared at around 33 kDa (molecular weight of soluble Tim-
3 – sTim-3) and around 20 kDa. This 20 kDa band is likely to be a
fragment of Tim-3 shed together with galectin-9 being released from
the complex during theWestern blot procedure (Fig. 1A). This suggests
that the Tim-3 protein fragment complexed with galectin-9 might be
shed at different cleavage site(s). Interestingly, the amount of all the
proteins detected was clearly higher in PMA-treated samples.
It has recently been found that Tim-3 can be shed from the cell sur-
face by a disintegrin andmetalloproteinase domain-containing proteins
(ADAM) 10/17 (Moller-Hackbarth et al., 2013). We therefore investi-
gated whether these proteases are associated with release of free Tim-
3 and/or of the galectin-9-Tim-3 complex. We exposed THP-1 cells for
16 h to 100 nM PMA, after which the PMA-containing medium was re-
moved and replaced with the same medium containing 100 μM
GI254023X (ADAM 10 and 17 inhibitor) or 100 μMBB-94, a matrix me-
talloproteinase inhibitor. The cells were incubated for 4 h and levels of
Tim-3 and galectin-9 were then measured in the culture medium by
ELISA. We also measured soluble Tim-3-galectin-9 complex by captur-
ing Tim-3 using a single-chain antibody and then detecting galectin-9
using a biotinylated anti-galectin-9 antibody. We found that PMA
treatment signiﬁcantly upregulated sTim-3 release as well as the release
of galectin-9 (a similar increase was observed in the Tim-3-galectin-9
complex, Fig. 1B). GI254023X and BB-94 decreased PMA-induced sTim-
3 release but did not affect the release of either galectin-9 or the Tim-3-
galectin-9 complex (Fig. 1B), suggesting that this complex is differentially
shed from the cell surface.
3.2. Protein Kinase C is Involved in the Activation of Tim-3 and Galectin-9
co-secretion by AML Cells
We considered the levels of Tim-3 and galectin-9 remaining in
THP-1 cells following 16 h of exposure to speciﬁc PKC activator
PMA. It was found that, despite the levels of released sTim-3,
galectin-9 and Tim-3-galectin-9 complex were increased in PMA-
treated cells, the levels of respective cell-associated proteins
decreased (Fig. 2). Interestingly, a speciﬁc band in the range of
70 kDa detectable by both anti-Tim-3 and anti-galectin-9 antibodies
was present in all the assays (Fig. 2). This molecular weight
corresponds to a sum of those of uncleaved Tim-3 and galectin-9.
This indicates that a complex between full Tim-3 and galectin-9 is
ﬁrst formed before undergoing shedding, which results in a release
of its soluble form corresponding to the 52 kDa species, as described
above. Our observations were conﬁrmed by co-localization assays
using confocal microscopy (Fig. 3). Following 24 h exposure to
100 nM PMA, paraformaldehyde-ﬁxed non-permeabilized and
methanol-permeabilized THP-1 human AML cells were investigated.
We found that both galectin-9 and Tim-3 were present on the cell
surface. In permeabilized cells there was clear evidence of co-localization
Fig. 1. Free and galectin-9-bound Tim-3 is shed differentially from the cell surface. THP-1 cells were exposed for 16 h to 100 nM PMA; medium was then exchanged for fresh PMA-free
medium and cells exposed to the indicated concentrations of GI254023X (ADAM10/17 inhibitor) and BB-94 (matrix metalloproteinase inhibitor). Non treated THP-1 cells were
incubated for 16 h after which medium was changed and cells incubated for further 4 h and used as a control. Western blot characterization of galectin-9 and Tim-3 variants (20 kDa
fragment (Tim-3 (fr)) and 33 kDa (sTim-3)) was performed in medium collected after ﬁnal 4 h of incubation of resting and PMA-pre-treated THP-1 cells as outlined in the Materials
and Methods (A). All the samples were subjected to ELISA-based detection of galectin-9, soluble Tim-3 and Tim-3-galectin-9 complex (B). Images are from one experiment
representative of six which gave similar results. Quantitative data represent mean values ± SEM of six independent experiments; *p b 0.05; **p b 0.01 vs. control.
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of both proteins. These ﬁndings were conﬁrmed using imaging ﬂow
cytometry (Supplementary Fig. 1). In non-permeabilized cells we saw
sectors full of either Tim-3 or galectin-9, without substantial co-localiza-
tion. Given that galectin-9 is soluble, it can remain on the cell surface
only if it is bound to its receptor, Tim-3 (Fig. 3). Taken together our
ﬁndings suggest that Tim-3 is either externalized on its own or acts as a
trafﬁcker for galectin-9 (which lacks the signal domain required for
secretion and thus requires a trafﬁcker). Given that PMA, a speciﬁc PKC
activator, signiﬁcantly increases Tim-3 and galectin-9 secretion, it is likely
that PKC is involved in the Tim-3 and galectin-9 co-secretion process.
3.3. Levels of Soluble Tim-3 andGalectin-9 are Highly Increased in the Blood
Plasma of AML Patients: Characterization of the Tim-3-galectin-9 Complex
in Human Blood Plasma
We then sought to conﬁrmourﬁndings in primary samples collected
from AML patients. We analyzed plasma samples from 98 AML patients
versus healthy donors and found that galectin-9 and Tim-3 levels were
strikingly increased in blood plasma of AMLpatients (Fig. 4A, B, E and F).
Five randomly selected plasma samples from the group of studied AML
patients and ﬁve from healthy donors were then subjected to detection
Fig. 2.PMAactivates Tim-3 andgalectin-9production and release aswell as generation of Tim-3-galectin-9 complex. THP-1 cellswere treatedwith 100nMPMA for 16 h.Non-treated THP-
1 cells were used as a control. Cells were then harvested and galectin-9 as well as Tim-3 were analyzed in whole cell extracts by Western blot. Both proteins and Tim-3-galectin-9
complexes were analyzed by ELISA in the medium used to treat the cells. The bar diagram on the top shows the comparative analysis (expressed in % control) of galectin-9 and Tim-3-
galectin-9 complex levels released by non-treated and PMA-treated THP-1 cells. Images are from one experiment representative of three which gave similar results. Quantitative data
are the mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
Fig. 3. Co-localization of Tim-3 and galectin-9 in PMA-activated THP-1 cells. Co-localization of Tim-3 and galectin-9 was analyzed in non-permeabilized and permeabilized THP-1 cells
following 24 h of exposure to 100 nM PMA using confocal microscopy (see Materials and Methods for details). Images are from one experiment representative of six which gave
similar results.
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of Tim-3-galectin-9 complex by ELISA as described above. The level of
increase in Tim-3-galectin-9 complex in AML samples was similar to
that of galectin-9 (Fig. 4C and G). We then randomly chose ﬁve plasma
samples from the group of studied AML patients and analyzed Tim-3
and galectin-9 levels by Western blot (Fig. 4D). Prior to loading onto
the SDS-PAGE, samples were sonicated and boiled for 5 min at 95 °C.
We found that sTim-3 and galectin-9 were clearly detectable. We
could also see a clear band (probably representing the soluble form of
the Tim-3-galectin-9 complex) at around 52 kDa (detectable by both
anti-Tim-3 and anti-galectin-9 antibodies). This suggests that the com-
plex released by THP-1 cells (Fig. 1) and the one found in blood plasma
is unlikely to be formed after secretion. If this had been the case, its mo-
lecular weight would have been around 65 kDa (33 kDa for sTim-3 and
32 kDa for galectin-9) rather than 52 kDa. A speciﬁc band was also de-
tectable at around 20 kDa (Fig. 4D). These results are in line with
those obtained for soluble forms of Tim-3, galectin-9 and Tim-3-
galectin-9 complex released by THP-1 cells conﬁrming that sTim-3
and Tim-3 complexed with galectin-9 are likely to be differentially
shed from plasma membranes of AML cells. Interestingly, there is a
clear evidence of a correlation between Tim-3 and galectin-9 levels in
the plasma of both healthy donors and AML patients and these correla-
tion levels were very similar to each other (Fig. 4H and I) suggesting a
co-release of both proteins in both cohorts.
3.4. Tim-3 Binding Alters the Conformation of Galectin-9
In order to assess the biophysical properties of Tim-3, galectin-9 and
the Tim-3-galectin-9 complex we investigated them using synchrotron
radiation circular dichroism (SRCD) spectroscopy at Diamond Light
Source (Beam Line 23, Supplementary Fig. 2). Structural organization
of Tim-3 and galectin-9 as well as their interaction are schematically
presented in the Fig. 5A. Galectin-9 interacts with non-glycosylated
Tim-3 with nanomolar afﬁnity (Kd = 2.8 × 10−8 M); the binding can
be further strengthened by interaction of galectin-9 with glycosylated
Tim-3 (Prokhorov et al., 2015). Indeed, the complex is detectable by
Western blot, which means that interaction between a lectin and
sugar is taking place. SRCD spectroscopy was also performed on
galectin-9 and Tim-3 mixed to a stoichiometry of 1:1 molar ratio (Fig.
5B). Galectin-9 when mixed with Tim-3 showed a CD spectrum signiﬁ-
cantly different from the simulated spectrum indicating that the inter-
action of galectin-9 with Tim-3 causes signiﬁcant conformational
change of the proteins with a clear increase in β-strand component.
Based on the above, one might speculate that Tim-3 binding could
alter the conformation of galectin-9, resulting in increased ability to in-
teract with receptors in target cells. Since galectin-9 is a tandem protein
with two sugar binding domains, one domain could bind Tim-3 (or
other proteins) and leave the other domain open for interaction with
a receptor molecule associated with the plasma membrane of a target
cell (for example membrane associated Tim-3).
3.5. Latrophilin 1, Protein Kinase C andmTOR-Dependent Translation Play a
Crucial Role in Tim-3 and Galectin-9 Production and Secretion
LPHN1mRNAwas found in primary humanCD34-positive stem cells
(Maiga et al., 2016).Wewere able to detect LPHN1 protein in them (at a
slightly highermolecular weight than in THP-1 cells (around 140 kDa)),
while in THP-1 it is detectable at 130 kDa (Supplementary Fig. 3) aswell
as in primary AML cells (Sumbayev et al., 2016). No Tim-3 or galectin-9
protein expression was detectable in primary human CD34-positive
stem cells (Supplementary Fig. 3).
For this experimental set-up we used THP-1 cells and exposed
them to 100 nM PMA or 250 pM α-latrotoxin (LTX, a highly speciﬁc
and potent ligand of LPHN1 (Sumbayev et al., 2016)). We found that
both PMA and LTX downregulated intracellular Tim-3 and galectin-9
levels (though not signiﬁcantly) and signiﬁcantly increased activat-
ing phosphorylation of the mammalian target of rapamycin
(mTOR) at S2448 (Fig. 6A and B). One hour pre-treatment of THP-1
cells with 70 nM Gö6983 (PKCα inhibitor) before exposure to PMA
or LTX led to attenuation of stimulus-induced mTOR activation and
downregulation of intracellular Tim-3 and galectin-9 levels.
Interestingly, in the cells exposed just to Gö6983, phospho-S2448
mTOR and intracellular Tim-3/galectin-9 levels were not different
Fig. 4. Levels of galectin-9 and soluble Tim-3 are highly increased in blood plasma of AML patients. Galectin-9 and Tim-3 were measured by ELISA in blood plasma obtained from healthy
donors and AML patients (A, B, E and F). The levels of Tim-3-galectin-9 complexweremeasured by ELISA in blood plasma of ﬁve randomly picked healthy donors and AML patients (C and
G). Tim-3 and galectin-9were characterized byWestern blot in blood plasma fromﬁve randomly chosen AML patients (D). Correlations between Tim-3 and galectin-9 aswell as between
galectin-9 andTim-3-galectin-9 complexwas then determined (H, I, J and K). Images are fromone experiment representative ofﬁvewhich gave similar results. Quantitativedata represent
mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
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from the control. Both PMA and LTX highly upregulated release of
both sTim-3 and galectin-9 from THP-1 cells. Gö6983 completely
attenuated this increase in both cases, but did not change basic levels
of Tim-3 and galectin-9 secretion, which suggests that basic
(background) release of galectin-9 and Tim-3 does not depend on
PKCα (Fig. 6D).
In summary, both PMA and LTX induce production of both Tim-3
and galectin-9 in THP-1 cells. We conﬁrmed that THP-1 cells express
Gαq (Supplementary Fig. 4A) and PMA aswell as LTX induce highly sig-
niﬁcant upregulation of PKCα kinase activity (Supplementary Fig. 4B).
Pre-treatment of THP-1 cells with 10 μM AZD2014 (a highly speciﬁc
mTOR inhibitor) before exposure to PMA or LTX reduced intracellular
Tim-3 and galectin-9 levels as well as release of both proteins (Fig. 6C
and D). This indicates that PMA or LTX-induced translation of both pro-
teins depends on the mTOR pathway. Importantly, the solvents used to
dissolve pharmacological inhibitors had no effect on any of the studied
protein levels or their secretion (data not shown).
These results were validated using primary human AML cells. For
this purpose we exposed primary human AML mononuclear blasts
AML-PB001F for 24 h to LTX followed by detection of secreted
galectin-9 and Tim-3. We found that AML-PB0011F expressed LPHN1
and the secreted levels of both proteins were signiﬁcantly increased in
LTX-treated AML cells (Supplementary Fig. 5) conﬁrming the ﬁndings
obtained in THP-1 cells.
To conﬁrm the physiological role of LPHN1 in galectin-9 release we
exposed THP-1 cells to FLRT3, which is one of physiological ligands of
LPHN1 (Boucard et al., 2014). We found that 10 nM FLRT3 induced sig-
niﬁcant upregulation of galectin-9 and sTim-3 release (Fig. 7A, a scheme
of the experiment is presented in Supplementary Fig. 6A); it also upreg-
ulated PKCα activity in THP-1 cells (Supplementary Fig. 4B). To conﬁrm
Fig. 5. Interaction of Tim-3with galectin-9 leads to major conformational changes increasing solubility of the protein complex. (A) The schematic structural models of Tim-3 extracellular
domain (left) and galectin-9 (right). In the Tim-3 structure, amino acid residues involved in galectin-9-independent binding are highlighted in green. Residues, which are potential targets
for glycosylation, are highlighted in red. In galectin-9, sugarmolecules,which could potentially bind theprotein, located close to the carbohydrate binding sites are shown in green. (B) The
SRCD spectroscopy of Tim-3, galectin-9 and Tim-3-galectin-9 interaction (both simulated and real curves are presented).
Fig. 6. LPHN1, PKCα andmTOR pathways are involved in Tim-3 and galectin-9 production and secretion in AML cells. THP-1 cells were exposed to the indicated concentrations of PMA or
LTX for 16 h with or without 1 h pre-treatment with the PKCα inhibitor Gö6983 (A, B, D) or themTOR inhibitor AZD2014 (C, D). Cellular levels of Tim-3 and galectin-9 were analyzed by
Western blot. Released Tim-3 and galectin-9 were detected by ELISA. Images are from one experiment representative of three which gave similar results. Quantitative data are the mean
values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate differences vs. PMA and LTX-treated
cells, respectively.
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that this effect was physiologically relevant, we exposed THP-1 cells for
16 h to mouse bone marrow (mBM) extracts (10 μg protein/ml, which
contain FLRT3, Fig. 7B, a scheme of the experiment is presented in Sup-
plementary Fig. 6B) obtained as outlined in the Materials and Methods.
Treatments were conducted with or without 1 h pre-treatment with 5
μg/ml FLRT3 neutralizingmouse antibody.We found that mBMextracts
signiﬁcantly upregulated galectin-9 and sTim-3 secretion in THP-1 cells.
FLRT3 neutralizingmouse antibody reduced the effects of mBM extracts
but did not block them (Fig. 7B). This means that BM contains several
activators of galectin-9 secretion in AML cells. Finally, we co-cultured
THP-1 cells with RCC-FG1 renal carcinoma cells (which are highly ad-
herent) in the ratio 1 THP-1:2 RCC-FG1. RCC-FG1 cells express high
levels of FLRT3 and release almost undetectable amounts of galectin-9
(Fig. 7C, a scheme of the experiment is presented in Supplementary
Fig. 6C). Cells were kept together for 16 h in the absence or presence
of 5 μg/ml FLRT3 neutralizing antibody and then galectin-9 and sTim-
3 secretion levels were analyzed. We found that the presence of RCC-
FG1 cells signiﬁcantly increased galectin-9 and sTim-3 release and
FLRT3 neutralization attenuated these effects. The presence of RCC-
FG1 cells signiﬁcantly upregulated PKCα activity, an effect that was
also attenuated by neutralization of the FLRT3 (Supplementary Fig.
4C). These results suggest that FLRT3 stimulates the release of
galectin-9 from AML cells.
3.6. Galectin-9 and sTim-3 Attenuate AML Cell Killing Activity of NK Cells
Recent evidence suggested that galectin-9 (either soluble or cell sur-
face associated) can interact with Tim-3 or possibly other receptors on
Fig. 7. FLRT3, a physiological ligand of LPHN1, induces galectin-9 and Tim-3 secretion. (A) THP-1 cells were exposed for 16 h to 10 nM extracellular domain of human recombinant FLRT3
followedbymeasurement of released Tim-3 and galectin-9 by ELISA. (B) THP-1 cellswere exposed tomouse bonemarrow (mBM) extracts for 16 hwith orwithout 1 h pre-treatmentwith
5 μg/ml anti-FLRT3 antibody. The presence of FLRT3 in mBM extracts was conﬁrmed by Western blot analysis. Secreted Tim-3 and galectin-9 were measured by ELISA. (C, left) RCC-FG1
cells express FLRT3 as conﬁrmed byWestern blotting. (C, right) RCC-FG1 cells were co-culturedwith THP-1 cells at a ratio of 1 THP-1:2 RCC-FG1with orwithout 1 h pre-treatmentwith 5
μg/ml FLRT3 neutralizing antibody. Secreted galectin-9 and Tim-3 were measured by ELISA. Images are from one experiment representative of three which gave similar results.
Quantitative data depict mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate
differences vs. cells treated with mBM extracts or co-cultured with RCC-FG1 cells, respectively.
Fig. 8. LAD2 cells express and externalize Tim-3 and galectin-9. Left panel: surface-based and total Tim-3 and galectin-9 were measured in LAD2 humanmast cell sarcoma cells using LI-
COR in cell assay (ICA, non-permeabilized cells) and in cell Western (ICW, permeabilized cells). Right panel: protein levels of Tim-3 and galectin-9 were measured in resting and IgE-
sensitized LAD2 cells by Western blot. Galectin-9 release was characterized using ELISA. Images are from one experiment representative of three which gave similar results.
Quantitative data show mean values ± SEM of three independent experiments; ***p b 0.001 vs. control.
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cytotoxic lymphoid cells including NK cells and cytotoxic T cells
(Gleason et al., 2012). Itmay be proposed that Tim-3-galectin-9 interac-
tion is involved in the creation of immunological synapses between tar-
get cells and cytotoxic lymphoid cells. To investigate this we used LAD2
humanmast cell sarcoma cells kindly provided by Prof. Metcalfe andDr.
Kirshenbaum (NAID, NIH, USA; Kirshenbaum et al., 2003). These cells
express both Tim-3 and galectin-9 with both proteins located mostly
on the cell surface (Fig. 8) and not rapidly shed. This can thus be used
to visualize the formation of immunological synapses between the
two cell types. They also express high afﬁnity IgE receptors (FcɛRI)
which are not expressed by NK cells and thus can be used to distinguish
between the two cell types.
Resting LAD2 cells do not release detectable amounts of galectin-9
and sensitization with IgE (which was used in order to label the cells
for visualization) does not augment galectin-9 secretion considerably
(Fig. 8). We therefore immobilized primary human NK cells isolated
frombuffy coats of human blood on ELISA plates as outlined inMaterials
and Methods. NK cells express Tim-3 (several glycosylation variants,
Supplementary Fig. 7) but do not produce detectable amounts of
galectin-9 protein. We applied IgE-sensitized LAD2 cells (Sumbayev et
al., 2012) to the NK cells at a ratio of 1:1 with or without 15 min pre-in-
cubationwith galectin-9 neutralizing antibody. Isotype control antibody
was also used instead of galectin-9 antibody to rule out the IgG effect.
LAD2 cells were then ﬂagged using mouse IgM anti-IgE followed by vi-
sualization using anti-mouse LI-COR secondary antibody (which recog-
nizes IgM, seeMaterials andMethods for further details).We found that
LAD2 cells were binding to NK cells and the presence of galectin-9 neu-
tralizing antibody (but not isotype control antibody) abrogated this ef-
fect (Fig. 9, a scheme of the experiment is presented in Supplementary
Fig. 8). These results conﬁrm that galectin-9 produced by LAD2 cells
participates in their interactions with NK cells. Furthermore, abrogation
of the effect by anti-galectin-9 antibodies may indicate that the Tim-3-
galectin-9 interaction is the only pathway through which these cells
could interact. This is most likely a result of IgE sensitization of LAD2
cells which highly increases the presence of galectin-9 on their surface.
We then used K562 chronic myeloid leukemia cells which do not re-
lease detectable amounts of galectin-9 (as conﬁrmed by ELISA). K562
cells were exposed to PMA for 24 h in 96well Maxisorp plates. Medium
was replaced with PMA-free RPMI-1640 medium containing isolated
primary humanNK cells at a ratio of 1 K562:2 NK in the absence or pres-
ence of 5 ng/ml human recombinant galectin-9. Cells were co-incubated
for 16 h and their viability was then assessed using an MTS test. We
found that the presence of NK cells signiﬁcantly reduced the viability
of K562 cells however, the presence of galectin-9 attenuated K562 kill-
ing effect (Fig. 10A). Viability of NK cells was not affected in any of the
cases (Fig. 10A). Interestingly, the cytotoxic attack by NK cells also led
to a dramatic change in the behavior of K562 cells, causing theirmassive
aggregation. Usingphase contrastmicroscopy,we determined the effect
of galectin-9 on cell aggregation in individual or combined K562 andNK
cell cultures. In the absence of galectin-9, there was clear evidence of
K562 cells aggregating in the presence of NK cells (Fig. 10B). Galectin-
9, in a dose-dependent manner, decreased the aggregation of K562
cells by NK cells, such that no K562 cell aggregation was detectable in
the presence of 5 ng/ml galectin-9 (Fig. 10C). Galectin-9 itself had no
visible effect on either of the two cell types alone. Thus, galectin-9 clear-
ly protects myeloid leukemia cells from being killed by NK cells.
We then investigated the interactions between AML THP-1 cells and
primary human NK cells. THP-1 cells were exposed to 100 nM PMA for
16 h. The medium was then replaced with PMA-free medium contain-
ing NK cells at a ratio of 2 NK cells:1 THP-1 cells and left for 6 h in the
absence or presence of 5 μg/ml galectin-9-neutralizing antibody. Tim-
3 and galectin-9 were then measured in the NK cells by Western blot
analysis, and viability of THP-1 cells, activities of granzyme B, caspase-
3 and galectin-9 release were monitored. We found that THP-1 cell via-
bility was reduced when galectin-9 was neutralized (Fig. 11). This was
in line with increased caspase-3 activity and granzyme B activities.
Galectin-9 releasewas not affected (Fig. 11, galectin-9 bound to neutral-
izing antibody is detectable in our system). We conﬁrmed that resting
NK cells did not produce detectable amounts of galectin-9. However,
this protein on its own, and in the form of unbroken Tim-3-galectin-9
complex, was detectable in NK cells co-cultured with THP-1 cells and
was reduced in the presence of galectin-9 neutralizing antibody. This
suggests that THP-1 cells were the source of galectin-9, which was
most likely bound to Tim-3 on the surface of NK cells, preventing the de-
livery of NK cell-derived granzyme B into THP-1 cells and inhibiting the
caspase-3-dependent apoptotic pathway.
Recently, a possible reciprocal link between levels of sTim-3 and IL-
2, a cytokine, which activates cytotoxic activity of NK cells and T cells,
was reported (Geng et al., 2006). We also found that in the plasma of
healthy donors the levels of sTim-3 were signiﬁcantly lower compared
to AML patients (Fig. 4) whereas the levels of IL-2 were signiﬁcantly
higher (Fig. 12A and B). To investigate a possible direct inﬂuence of
sTim-3, we exposed Jurkat T cells (resting Jurkat T cells produce detect-
able amounts of IL-2) to increasing concentrations of Tim-3 for 24 h.We
found a striking sTim-3 concentration-dependent and signiﬁcant reduc-
tion of IL-2 release from Jurkat T cells. This indicates that sTim-3 is capa-
ble of binding a target protein (or a group of target proteins) and
reducing IL-2 production thus preventing induction of NK cell and T
lymphocyte anti-cancer activities.
Taken together, our results demonstrate a pathobiochemical path-
way in AML cells. It is associated with activation of PKCα by LPHN1
(or any other receptors with similar activity) leading to the expression
and exocytosis of sTim-3 and galectin-9, which prevent the activation
of cytotoxic lymphocytes and impair their malignant cell killing activity.
4. Discussion
AML is a malignancy affecting bone marrow and blood and is a se-
vere, and often fatal, systemic disease. AML cells escape host immune
attack involving NK and cytotoxic T cells by impairing their activity
(Golden-Mason et al., 2013; Kikushige et al., 2015; Gonçalves Silva et
al., 2016). However, the biochemical mechanisms underlying the im-
mune escape of malignant white blood cells remain unclear. Recently,
it was shown that AML cells express high levels of the immune receptor
Tim-3 and release galectin-9 which impairs the activity of NK cells and
cytotoxic T cells (Gonçalves Silva et al., 2016). We have also suggested
that Tim-3, as a membrane associated glycoprotein, might act as a traf-
ﬁcker for galectin-9 (Gonçalves Silva et al., 2016). As for all galectins,
Fig. 9.Galectin-9participates in the formation of an “immunological synapse” betweenNK
cells and LAD2cells. Primary humanNK cellswere immobilized on the surface ofMaxisorp
plates. Cells were then co-incubated for 30 min with LAD2 cells with or without 30 min
pre-treatment of LAD2 cells with 5 μg/ml galectin-9 neutralizing antibody (or the same
amount of isotype control antibody). LAD2 cells were then visualized using LI-COR assay
as outlined in Materials and Methods. Images are from one experiment representative of
ﬁve which gave similar results. Quantitative data represent mean values ± SEM of ﬁve
independent experiments; *p b 0.05; **p b 0.01.
52 I. Gonçalves Silva et al. / EBioMedicine 22 (2017) 44–57
galectin-9 is synthesized on free ribosomes and since it lacks the signal
domain required for secretion it thus needs a trafﬁcker in order to be re-
leased (Delacour et al., 2009). When on the cell surface, Tim-3 is known
to be shed by ADAM 10/17 proteolytic enzymes thus producing sTim-3,
the function of which remains unknown (Moller-Hackbarth et al.,
2013). We found, that Tim-3 could be shed in its free form as well as
in complex with galectin-9; however, differential shedding is taking
place. The Tim-3 fragment in the complex is about 20 kDa molecular
weight, while sTim-3 is around 33 kDa. SRCD analysis of the complex
suggests that the interaction between Tim-3 and galectin-9 proteins
leads to major conformational change, possibly increasing the ability
of galectin-9 to interact with the target proteins. Since galectin-9 is a
tandem protein containing two domains (Delacour et al., 2009), one of
them might be interacting with Tim-3, while the other one could bind
to a target receptor molecule, for example another molecule of Tim-3
associated with the plasma membrane of the target cell (Nagae et al.,
2006). This may explain the high efﬁciency of galectin-9 in triggering
Tim-3 onNK cells, which do not express galectin-9 and thus contain un-
occupied Tim-3 on their surface.
Since we can observe the Tim-3-galectin-9 complex on Western
blots following denaturing SDS-gel electrophoresis (Figs. 1, 2 and 4;
~52 kDa soluble form and ~70 kDa cell-derived form), it is likely that
Fig. 10.Galectin-9 protectsmyeloid leukemia K562 cells frombeing killed by primary humanNK cells. (A) K562 cellswere co-cultured for 16 hwith primary humanNK cells (at a ratio of 1
K562:2 NK) in the absence or presence of 5 ng/ml galectin-9. Viability of K562 and NK cells was thenmeasured using anMTS test. Images are from one experiment representative of three
which gave similar results. Quantitative data represent mean values ± SEM of three independent experiments; ***p b 0.001 vs. control. (B) K562 cells were co-cultured for 16 h with
primary human NK cells (at a K562:NK ratio of 1:2) in the presence of different concentrations of galectin-9 (0–5 ng/ml). Cells were imaged using phase-contrast microscopy. The
images are from one representative experiment of six (n= 6), which gave similar results. Scale bar (the same for all images), 50 μm. (C) The NK cell-induced aggregation of K562 cells
was quantiﬁed as a function of galectin-9 concentration. Left panel: percent of cells found in aggregates in individual cultures and in co-culture. Right panel: the size of cell aggregates
in individual cultures and in co-culture. The data represent the mean values ± SD of six independent experiments; *, p b 0.05; **, p b 0.01; ****, p b 0.0001.
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the binding between proteins is further strengthened by the interaction
of galectin-9 with Tim-3-associated glycosides. Interestingly, the com-
plex is detectable by Western blot with both anti-Tim-3 and anti-
galectin-9 antibodies. However, when these antibodies are sequentially
applied to the same blot, the second antibody fails to detect the respec-
tive protein in the same band (unless the ﬁrst antibody is stripped off),
due to steric hindrance. This effect explains why Tim-3 located on the
cell surface and covered by galectin-9 cannot be co-stained by the anti-
body in confocal microscopy co-localization analysis (Fig. 3). Another
point supporting this conclusion is that there was also clear evidence
of co-localization of Tim-3 and galectin-9 in permiabilized THP-1 cells
upon exposure to PMA (Fig. 3, Supplementary Fig. 1).
Previously it was reported that the release of both Tim-3 and
galectin-9 depends on PKCα and proteolysis (Chabot et al., 2002). Our
Fig. 11. Cell-derived galectin-9 attenuates AML cell killing activity of primary human NK cells. THP-1 cells were co-incubated with primary human NK cells (ratio – 1 THP-1:2 NK) for 6 h
followed by detection of THP-1 cell viability by the MTS test, measurement of activities of granzyme B and caspase 3 in THP-1 cell lysates and released galectin-9 (left panel). Galectin-9
levels from NK cells were determined by Western blot (right panel). Images are from one experiment representative of three which gave similar results. Quantitative data show mean
values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs control.
Fig. 12. Soluble Tim-3 attenuates IL-2 release. (A and B) IL-2 levels were measured by ELISA in blood serum of healthy donors and AML patients. (C) Jurkat T cells were exposed to the
increasing concentrations of Tim-3 for 24 h followed by detection of secreted IL-2 by ELISA. Data show mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01.
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results conﬁrmed these ﬁndings. PMA treatments induced PKCα activa-
tion, which activated exocytosis of Tim-3 and galectin-9 as well as their
mTOR-dependent production in THP-1 AML cells (Fig. 6).
Interestingly, natural and exogenous ligands of LPHN1, a G-protein
coupled neuronal receptor expressed also in CD34-positive human
stem cells (Supplementary Fig. 3) and AML cells but not healthy white
blood cells, activated the PKCα pathway. They also induced both
mTOR-dependent translation of Tim-3 and galectin-9 as well as their
exocytosis. The effect was observed in THP-1 and primary human AML
blasts. PKCα is known to provoke agglomeration of SNARE complex re-
sponsible for exocytosis (Stockli et al., 2011; Morgan et al., 2005). Since
FLRT3, one of natural ligands of LPHN1, is present in bone marrow (Fig.
7) it might explain how LPHN1 causes PKCα activation. Interestingly,
constitutively active PKCα in malignant primary AML cells correlates
with a very poor prognosis and high mortality rate of patients
(Kurinna et al., 2006). This suggests that AML cells constantly release
high levels of Tim-3 and galectin-9. Bone marrow also expresses other
PKCα-activating proteins. When we exposed THP-1 cells to mouse
bone marrow extracts, galectin-9 release was signiﬁcantly higher
compared to resting THP-1 cells. FLRT3 neutralizing antibody signiﬁ-
cantly reduced but did not abolish FLRT3 induced PKCα-dependent
galectin-9 release. This suggests that galectin-9 and Tim-3 are synthe-
sized and exocytozed by AML cells in a PKCα and mTOR-dependent
manner, using available plasma membrane-associated PKCα activating
receptors (for example LPHN1) to induce the whole pathway.
Galectin-9 prevents thedelivery of granzymeB into AML cells (this is
a perforin and mannose-6-phosphate receptor-dependent process
(Supplementary Fig. 9)). Inside AML cells granzyme B performs cleav-
age of the protein Bid into tBid, thus inducing mitochondrial dysfunc-
tion and cytochrome C release followed by caspase 3 activation.
Proteolytic activation of caspase 3, in addition to the classic pathway,
might also be directly catalyzed by granzyme B (Lee et al., 2014). Our re-
sults with galectin-9 conﬁrmed this concept (Fig. 11). Recently it was
reported that galectin-9 induces interferon-gamma (IFN-γ) release
from NK cells (Gleason et al., 2012). IFN-γ interacts with AML cells in-
ducing the activity of indoleamine 2,3-dioxygenase (IDO1), an enzyme
which converts L-tryptophan into formyl-L-kynurenine, which is then
converted into L-kynurenine and released (Corm et al., 2009; Folgiero
Fig. 13.AML cell-based pathobiochemical pathway showing LPHN1-induced classic activation of PKCα, which triggers translation of Tim-3 and galectin-9 aswell as their secretionwhich is
required for immune escape. The interaction of FLRT3 located on the surface of endothelial cells (EC)with LPHN1 leads to the activation of PKCα through the classic Gq/PLC/Ca2+ pathway.
Ligand-bound LPHN1 activates Gq, which in then stimulates PLC. This leads to phosphatidyl-inositol-bisphosphate (PIP2) degradation and production of inositol-trisphospate (IP3) and
diacylglycerol (DAG). IP3 interacts with ER-associated IP3 receptor (IP3R) leading to Ca2+ mobilization. PKCα is activated by DAG and Ca2+ activates mTOR translational pathway
through downregulation of TSC1/TSC2. mTOR controls translation of Tim-3 and galectin-9. PKCα also phosphorylates Munc18 exocytosis regulator protein which provokes formation
of SNARE complexes that tether vesicles to the plasma membrane. This pre-activates the release machinery, and elevated cytosolic Ca2+ lead to exocytosis of free and galectin-9-
complexed Tim-3. Both types of Tim-3 are differentially shed from the cell surface by proteolytic enzymes. Soluble Tim-3 prevents IL-2 secretion required for activation of NK cells and
cytotoxic T cells. Galectin-9 impairs AML cell killing activity of NK cells (and other cytotoxic lymphocytes).
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et al., 2015; Mabuchi et al., 2016). L-kynurenine affects the ability of NK
cells to kill AML cells, an effect which was seen in our experiments and
presented in Supplementary Fig. 9. Soluble Tim-3 was shown to
signiﬁcantly downregulate production of IL-2, a cytokine required for
activation of NK cells and cytotoxic T lymphocytes.
Taken together, our results show that human AML cells possess a se-
cretory pathway which leads to the production and release of sTim-3
and galectin-9. Both proteins prevent the activation of NK cells and im-
pair their AML cell-killing activity. This pathway, which involves the
LPHN1-dependent activation of Tim-3 and galectin-9 production is
summarized in Fig. 13. The described pathway presents both bio-
markers for AML diagnostics and potential targets (both sTim-3 and
galectin-9) for AML immune therapy and thus can be considered as a
fundamental discovery.
Grant Support
This work was supported by a Daphne Jackson Trust postdoctoral
fellowship (to IMY), University of Kent Faculty of Sciences Research
Fund (to VVS and YAU), Batzebär grant (to EFK and SB) and Oncosuisse
grant KFS-3728-08-2015 (to LV and MB). Funders had no role in study
design, data collection, data analysis, interpretation or writing of the
report.
Acknowledgements
We thank Prof. Michelle D. Garrett (School of Biosciences, University
of Kent, UK) for generously providing us with AZD2014.We are grateful
to Dr. Gurprit S. Lall (School of Pharmacy, University of Kent, UK) for
kindly providing us with biological materials for bone marrow extrac-
tion. Antibody against Gαq was generously provided by Dr. Emma
Veale, School of Pharmacy, University of Kent, UK.We are most grateful
to Dr. Natasha S. Barteneva, School of Science and Technology,
Nazarbayev University, Astana, Kazakhstan for her generous help with
imaging ﬂow cytometry. We thank Diamond Light Source for access to
B23 beamline (SM12578).
Conﬂict of Interest
The authors declare no potential conﬂicts of interest.
Author Contributions
IGS and IMY conducted most of the experiments, analyzed the data
and contributed to manuscript writing, data interpretation and ﬁgure
assembly. SSS conducted the experiments reported in Figs. 2 and 7 as
well as Supplementary Figs. 4 and 6, analyzed the data, contributed to
manuscript writing and ﬁgure assembly. WF and JW were collecting
plasma/providing blood plasma samples obtained from AML patients.
MB and LV generated antibodies against Tim-3 andhuman recombinant
Tim-3 protein fragment used in the study. RH, GS and GC conducted the
experiments associated with SRCD and analyzed the data. SB contribut-
ed to the study design and concept development. YAU andBFGdesigned
the experiments associated with cell-cell interactions, analyzed and
interpreted the data, contributed to the concept development andman-
uscript writing. EFK designed and interpreted co-localization experi-
ments, strongly contributed to design of experiments associated with
Tim-3 and galectin-9 secretion, concept development and manuscript
writing. VVS – designed the whole study, strongly participated in all
the data collection, data analysis and interpretation, developed the con-
cept and wrote the manuscript.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.07.018.
References
Abooali, M., Lall, G.S., Coughlan, K., Lall, H.S., Gibbs, B.F., Sumbayev, V.V., 2014. Crucial in-
volvement of xanthine oxidase in the intracellular signalling networks associated
with human myeloid cell function. Sci. Rep. 4, 6307.
Ashton, A.C., Rahman, M.A., Volynski, K.E., Manser, C., Orlova, E.V., Matsushita, H.,
Davletov, B.A., van Heel, M., Grishin, E.V., Ushkaryov, Y.A., 2000. Tetramerisation of
α-latrotoxin by divalent cations is responsible for toxin-induced non-vesicular re-
lease and contributes to the Ca2+-dependent vesicular exocytosis from synapto-
somes. Biochimie 82, 453–468.
Boucard, A.A., Maxeiner, S., Sudhof, T.C., 2014. Latrophilins function as heterophilic cell-
adhesion molecules by binding to teneurins: regulation by alternative splicing.
J. Biol. Chem. 289, 387–402.
Chabot, S., Kashio, Y., Seki, M., Shirato, Y., Nakamura, K., Nishi, N., Nakamura, T.,
Matsumoto, R., Hirashima, M., 2002. Regulation of galectin-9 expression and release
in Jurkat T cell line cells. Glycobiology 12, 111–118.
Corm, S., Berthon, C., Imbenotte, M., Biggio, V., Lhermitte, M., Dupont, C., Briche, I.,
Quesnel, B., 2009. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia
cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.
Leuk. Res. 33, 490–494.
Davletov, B.A., Meunier, F.A., Ashton, A.C., Matsushita, H., Hirst, W.D., Lelianova, V.G.,
Wilkin, G.P., Dolly, J.O., Ushkaryov, Y.A., 1998. Vesicle exocytosis stimulated by α-
latrotoxin is mediated by latrophilin and requires both external and stored Ca2+.
EMBO J. 17, 3909–3920.
Davydov, I.I., Fidalgo, S., Khaustova, S.A., Lelyanova, V.G., Grebenyuk, E.S., Ushkaryov, Y.A.,
Tonevitsky, A.G., 2009. Prediction of epitopes in closely related proteins using a new
algorithm. Bull. Exp. Biol. Med. 148, 869–873.
Delacour, D., Koch, A., Jacob, R., 2009. The role of galectins in protein trafﬁcking. Trafﬁc 10,
1405–1413.
Dhupkar, P., Gordon, N., 2017. Interleukin-2: old and new approaches to enhance im-
mune-therapeutic efﬁcacy. Adv. Exp. Med. Biol. 995, 33–51.
Fasler-Kan, E., Barteneva, N., Ketterer, S., Wunderlich, K., Huwyler, J., Gygax, D., Flammer,
J., Meyer, P., 2010. Activation of the JAK-STAT intracellular pathway in human retinal
pigment epithelial cell line ARPE-19. Int. J. Interf. Cytokine Mediat. Res. 2, 127–136.
Fasler-Kan, E., Baiken, Y., Vorobjev, I.A., Barteneva, N.S., 2016. Analysis of nucleocytoplasmic
protein shuttling by imaging ﬂow cytometry. Methods Mol. Biol. 1389, 127–137.
Folgiero, V., Cifaldi, L., Li Pira, G., Goffredo, B.M., Vinti, L., Locatelli, F., 2015. TIM-3/Gal-9
interaction induces IFNgamma-dependent IDO1 expression in acute myeloid leuke-
mia blast cells. J. Hematol. Oncol. 8, 36.
Geng, H., Zhang, G.M., Li, D., Zhang, H., Yuan, Y., Zhu, H.G., Xiao, H., Han, L.F., Feng, Z.H.,
2006. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated
immune response. J. Immunol. 176, 1411–1420.
Gleason, M.K., Lenvik, T.R., McCullar, V., Felices, M., O'Brien, M.S., Cooley, S.A., Verneris,
M.R., Cichocki, F., Holman, C.J., Panoskaltsis-Mortari, A., et al., 2012. Tim-3 is an induc-
ible human natural killer cell receptor that enhances interferon gamma production in
response to galectin-9. Blood 119, 3064–3072.
Golden-Mason, L., McMahan, R.H., Strong, M., Reisdorph, R., Mahaffey, S., Palmer, B.E.,
Cheng, L., Kulesza, C., Hirashima, M., Niki, T., et al., 2013. Galectin-9 functionally im-
pairs natural killer cells in humans and mice. J. Virol. 87, 4835–4845.
Gonçalves Silva, I., Ruegg, L., Gibbs, B.F., Bardelli, M., Fruehwirth, A., Varani, L., Berger, S.M.,
Fasler-Kan, E., Sumbayev, V.V., 2016. The immune receptor Tim-3 acts as a trafﬁcker
in a Tim-3/galectin-9 autocrine loop in human myeloid leukemia cells.
Oncoimmunology 5, e1195535.
Hughes, R.C., 1999. Secretion of the galectin family of mammalian carbohydrate-binding
proteins. Biochim. Biophys. Acta 1473, 172–185.
Hussain, R., Javorﬁ, T., Siligardi, G., 2012a. Circular dichroism beamline B23 at the Dia-
mond Light Source. J. Synchrotron Radiat. 19, 132–135.
Hussain, R., Jávorﬁ, T., Siligardi, G., 2012b. Spectroscopic analysis: synchrotron radiation
circular dichroism. Compr. Chiral. 8, 438–448.
Hussain, R., Benning, K., Myatt, D., Javorﬁ, T., Longo, E., Rudd, T.R., Pulford, B., Siligardi, G.,
2015. CDApps: integrated software for experimental planning and data processing at
beamline B23, Diamond Light Source. J. Synchrotron Radiat. 22, 862.
Khaznadar, Z., Henry, G., Setterblad, N., Agaugue, S., Raffoux, E., Boissel, N., Dombret, H.,
Toubert, A., Dulphy, N., 2014. Acute myeloid leukemia impairs natural killer cells
through the formation of a deﬁcient cytotoxic immunological synapse. Eur.
J. Immunol. 44, 3068–3080.
Kikushige, Y., Miyamoto, T., Yuda, J., Jabbarzadeh-Tabrizi, S., Shima, T., Takayanagi, S.,
Niiro, H., Yurino, A., Miyawaki, K., Takenaka, K., et al., 2015. A TIM-3/Gal-9 autocrine
stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leu-
kemic progression. Cell Stem Cell 17, 341–352.
Kirshenbaum, A.S., Akin, C., Wu, Y., Rottem, M., Goff, J.P., Beaven, M.A., Rao, V.K., Metcalfe,
D.D., 2003. Characterization of novel stem cell factor responsive human mast cell
lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; acti-
vation following aggregation of FcepsilonRI or FcgammaRI. Leuk. Res. 27, 677–682.
Kurinna, S., Konopleva, M., Palla, S.L., Chen, W., Kornblau, S., Contractor, R., Deng, X., May,
W.S., Andreeff, M., Ruvolo, P.P., 2006. Bcl2 phosphorylation and active PKC alpha are
associated with poor survival in AML. Leukemia 20, 1316–1319.
Lee, J., Lee, S.J., Lim, K.T., 2014. ZPDC glycoprotein (24 kDa) induces apoptosis and enhances
activity of NK cells in N-nitrosodiethylamine-injected Balb/c. Cell. Immunol. 289, 1–6.
Liu, J., Wan, Q., Lin, X., Zhu, H., Volynski, K., Ushkaryov, Y., Xu, T., 2005.α-Latrotoxin mod-
ulates the secretory machinery via receptor-mediated activation of protein kinase C.
Trafﬁc 6, 756–765.
Mabuchi, R., Hara, T., Matsumoto, T., Shibata, Y., Nakamura, N., Nakamura, H., Kitagawa, J.,
Kanemura, N., Goto, N., Shimizu, M., et al., 2016. High serum concentration of L-
kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia.
Leuk. Lymphoma 57, 92–98.
56 I. Gonçalves Silva et al. / EBioMedicine 22 (2017) 44–57
Maiga, A., Lemieux, S., Pabst, C., Lavallee, V.P., Bouvier, M., Sauvageau, G., Hebert, J., 2016.
Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups
of acute myeloid leukemia: identiﬁcation of potential disease-speciﬁc targets. Blood
Cancer J. 6, e431.
Micol, V., Sanchez-Pinera, P., Villalain, J., de Godos, A., Gomez-Fernandez, J.C., 1999. Corre-
lation between protein kinase C alpha activity and membrane phase behavior.
Biophys. J. 76, 916–927.
Moller-Hackbarth, K., Dewitz, C., Schweigert, O., Trad, A., Garbers, C., Rose-John, S.,
Scheller, J., 2013. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are
major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3). J. Biol.
Chem. 288, 34529–34544.
Morgan, A., Burgoyne, R.D., Barclay, J.W., Craig, T.J., Prescott, G.R., Ciufo, L.F., Evans, G.J.,
Graham, M.E., 2005. Regulation of exocytosis by protein kinase C. Biochem. Soc.
Trans. 33, 1341–1344.
Nagae, M., Nishi, N., Murata, T., Usui, T., Nakamura, T., Wakarsuki, S., Kato, R., 2006. Crystal
structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus
musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem.
281, 35884–35893.
Prokhorov, A., Gibbs, B.F., Bardelli, M., Ruegg, L., Fasler-Kan, E., Varani, L., Sumbayev, V.V.,
2015. The immune receptor Tim-3mediates activation of PI3 kinase/mTOR and HIF-1
pathways in human myeloid leukemia cells. Int. J. Biochem. Cell Biol. 59, 11–20.
Schindelin, J., Rueden, C.T., Hiner, M.C., et al., 2015. The ImageJ ecosystem: an open plat-
form for biomedical image analysis. Mol. Reprod. Dev. 82, 518–529.
Siligardi, G., Hussain, R., 2015. CD Spectroscopy: An Essential Tool for Quality Control of
Protein Folding. RJ Owen, ed. Methods Mol. Biol 1261. Springer, NY, pp. 255–276.
Silva, J.P., Ushkaryov, Y.A., 2010. The latrophilins, “split-personality” receptors. Adv. Exp.
Med. Biol. 706, 59–75.
Silva, J.P., Lelianova, V.G., Ermolyuk, Y.S., Vysokov, N., Hitchen, P.G., Berninghausen, O.,
Rahman, M.A., Zangrandi, A., Fidalgo, S., Tonevitsky, A.G., Dell, A., Volynski, K.E.,
Ushkaryov, Y.A., 2011. Latrophilin 1 and its endogenous ligand Lasso/teneurin-2
form a high-afﬁnity transsynaptic receptor pair with signaling capabilities. Proc.
Natl. Acad. Sci. U. S. A. 108, 12113–12118.
Stockli, J., Fazakerley, D.J., James, D.E., 2011. GLUT4 exocytosis. J. Cell Sci. 124, 4147–4159.
Sumbayev, V.V., Nicholas, S.A., 2010. Hypoxia-inducible factor 1 as one of the “signaling
drivers” of toll-like receptor-dependent and allergic inﬂammation. Arch. Immunol.
Ther. Exp. 58, 287–294.
Sumbayev, V.V., Yasinska, I., Oniku, A.E., Streatﬁeld, C.L., Gibbs, B.F., 2012. Involvement of
hypoxia-inducible factor-1 in the inﬂammatory responses of human LAD2 mast cells
and basophils. PLoS One 7, e34259.
Sumbayev, V.V., Gonçalves Silva, I., Blackburn, J., Gibbs, B.F., Yasinska, I.M., Garrett, M.D.,
Tonevitsky, A.G., Ushkaryov, Y.A., 2016. Expression of functional neuronal receptor
latrophilin 1 in human acute myeloid leukemia cells. Oncotarget 7, 45575–45583.
Swamydas, M., Lionakis, M.S., 2013. Isolation, puriﬁcation and labeling of mouse bone
marrow neutrophils for functional studies and adoptive transfer experiments. JoVE
e50586.
Ushkaryov, Y., 2002. α-Latrotoxin: from structure to some functions. Toxicon 40, 1–5.
Volynski, K.E., Capogna, M., Ashton, A.C., Thomson, D., Orlova, E.V., Manser, C.F.,
Ribchester, R.R., Ushkaryov, Y.A., 2003. Mutant α-latrotoxin (LTXN4C) does not form
pores and causes secretion by receptor stimulation: this action does not require
neurexins. J. Biol. Chem. 278, 31058–31066.
Wang, F., He, W., Zhou, H., Yuan, J., Wu, K., Xu, L., Chen, Z.K., 2007. The Tim-3 ligand
galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of
skin graft. Cell. Immunol. 250, 68–74.
Yasinska, I.M., Gibbs, B.F., Lall, G.S., Sumbayev, V.V., 2014. The HIF-1 transcription complex
is essential for translational control of myeloid hematopoietic cell function by
maintaining mTOR phosphorylation. Cell. Mol. Life Sci. 71, 699–710.
57I. Gonçalves Silva et al. / EBioMedicine 22 (2017) 44–57
ORIGINAL RESEARCH
High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute myeloid
leukaemia progression
Inna M. Yasinskaa,*, Isabel Gonc¸alves Silvaa,*, Svetlana S. Sakhnevycha, Laura Ruegga, Rohanah Hussainb,
Giuliano Siligardib, Walter Fiedlerc, Jasmin Wellbrockc, Marco Bardellid, Luca Varanid, Ulrike Raape, Steffen Bergerf,
Bernhard F. Gibbse,a, Elizaveta Fasler-Kanf,g, and Vadim V. Sumbayeva
aMedway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, United Kingdom; bBeamline 23, Diamond Light Source, Didcot,
UK; cDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center,
University Medical Center Hamburg-Eppendorf, Germany; dInstitute for Research in Biomedicine, Universita’ della Svizzera italiana (USI), Bellinzona,
Switzerland; eDepartment of Medicine (Dermatology and Allergology), University of Oldenburg, Germany; fDepartment of Pediatric Surgery and
Department of Biomedical Research, Children’s Hospital, Inselspital, University of Bern, Switzerland; gDepartment of Biomedicine, University Hospital
Basel and University of Basel, Basel, Switzerland
ARTICLE HISTORY
Received 7 December 2017
Revised 30 January 2018
Accepted 2 February 2018
ABSTRACT
High mobility group box 1 (HMGB1) is a non-histone protein localised in the cell nucleus, where it interacts
with DNA and promotes nuclear transcription events. HMGB1 levels are elevated during acute myeloid
leukaemia (AML) progression followed by participation of this protein in triggering signalling events in
target cells as a pro-inﬂammatory stimulus. This mechanism was hypothesised to be employed as a
survival pathway by malignant blood cells and our aims were therefore to test this hypothesis
experimentally. Here we report that HMGB1 triggers the release of tumour necrosis factor alpha (TNF-a) by
primary human AML cells. TNF-a induces interleukin 1 beta (IL-1b) production by healthy leukocytes,
leading to IL-1b-induced secretion of stem cell factor (SCF) by competent cells (for example endothelial
cells). These results were veriﬁed in mouse bone marrow and primary human AML blood plasma samples.
In addition, HMGB1 was found to induce secretion of angiogenic vascular endothelial growth factor
(VEGF) and this process was dependent on the immune receptor Tim-3. We therefore conclude that
HMGB1 is critical for AML progression as a ligand of Tim-3 and other immune receptors thus supporting
survival/proliferation of AML cells and possibly the process of angiogenesis.
KEYWORDS
Acute myeloid leukaemia;
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High mobility group box 1 (HMGB1) is a non-histone protein
localised in the nucleus, where it binds DNA in order to pro-
mote nuclear transcription processes.1 In addition, HMGB1
was recently found to function as a damage-associated molec-
ular pattern (DAMP) when released passively from either
dead, dying/injured cells or secreted by immune/cancer cells
in response to endogenous and/or exogenous stimuli, such as
hypoxia, endotoxin etc..2-4 This process is followed by partici-
pation of HMGB1 in triggering signalling events in target
cells.1-4 Therefore, it is often called “alarmin” in order to
reﬂect its function as a factor secreted by cells affected by a
stressor.1 It has recently been found that HMGB1 levels are
signiﬁcantly elevated during acute myeloid leukaemia (AML,
blood/bone marrow cancer).5,6 Moreover, AML cells were
shown to express high levels of HMGB1.5,6 Elevated levels of
secreted HMGB1 associated with AML progression are likely
to be caused by a combination of increased expression of this
protein in AML cells and conditions supporting its secretion
such as hypoxia and death of the cells in the tumour microen-
vironment.5-7
Upon release, HMGB1 can interact with several immune
receptors, including Toll-like receptors 2 and 4 (TLRs 2 and
4) as well as receptor of advanced glycation end products
(RAGE).8 Recent evidence has suggested a possible interac-
tion of HMGB1 with the immune receptor Tim-3 (T cell
immunoglobulin and mucin domain 3) which is highly
expressed in human acute myeloid leukaemia (AML) cells.1,2
However, the role of HMGB1 in leukaemia progression
remains unstudied. Interestingly, signalling pathways trig-
gered by TLRs 2/4, RAGE and Tim-3 include activation of the
phosphatidylinositol-3 kinase (PI-3 K)/mammalian target of
rapamycin (mTOR) pathway, which directly controls initia-
tion of translation of proteins crucial for cell survival as well
as cytokines including tumour necrosis factor a (TNF-a), a
pleiotropic inﬂammatory cytokine participating in a variety of
physiological processes associated with control of host
immune defence and respectively haematopoiesis.9-14 This
pathway also triggers accumulation of hypoxia-inducible fac-
tor-1 a (HIF-1a), an inducible subunit of HIF-1 transcription
complex, which induces glycolysis and angiogenesis on
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genomic level.9,12 However, the effects of HMGB1 on signal-
ling events described above remain hypothetic and are not
comprehensively or conceptually studied yet.
Here we report for the ﬁrst time that HMGB1 triggers the
release of TNF-a by primary human AML cells independently
of Tim-3. TNF-a induces interleukin 1 beta (IL-1b) production
by healthy leukocytes and subsequent IL-1b-induced secretion
of stem cell factor (SCF) by competent cells (for example endo-
thelial cells). Treatment of mouse bone marrow cells with
HMGB1 led to signiﬁcant increase in TNF-a, IL-1b and SCF
production. The levels of TNF-a, IL-1b and SCF in blood
plasma of AML patients were also signiﬁcantly upregulated in
comparison to healthy individuals. SCF, a ligand of the Kit
growth factor receptor is required for survival and proliferation
of AML cells. We also show that HMGB1 induces the secretion
of angiogenic protein vascular endothelial growth factor
(VEGF) and this process is controlled by Tim-3. Synchrotron
radiation circular dichroism (SRCD) spectroscopy conﬁrmed
that HMGB1 can speciﬁcally bind Tim-3. We conclude that
HMGB1 as an alarmin participates in AML progression by
interacting with Tim-3 and other immune receptors thus sup-




RPMI-1640 medium, foetal bovine serum, supplements as well
as basic laboratory chemicals were purchased from Sigma (Suf-
folk, UK). MaxisorpTM microtitre plates were obtained from
Nunc (Roskilde, Denmark) and Oxley Hughes Ltd (London,
UK). Mouse monoclonal antibodies directed against HIF-1a,
mTOR and b-actin, as well as rabbit polyclonal antibodies
against phospho-S2448 mTOR, RAGE and HRP-labelled rabbit
anti-mouse secondary antibody were purchased from Abcam
(Cambridge, UK). Antibodies against phospho-S65 and non-
phosphorylated (total) eukaryotic initiation factor 4E binding
protein 1 (eIF4E-BP1) were obtained from Cell Signaling Tech-
nology (Danvers, MA USA). Goat anti-mouse and goat anti-
rabbit ﬂuorescence dye-labelled antibodies were obtained from
LI-COR (Lincoln, Nebraska USA). ELISA-based assay kits for
the detection of TNFa, IL-1b, SCF and VEGF were purchased
from Bio-Techne (R&D Systems, Abingdon, UK). Anti-Tim-3
mouse monoclonal antibody, its single chain variant as well as
human Ig-like V-type domain of Tim-3 (amino acid residues
22–124) and human HMGB1 expressed and puriﬁed from E.
coli (see below for more details) were used in our experi-
ments.11,15 All other chemicals purchased were of the highest
grade of purity commercially available.
Cell lines and primary cells
THP-1 human myeloid leukemia monocytes and MCF-7 epi-
thelial breast cancer cells were obtained from the European
Collection of Cell Cultures (Salisbury, UK). Cells were cultured
in RPMI 1640 medium (R8758 – Sigma (Suffolk, UK) with L-
glutamine and sodium bicarbonate, liquid, sterile-ﬁltered, suit-
able for cell culture) supplemented with 10% foetal bovine
serum, penicillin (50 IU/ml) and streptomycin sulphate
(50 mg/ml).
Primary human AML mononuclear blasts (AML-PB001 F,
newly diagnosed/untreated) were purchased from AllCells
(Alameda, CA, USA) and handled in accordance with the man-
ufacturer’s instructions following ethical approval (REC refer-
ence: 16-SS-033).
Bone marrow was isolated from femur bones of six-week-
old C57 BL16 mice (25 § 2.5 g, kindly provided by Dr. Gurprit
Lall, School of Pharmacy, University of Kent) which were used
for the experiments following approval by the Institutional
Animal Welfare and Ethics Review Body. Animals were han-
dled by authorised personnel in accordance with the Declara-
tion of Helsinki protocols. Bone marrow was isolated from
femur bone heads as described before.15,16 Cells were kept in
RPMI 1640 medium supplemented with 10% foetal bovine
serum, penicillin (50 IU/ml) and streptomycin sulphate
(50 mg/ml).
Primary human blood plasma samples
Blood plasma from healthy donors was obtained from buffy coat
blood (which originated from donors undergoing routine blood
donation) provided by the National Health Blood and Transfu-
sion Service (NHSBT, UK) following ethical approval (REC ref-
erence: 16-SS-033). Primary human AML plasma samples were
obtained from the sample bank of University Medical Centre
Hamburg-Eppendorf (Ethik-Kommission der €Arztekammer
Hamburg, reference: PV3469).
HMGB1 puriﬁcation
HMGB1 was produced and puriﬁed from E. Coli Rosetta DE2
competent. Cells were grown at 37C in LB medium and har-
vested 3 hours after induction with isopropyl b-D-1-thiogalac-
topyranoside (IPTG) at OD600 0.7. The pellet was collected by
centrifugation, re-suspended and sonicated on ice with 5 £ 30
seconds of pulsing and 30 seconds rest (buffer contained
20 mM TrisHCl pH 8; 150 mM NaCl; 10 mM imidazole; 2
Beta-SH and 0.2% Triton X100). Following high-speed centri-
fugation, HMGB1 containing supernatant was subjected to Ni-
afﬁnity and size exclusion chromatography. The protein was
then eluted at a volume consistent with monomeric HMGB1.
After size exclusion HMGB1 was passed through an anion
exchange (Q) column to ensure LPS removal, eluted in sodium
phosphate buffer with 1.5M NaCl and ﬁnally dialysed exten-
sively (at least 36 hours) against PBS buffer. Absence of LPS
contamination was conﬁrmed using mammalian cell lines.
HMGB1 protein was prepared for structural studies and
hence highly pure. It was routinely tested for size and degrada-
tion by size exclusion (during puriﬁcation) and dynamic light
scattering (ﬁnal product). Sample concentration was deter-
mined by UV spectroscopy. Proper folding was controlled by
NMR and CD spectroscopy (all samples required a CD spec-
trum equivalent to that of the samples characterised with bidi-
mensional 15 N NMR spectroscopy). This protein displayed
activity similar to the human recombinant protein expressed in
HEK293 cells obtained from Sigma (Suffolk, UK, SRP6265, as
veriﬁed using THP-1 and primary human AML cells). The
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ability of HMGB1 to interact with TLRs seen in our experi-
ments conﬁrmed similarities in the redox state of preparations
used in our work in comparison to the pro-inﬂammatory form
of HMGB1 released by dead/dying or stressed cancer/immune
and other cells.
Western blot analysis
Tim-3, HIF-1a, phospho-S65 and total eIF4E-BP1 as well as
RAGE were analysed using Western blot.13,14 b-actin stain-
ing was used to conﬁrm equal protein loading as described
previously. LI-COR goat secondary antibodies (dilution
1:2000), conjugated with ﬂuorescent dyes, were used in
accordance with manufacturer’s protocol to visualise target
proteins (using a LI-COR Odyssey imaging system). West-
ern blot data were quantitatively analysed using Odyssey
software and values were subsequently normalised against
those of b-actin. In order to quantitate levels of mTOR-
dependent phosphorylation of eukaryotic initiation factor 4
E binding protein 1 (eIF4E-BP), we measured phospho-S65-
eIF4E-BP and total quantity of eIF4E-BP on a different
membrane to avoid the inﬂuence of possible incomplete
membrane stripping following quantitative analysis. Values
were normalised against those of b-actin for corresponding
membranes. The ratio between normalised phospho-S65-
eIF4E-BP and total eIF4E-BP was calculated in order to
characterise eIF4E-BP phosphorylation levels. The following
equation was implemented:




This ratio in control samples was considered as 100%.
Enzyme-linked immunosorbent assays (ELISAs)
Human or mouse TNF-a, IL-1b, SCF as well as human VEGF,
either in cell culture media or human blood plasma were mea-
sured by ELISA using R&D Systems kits according to manufac-
turer’s protocols. Phosphorylation of mTOR was analysed by
ELISA as previously described.13
In cell assays and in cell Westerns
We employed a standard LI-COR in-cell Western (ICW)
assay (methanol was used as permeabilization agent) to
characterise Tim-3 total levels in studied cells. The in-cell
(ICA, also called on-cell) assay was employed to detect
Tim-3 surface presence in the cells. Following washing with
PBS, cells were scanned using a LI-COR Odyssey imaging
system.17
Detection of PI-3K activity
PI-3K activity was measured in cell lysates as described
previously.18 Brieﬂy, cell lysates were incubated with 30 ml
0.1 mg/ml substrate (PI-4,5-diphosphate emulsion) in kinase
assay buffer. The latter was prepared from 20 mM Tris (pH
7.5), 100 mM NaCl, 0.5 mM EDTA, 8 mM MgCl2 and
40 mM ATP in a total volume of 100 ml at 37C with con-
stant agitation. Reactions were terminated by adding 1 ml of
hexane/isopropanol (13:7, v:v) mixture and 0.2 ml of a mix-
ture of 2 M KCl/HClconc (8:0.25, v:v). After vortexing the
organic phases were washed with HCl (0.5 ml; 0.1 M). This
was followed by detection of phosphate groups using a col-
orimetric assay. The values obtained in the control samples
of each experiment per 1 mg protein were counted as 100%
of the PI-3 K activity. Other values were normalised and
expressed as % control.
Synchrotron radiation circular dichroism (SRCD)
spectroscopy
Human recombinant Tim-3 and HMGB-1, either alone or
in combination, were analysed using SRCD spectroscopy at
beamline B23, Diamond Light Source (Didcot, UK). B23,
equipped with a highly collimated microbeam, allows for
the use of a small aperture long path length microcuvette
which is unattainable with benchtop instruments due to
divergent beams since samples available are of very low
volume and concentrations. SRCD measurements were per-
formed using 0.2 mM of samples in a 1 cm path length cell
of 3 mm aperture diameter and 60 ml capacity using a
Module B instrument with a 1 nm increment, 1 s integra-
tion time, 1.2 nm bandwidth at 23 C.19-24 Temperature
denaturation measurements were collected over the temper-
atures 20C – 95C (in 5C increments) for HMGB1, Tim-
3 and the 1:1 mixture. The results obtained were processed
using CDApps25 and OriginPro. For thermal denaturation
measurements, change in CD (mdeg) at a speciﬁc wave-
length was plotted against the corresponding temperature
for ﬁtting using the Gibbs-Helmholtz equation derived
from Boltzmann distribution,26,27 sigmoidal two-state dena-
turation curve to a Boltzmann distribution and the expres-
sion modiﬁed to include parameters for ﬁtting of thermal
denaturation data for the calculation of the melting tem-
perature (Tm). Titration experiments were conducted as
described for standard far-UV measurements, with the
modiﬁcation of measurements collected after the addition
of incremental volumes of Tim-3 stock as described previ-
ously.28 The change of CD (mdeg) at single wavelength
was plotted against respective ligand concentration (mM)
using OriginPro and ﬁtted with the Hill binding29 func-
tion to determine the Kd for binding.
Statistical analysis
Each ELISA and cell experiment was performed at least three
times and statistical analysis when comparing two events at a
time was conducted using a two-tailed Student’s t-test. Multiple
comparisons were performed using an ANOVA test. Post-hoc
Bonferroni correction was applied. Statistical probabilities (p)




HMGB1 induces moderate activation of PI3-K/mTOR
pathway, TNF-a and VEGF secretion in human AML cells
We used monocytic THP-1 human acute myeloid leukaemia
cells which express Tim-3, but keep most of it inside the cell
(Fig. 1 left panel), and primary human AML cells (AML-
PB001F) where most Tim-3 is expressed on the cell surface
(Fig. 1 right panel). Cells were exposed for 4 h to 1 mg/ml
HMGB1 with or without 1 h pre-treatment with single-chain
antibody against Tim-3, which does not display Tim-3 agonis-
tic properties and also prevents the interaction of other ligands
with it. We found that HMGB1 induced activation of PI-3K in
both THP-1 and primary human AML cells. In both cell types
this effect was non-signiﬁcantly downregulated by the presence
of anti-Tim-3 antibody (Fig. 1). This was consistent with a
moderate activation of mTOR (phosphorylation at S2448) and
increased phosphorylation of mTOR substrate eukaryotic initi-
ation factor 4 E binding protein 1 (eIF4E-BP1). Increased TNF-
a secretion took place in both cases. Neither process observed
was inﬂuenced by the presence of anti-Tim-3 antibody, sug-
gesting that the effects observed are Tim-3-independent.
Pre-treatment of THP-1 cells for 1 h with 2 mg/ml neutralis-
ing antibodies directed against TLR2, TLR4 and RAGE
Figure 1. Differential receptors are involved in HMGB1-induced biological responses of human AML cells. Total levels of the immune receptor Tim-3 and its surface pres-
ence were characterised in THP-1 and primary human AML-PB001F cells by in-cell Western (ICW) and in-cell (on-cell) assay (ICA) respectively (see Materials and Methods
for details). Both cell types were exposed to 1 mg/ml HMGB1 for 4 h with or without 1 h pre-treatment with single chain anti-Tim-3 antibody (aTim-3 (-)) followed by
Western blot analysis of phospho-S65 vs total eIF4E-BP1, HIF-1a and RAGE expression as well as by detection of phospho-S2448 mTOR, release of TNF-a and VEGF using
ELISA. PI-3 K activity was monitored by colorimetric assay. Images are from one experiment representative of ﬁve which gave similar results. Data is shown as mean values
§ SEM of ﬁve independent experiments.  p < 0.05; , p < 0.01 and  when p < 0.001 vs control; a p < 0.05; aa, p < 0.01 vs HMGB1.
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followed by 4 h of exposure to 1 mg/ml HMGB1 showed that
TLRs 2 and 4, but not RAGE, are involved in HMGB1-induced
TNF-a secretion (Supplementary Fig. 1). However, it does not
rule out the fact that during long-term exposure RAGE might
contribute to HMGB1-induced intracellular TNF-a expression
which can be upregulated by RAGE ligands30
Consequently, we detected the activation of HIF-1a accu-
mulation in THP-1 cells but not in AML cells which had
high background levels of HIF-1a and thus probably did
not respond to HMGB1 treatment (Fig. 1). In both cell
types, however, we observed a signiﬁcant increase in VEGF
secretion (Fig. 1) which was signiﬁcantly reduced (but not
HIF-1a accumulation as seen from either Western blot data
or intracellular VEGF levels (this was veriﬁed by ELISA
performed on the cell lysates – data not shown)) by the
presence of anti-Tim-3 antibody. The level of downregula-
tion was proportional to the amount of Tim-3 present on
the surface of each cell type. THP-1 and primary AML cells
express TLRs 2 and 4. They also express high levels of
RAGE, as veriﬁed by Western blot analysis (Fig. 1), which
suggests that HMGB1 induces activation of the PI-3K/
mTOR pathway and HIF-1a accumulation as well as TNF-
a secretion through classic immune receptors like TLRs2/4,
and RAGE, while secretion of VEGF is a Tim-3-dependent
process.
Characterisation of HMGB1-Tim-3 interactions in vitro
We then sought to obtain conﬁrmation of direct interac-
tions between HMGB1 and Tim-3 using the recombinant,
puriﬁed Ig-like V-type domain of human Tim-3 (residues
22–124) and human HMGB1. We employed SRCD spec-
troscopy for both qualitative and quantitative binding
assays. Titration of 200 nM HMGB1 with increasing
amounts of Tim-3 (Fig. 2A) indicated a high nanomolar
binding afﬁnity (Kd D 10¡7 M). The SRCD spectrum of a
1:1 HMGB1-Tim-3 complex appeared different from the
sum of the SRCD spectra of the individual components
(Fig. 2B), suggesting the presence of conformational rear-
rangements upon formation of the complex. Far UV ther-
mal denaturation studies were also performed on the
complex, further supporting the above data (Supplementary
Figs. 2 and 3).
HMGB1 induces TNF-a secretion by human AML leading
to upregulation of SCF production
Since it was obvious that both the AML cell line (THP-1) and
primary AML cells secreted TNF-a in response to stimulation
with HMGB1, we studied the effects of released TNF-a on the
production of IL-1b by primary healthy human leukocytes
(PHL). Cell culture medium obtained after stimulation of
THP-1 cells with 1 mg/ml HMGB1 was used to treat primary
healthy leukocytes for 4 h with or without 1 h pre-treatment
with 2 mg/ml TNF-a-neutralising antibody. We found that in
the absence of TNF-a-neutralising antibody, PHL released IL-
1b, while in the presence of TNF-a-neutralising antibody PHL
did not release detectable amounts of IL-1b. Medium contain-
ing IL-1b was used to culture MCF-7 breast cancer epithelial
cells (these cells express IL-1 receptor type 1 and are capable of
releasing stem cell factor (SCF)) for 24 h in the absence or pres-
ence of 2 mg/ml of IL-1b-neutralising antibody. We found that,
in the presence of IL-1b-neutralising antibody, MCF-7 did not
release detectable amounts of SCF, while in the absence of it
SCF release was clearly detectable. These results (all shown in
Fig. 3A) suggest that HMGB1 induces the release of TNF-a by
AML cells. TNF-a induces IL-1b secretion by PHL. Released
IL-1b stimulates the production of SCF by endothelial/epithe-
lial cells. SCF is required for proliferation of AML cells and
thus supports leukaemia progression.
We sought to obtain conﬁrmation of this biological test
using mouse bone marrow cells ex vivo. Mouse bone marrow
cells were exposed to 1 mg/ml HMGB1 for 24 h. We observed
that the levels of secreted TNF-a, IL-1b and SCF were signiﬁ-
cantly increased compared to non-treated bone marrow cells
(Fig. 3B) and that the ratio between these cytokines was similar
to that observed in the biological test shown in Fig. 3A.
We then measured the levels of TNF-a, IL-1b and SCF in
the blood plasma of 10 healthy human donors and 45 AML
patients. We found that the levels of all three factors were sig-
niﬁcantly increased (Fig. 3C – I). There was a clear evidence of
correlation between IL-1b vs TNF-a, SCF vs IL-1b and SCF vs
Figure 2. Interaction of HMGB1 and the immune receptor Tim-3. Interaction of HMGB1 protein with Tim-3 was analysed using SRCD spectroscopy-based titration which
was conducted in the far UV region using 0.2 mM HMGB1 and increasing stoichiometric concentrations of Tim-3 (A). Changes in CD signal monitored at 222 nm were plot-
ted against Tim 3 concentration using Hill function. Qualitative binding was veriﬁed by analysis of interactions of equimolar concentrations of Tim-3 and HMGB1 using
SRCD spectroscopy (B).
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TNF-a (Fig. 3C and Supplementary Fig. 4) in the blood plasma
of both healthy donors and AML patients which contained
detectable amounts of all the studied cytokines/SCF suggesting
that there is a link between these three factors regardless of the
presence of HMGB1. But the increase in all three factors sug-
gests that HMGB1 activates this intercellular cascade in order
to increase the levels of secreted SCF thus supporting leukaemia
progression.
Discussion
HMGB1 is an “alarmin” which can be secreted by stressed and
dying cells as well as cancer and immune cells, and thus was
suggested to play a role in leukaemia progression.1-7 Recent evi-
dence demonstrated that HMGB1 can also act as a ligand of the
immune receptor Tim-3 which is highly expressed on the sur-
face of human AML cells.1,2 However, the signalling activity of
HMGB1 in AML cells has not been elucidated and was thus the
main aim of our work.
In both, a human AML cell line (THP-1 cells) and primary
AML cells (AML-PB001F) we demonstrated that HMGB1
upregulates the activity of the PI-3 K/mTOR pathway, thus
leading to increased TNF-a secretion and accumulation of
HIF-1a as well as VEGF release (Fig. 1). However, except
VEGF secretion (not HIF-1a-dependent expression), these
effects were not Tim-3-mediated since Tim-3 neutralising
single-chain antibody did not affect any of the processes
described above (except for VEGF release). Importantly,
non-differentiated THP-1 cells express moderate levels of
Tim-3 on their surface – this process has to be induced by
activation of PKCa (for example PMA or latrophilin 1
ligands).15 Primary AML cells which use Tim-3/galectin-9
pathway in order to escape immune attack express much
higher levels of Tim-3 protein on their surface. This differ-
ence was proportional to that in HMGB1-induced VEGF
release in THP-1 and primary AML cells. Furthermore, neu-
tralisation of Tim-3 led to attenuation of HMGB1-induced
VEGF secretion in both cases suggesting that this is a Tim-3-
mediated process.
Highly sensitive SRCD spectroscopic analysis of HMGB1-
Tim-3 interactions conﬁrmed that these two proteins interact
with each other speciﬁcally, but the apparent afﬁnity was
moderately high (Kd D 10¡7 M). This afﬁnity, however, can
be increased by glycosides which normally bind to Tim-3 (the
protein used in the studies was sugar-free). All these results
suggest that this interaction is probably rather more secretory
than a signal transduction event per se. Interestingly, the for-
mation of the protein complex was accompanied by an
increase in a-helical content at the expense of the b-strand
presumably arising mainly from the Tim-3 protein. Biological
tests demonstrated that TNF-a released from primary human
AML cells in an HMGB1-dependent manner is capable of
inducing IL-1b secretion by primary human healthy leuko-
cytes. This is in line with recent observations suggesting upre-
gulation of both TNF-a and IL-1b secretion in response to
stimulation with HMGB1.5,6 This reaction is a very important
step in AML progression since IL-1b interacts with IL-1
receptor type I and induces production and secretion of SCF
required for proliferation of AML cells. Human AML cells
express high levels of Kit receptor, which recognises SCF, and
Figure 3. HMGB1 induces an intercellular signalling cascade leading to SCF secretion. (A) Primary human AML cells (AML-PB-001F) were exposed for 4 h to HMGB1 fol-
lowed by collection of the culture medium (detection of TNF-a was performed in this medium using ELISA), which was used to culture primary human healthy leukocytes
for 4 h in the absence or presence of TNF-a-neutralising antibody. Medium was collected (levels of IL-1b were measured by ELISA) and used to culture MCF-7 breast can-
cer epithelial cells for 4 h in the absence or presence of IL-1b-neutralising antibody. Following this exposure, medium was collected and SCF was measured in it by ELISA.
(B) Primary mouse bone marrow cells (106 cells per 3 ml medium) were exposed for 24 h to 1 mg/ml HMGB1 followed by detection of TNF-a, IL-1b and SCF by ELISA.
(C – I). Levels of TNF-a, IL-1b and SCF were measured in the blood plasma of healthy donors and AML patients by ELISA. Mean values§ SEM are presented as well as lev-
els of each protein in blood plasma of each analysed donor/patient. p < 0.05; p < 0.01 vs control.
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this haematopoietic factor thus becomes highly oncogenic
since AML cells are capable of inducing SCF production by
healthy cells. The same effect was seen in primary mouse
bone marrow cells. When exposed to HMGB1, levels of TNF-
a, IL-1b and SCF increased suggesting that HMGB1 can, in
principle, induce this effect in bone marrow too. However,
production of HMGB1 is not observed in healthy bone mar-
row1,2 since there are not enough stressed/dying or injured
cells in order to produce it (in our samples over 95% of cells
were viable as determined by trypan blue exclusion, data not
shown). However, in leukaemic bone marrow this process is
likely to take place due to lack of oxygen and increased
HMGB1 expression in transformed cells.
Finally, we found that in blood plasma of AML patients, the
levels of TNF-a, IL-1b and SCF were signiﬁcantly higher com-
pared to blood plasma from healthy donors.
We therefore concluded that in human bone marrow
affected by AML, and respectively, by hypoxic conditions, cells
release HMGB1 which induces TNF-a production and subse-
quent secretion of IL-1b which stimulates SCF production/
secretion by endothelial cells. This SCF is used to further stimu-
late the survival/proliferation of AML cells. While these pro-
cesses are Tim-3-independent, HMGB-1 interacts with Tim-3
and induces VEGF secretion, which is required to induce
angiogenesis in bone marrow so that hypoxic conditions caused
by increasing AML cell numbers can be relieved. This mecha-
nism is summarised in the Fig. 4 (a more detailed scheme illus-
trating the possible interactions in the bone marrow is shown
in Supplementary Fig. 5).
HMGB1 has already been considered as a possible therapeu-
tic target for leukaemia treatment.7 Furthermore, targeting
HMGB1 has recently been shown to increase drug sensitivity in
AML.30 Our ﬁndings demonstrate additional insights that
HMGB1 could be considered as a possible therapeutic target in
AML and further conﬁrm the efﬁciency of targeting Tim-3
(here to speciﬁcally block AML-induced angiogenesis) in anti-
AML therapy.
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Cortisol facilitates the immune escape of human acute myeloid
leukemia cells by inducing latrophilin 1 expression
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Dear Editor,
The progression of acute myeloid leukemia (AML)—the most
severe blood/bone marrow cancer—is determined by the ability
of malignant cells to escape host immune surveillance. However,
the systemic regulatory mechanisms underlying this phenomenon
remain largely unknown. In this study, we discovered a funda-
mental systemic biochemical strategy that allows AML cells to
employ physiological systems within the body to survive and
escape immune attack. We found that AML cells use a crucial
human adrenal cortex hormone (cortisol) to induce the expression
of neuronal receptor latrophilin 1 (LPHN1), which facilitates
exocytosis. This receptor interacts with the blood plasma protein
ﬁbronectin leucine rich transmembrane protein 3 (FLRT3) to cause
secretion of the immune suppressor galectin-9, which impairs the
anticancer activities of cytotoxic lymphoid cells.
AML is a cancer of the blood and bone marrow that originates
from self-renewing malignant immature myeloid cells and rapidly
progresses into a systemic, and very often fatal, malignancy.1 AML
cells employ physiological systems in the body to produce factors
required for proliferation/disease progression.2,3 This includes the
hijacking of stem cell factor (SCF), a major hematopoietic growth
factor that controls AML progression and thus can become highly
oncogenic.2,3 The expression and release of SCF can be triggered
by AML cells via cytokines (e.g., interleukin-1β).2 Recent evidence
clearly demonstrated that AML cells are also capable of impairing
the activities of cytotoxic lymphoid cells (e.g., natural killer (NK)
cells and cytotoxic T cells).4 One of the biochemical mechanisms
underlying this phenomenon lies in the ability of AML cells to
secrete the protein galectin-9. This tandem-type galectin binds the
immune receptor Tim-3 and induces a variety of intracellular and
cell-to-cell signaling events leading to the inactivation of NK cells,
as well as the death of cytotoxic T cells.4,5 We recently reported
that the process of galectin-9 secretion in AML cells is stimulated
by the unique G protein-coupled receptor LPHN1, which normally
functions in neurons to facilitate exocytosis.4,6 LPHN1 is also found
in hematopoietic stem cells (HSCs), but its expression disappears at
the early stages of their maturation.4,7 However, upon malignant
transformation, AML cells preserve their abilities to express LPHN1
and to produce high levels of galectin-9 and Tim-3, in which the
latter is involved in trafﬁcking galectin-9 during the secretion
process (HSCs express neither galectin-9 nor Tim-34).
It is currently unknown which molecular mechanisms trigger
elevated levels of LPHN1 expression in primary human AML cells,
and in general, the mechanisms of upregulation of LPHN1
expression at the genomic level remain unclear. It is also unknown
whether FLRT3, a natural LPHN1 ligand,4,8 is present in human
blood plasma and in other tissues associated with AML.
Unraveling these mechanisms is crucial to understanding the
pathways that control the ability of AML cells to protect
themselves against cytotoxic lymphoid cells and, thus, was the
aim of the present study.
RESULTS AND DISCUSSION
To investigate the effects of cortisol on LPHN1 transcription, we
exposed primary and THP-1 human AML cells, primary human
HSCs and primary healthy human leukocytes to 1 µM cortisol for
24 h and subjected to cells to quantitative real-time PCR to
analyze LPHN1 mRNA levels. We found that all the tested cell
types, except primary healthy leukocytes, transcribed detectable
amounts of LPHN1 mRNA, and, in all these cases, the levels were
signiﬁcantly upregulated by treatment with cortisol (Fig. 1a). In
both THP-1 and primary human AML cells, LPHN1 protein levels
were also clearly upregulated (Fig. 1b, c). In contrast, primary
human healthy leukocytes did not express detectable amounts of
LPHN1 protein, and this was not altered by the effects of cortisol
(Fig. 1d). Comparative analysis of LPHN1 protein expression in
primary human AML cells, THP-1 cells, and primary human healthy
leukocytes is shown in Supplementary ﬁgure 1.
Cortisol treatments did not upregulate galectin-9 secretion in
any of these cell types (Fig. 1b–d), suggesting that LPHN1 needs to
be activated by a ligand to induce galectin-9 release.
Analysis of blood plasma levels of cortisol in AML patients vs.
those in healthy donors (samples were collected at the same time
of the day to avoid the inﬂuence of circadian dynamics)
demonstrated that the cortisol levels were signiﬁcantly higher in
the blood plasma of AML patients than in healthy donors (Fig. 1e).
Galectin-9 levels were also substantially higher in AML patients
(Fig. 1f), which is in line with our previous observations.4
Furthermore, there was no correlation between cortisol and
galectin-9 levels in the blood plasma of healthy donors, while in
AML patients, there was a clear correlation (Fig. 1g), suggesting
that galectin-9 secretion might be linked to LPHN1 expression in
this circumstance.
If LPHN1 is expressed on the surface of blood cells, it can also be
shed by proteolysis and therefore be present in the plasma.
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LPHN1 in blood plasma samples from AML patients was
immunoprecipitated, extracted, and subjected to Western blot
analysis using several LPHN1 antibodies. A clear fragment was
detectable at ∼67–68 kDa, and smaller fragments were detectable
as well, but only in plasma from AML patients, while in the blood
plasma from healthy donors, there was no evidence of the
presence of LPHN1 fragments (Fig. 1h). These fragments were also
detectable by ELISA (Fig. 1i, see Materials and Methods for
description of the ELISA format).
As reported before,4 we observed that exposure of THP-1 AML
cells to 10 nM FLRT3 for 16 h resulted in a signiﬁcant increase in
galectin-9 secretion (Fig. 2a). This effect was not detectable in
primary healthy human leukocytes (Fig. 2a). Importantly, 1 h pre-
exposure of THP-1 cells to rabbit polyclonal antibody recognizing
LPHN1 (clone name RL19) prior to the 16-h treatment with 10 nM
FLRT3 attenuated FLRT3-induced galectin-9 release, conﬁrming
the involvement of LPHN1 in this process (Fig. 2a). The antibody
employed speciﬁcally recognized target molecules on the surface
of THP-1 cells (Supplementary ﬁgure 2). We used the mouse
neuroblastoma cell line NB2A, which does not express LPHN1,10 as
a negative control and measured the interaction of the antibody
with the cell surface using a Li-Cor on-cell assay as described in
the Materials and Methods (please see supplementary informa-
tion). Exposure of THP-1 cells to 1 µg/ml RL1 for 16 h did not affect
galectin-9 secretion levels (data not shown), suggesting that this
antibody does not exert an LPHN1 agonistic effect.
Interestingly, we found that blood plasma from both healthy
donors and AML patients contains approximately equal amounts
of secreted FLRT3 (most likely by proteolytic shedding) with a
molecular weight of approximately 55 kDa (which corresponds to
the molecular weight of FLRT3 shed from the cell surface by
proteinases11). Another speciﬁc band was observed at ∼27–28
kDa, which most likely corresponds to a smaller cleavage fragment
of the FLRT3 extracellular domain (Fig. 2b). The amounts of this
smaller fragment were also equal in blood plasma from healthy
donors and AML patients (Fig. 2b). To explore which blood
plasma-based ligands can induce galectin-9 secretion in AML cells,
we cultured THP-1 cells in RPMI 1640 medium containing
antibiotics (as outlined in Materials and Methods—see supple-
mentary information) and replacing the 10% fetal bovine serum
Fig. 1 Cortisol induces LPHN1 expression in human AML cells and in hematopoietic stem cells but not in primary healthy human leukocytes.
Primary human AML cells, THP-1 cells, and hematopoietic stem cells, as well as primary healthy leukocytes were exposed to 1 µM cortisol for
24 h followed by analysis of LPHN1 gene transcription via quantitative real-time PCR (a) and Western blot analysis (b primary AML cells,
(c) THP-1 cells, (d) PHL). For PHL, lysates from LPHN1-overexpressing NB2A cells were used as a positive control. ELISA was used to measure
secreted galectin-9 levels. Blood plasma from 10 healthy donors and 10 AML patients was collected at the same time of the day to ensure
comparability of the cortisol levels. Cortisol (e) and galectin-9 (f) levels were measured by ELISA, and the correlation between the levels of
these two proteins was analyzed (g). Soluble LPHN1 fragments were immunoprecipitated and detected by Western blot (h) and ELISA (i), as
outlined in the Materials and Methods section. Images are from one experiment but are representative of 4–6 replicates, all of which showed
similar results. Data represent the mean values ± SEM of 6–10 independent experiments.; *p < 0.05; **p < 0.01; ***p < 0.01 vs. control
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(FBS) with blood plasma from either healthy donors or AML
patients. Cells were incubated for 16 h with or without a 30-min
preincubation with anti-FLRT3 antibody to neutralize FLRT3
activity. Galectin-9 secretion levels were signiﬁcantly higher in
the presence of either sources of human blood plasma than in the
presence of FBS (negative control). Anti-FLRT3 antibody attenu-
ated galectin-9 secretion (Fig. 2c). The binding of LPHN1 and
FLRT3 was further conﬁrmed using SRCD spectroscopy. We found
that the two proteins interact with each other with high afﬁnity
such that a conformational change is induced in both proteins, as
seen from far UV synchrotron radiation circular dichroism (SRCD)
spectra (Fig. 2d). This is further conﬁrmation of the high-afﬁnity
interaction of LPHN1 and FLRT3 observed in previous studies8
using different techniques.
Taken together, our results demonstrate, for the ﬁrst time, that
cortisol upregulates LPHN1 expression at the transcriptional level,
thus stimulating its translation in human AML cells. AML leads to
decreased blood plasma glucose levels,5 which normally leads to
upregulation of the secretion of corticotropin-releasing hormone
(CTRH) from the hypothalamus.12 CTRH induces the secretion of
adrenocorticotropic hormone (ACTH) from the pituitary gland.12
ACTH upregulates cortisol production in the adrenal cortex.12
Cortisol is then employed by AML cells. In healthy human
leukocytes, cortisol is not capable of inducing LPHN1 transcrip-
tion/translation, possibly because of gene repression. Interaction
of AML cell-derived LPHN1 with released FLRT3 available in blood
plasma facilitates the secretion of galectin-9. The latter protects
AML cells against immune attack, which could otherwise be
performed by NK cells or cytotoxic T cells (Supplementary ﬁgure 3).
Importantly, LPHN1 fragments are present in the blood plasma
from AML patients but not from healthy donors. These fragments
were detectable by both Western blot analysis and ELISA, which
indicates the possibility of detecting these fragments for a rapid
AML diagnosis, although differential veriﬁcation tests have yet to
be performed. Our results suggest a fundamentally novel
mechanism used by AML cells to progress the disease. They use
a common endogenous human hormone (cortisol) to induce
LPHN1 expression by employing a widely available ligand (FLRT3,
which is always present in blood plasma) to escape host immune
surveillance. Thus, AML cells engage crucial functional systems of
the human body to support their survival and attenuate the
anticancer activities of cytotoxic lymphoid cells. Our work
indicates that galectin-9 and secreted FLRT3 are the most
promising targets for anti-AML immune therapy.
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The Tim-3-galectin-9 secretory pathway is known to protect various types of cancer
cells against host immune surveillance. We found that pharmacologically induced
mitochondrial dysfunction leads to a reduced galectin-9 expression/exocytosis in human
colorectal cancer cells and re-distribution of this protein (the effect described for various
cellular proteins) into mitochondria.
Keywords: galectin-9, Tim-3, immune surveillance, mitochondria, colorectal cancer
RESULTS
It has recently been discovered that the immune receptor Tim-3 (T cell immunoglobulin andmucin
domain-containing protein 3) and it’s ligand galectin-9 determines the capability of various types
of malignant cells [e.g., acute myeloid leukemia (AML), colorectal cancer] to escape host immune
surveillance (Kang et al., 2015; Gonçalves Silva et al., 2017; Sakhnevych et al., 2018; Yasinska et al.,
2018b). Also, some of the galectin family members (for example galectin-3) were found to be able
to protect AML and colorectal cancer cells against apoptosis through mitochondrial stabilization
in a B cell lymphoma protein (Bcl) 2-dependent manner (Lee et al., 2013; Ruvolo, 2016). We asked
whether galectin-9 has the same intracellular anti-apoptotic activity in addition to its extracellular
immunosuppressive role. We used a pharmacological inhibitor 5-[(4-bromophenyl)methylene]-
a-(1-methylethyl)-4-oxo-2-thioxo-3-thiazolidineacetic acid (BH3I-1, Figure 1A), a synthetic cell
permeable Bcl-XL antagonist, which induces apoptosis via inhibition of interactions between the
BH3 domain and Bcl-XL thus defunctionalyzing mitochondria. We found that BH3I-1 was capable
of inducing apoptosis in Colo 205 colorectal adenocarcinoma cells of epithelial origin (based
on increased caspase-3 activity and decreased viability of the cells, Figure 1A). Silencing either
galectin-9 or its receptor and possible trafficker Tim-3 did not affect the pro-apoptotic activity
of BH3I-1 suggesting that galectin-9 is unlikely to display anti-apoptotic activity in this case.
Interestingly, the action of BH3I-1 did not affect the activity of mammalian target of rapamycin
(mTOR) translational pathway as seen from its capability to phosphorylate eukaryotic initiation
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FIGURE 1 | Pro-apoptotic defunctionalization of mitochondria reduces galectin-9 expression and leads to its redistribution in human Colo 205 colorectal
adenocarcinoma cells. Colo 205 cells were exposed to 100µM BH3I-1 for 24 h followed by (A) detection of cell viability using an MTS test and colorimetric assay of
caspase-3 activity. Cell viability was also tested for normal and Tim-3 or galectin-9 knockdown Colo 205 cells. (B) Following 24 h of exposure to BH3I-1
S65-phosphorylation levels of eIF4E-BP were analyzed by Western blot. (C) Surface presence and total cellular levels of Tim-3 and galectin-9 were analyzed in Colo
205 cells using FACS. (D) Secreted levels of galectin-9 were analyzed in Colo 205 cells following 24 h of exposure to BH3I-1 by ELISA. (E) Surface levels of galectin-9
in non-treated and BH3I-1-stimulated Colo 205 cells were compared using an on-cell assay. (F) The presence of Tim-3-galectin-9 complex in Colo 205 cells was
confirmed using Western blot analysis (bands were appearing at around 70 KDa, better detectable when temperature denaturation is not applied). THP-1 cells were
used as a positive and K562 as a negative control. (G) Levels of Tim-3 and galectin-9 were analyzed in Colo 205 lysates following 24 h of exposure to BH3I-1 by
Western blot. (H) Mitochondrial extracts were obtained from non-treated and BH3I-1-stimulated Colo 205 cells and subjected to Western blot analysis to detect
Tim-3 and galectin-9. Total protein levels were measured using a Bradford assay and equal protein amounts were loaded onto the gels. (I) Galectin-9 mRNA levels
were analyzed in non-treated Colo 205 cells and those exposed to BH3I-1 using qRT-PCR. In the scheme galectin-9 is abbreviated as G9. Quantitative results are
shown as mean values (crucial mean values are written inside respective bars) ± SEM of 3–6 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 vs.
control. The scheme in the centre of the figure is based on our work on Tim-3-galectin-9 secretory pathway (Gonçalves Silva et al., 2017).
factor-4E-binding protein (eIF4E-BP, Figure 1B). Obviously, one
could suggest that Colo 205 cells accumulate galectin-9 on their
surface and inside the cells based on FACS analysis (Figure 1C).
Reduced levels of surface-based Tim-3might indicate its masking
by galectin-9 (Yasinska et al., 2018a). BH3I-1 does not affect
the ability of Colo 205 cells to secrete galectin-9 (Figure 1D)
but significantly reduces its surface presence (Figure 1E) as
measured by on-cell assay. Colo 205 cells accumulate the
Tim-3-galectin-9 complex (Figure 1F) at a level comparable to
THP-1 AML cells (K562 chronic ML cells expressing traces
Frontiers in Pharmacology | www.frontiersin.org 2 April 2019 | Volume 10 | Article 342
Sakhnevych et al. Defunctionalization of Mitochondria Downregulates the Tim-3-Galectin-9 Pathway
of galectin-9 were used as a negative control). Both proteins
are also clearly detectable in Colo 205 cells by Western blot
(Figure 1G) and treatment with BH3I-1 reduces intracellular
levels of galectin-9. Importantly, Western blot analysis of Colo
205 mitochondrial extracts showed that the Tim-3-galectin-9
complex is accumulated in mitochondria upon stimulation with
BH3I-1 (Figure 1H). The intracellular levels of galectin-9 mRNA
were significantly reduced upon stimulation with BH3I-1, as
detected by quantitative real-time PCR (qRT-PCR, Figure 1I).
Interestingly, the ability of Colo 205 cells to secrete galectin-
9 is lower compared to THP-1 AML cells and the levels
of secretion in both cell types are proportional to cellular
Tim-3 levels (Supplementary Figure 1). This further supports
conclusion regarding the involvement of Tim-3 in galectin-9
secretion (Gonçalves Silva et al., 2017).
We have also investigated two other types of epithelial
cells—non-malignant human kidney RC-124 and malignant
human HepG2 hepatoma cells. Both cell types have
abundant mitochondria, however they are often [especially
non-malignant, like RC-124—confirmed by a direct
chemical measurement as described of the drug-associated
bromine (Sollo et al., 1971) uptake in these cells, data
not shown] less permeable for inhibitors of this type
compared to colorectal cancer and AML cells. Therefore,
6 h of exposure to 1mM H2O2 was used in order to
defunctionalize mitochondria (Nicholas et al., 2011). We
found that galectin-9 levels were significantly reduced in
both cell types but the Tim-3-galectin-9 complex was only
accumulated in the mitochondria of HepG2 and not RC-124
cells (Supplementary Figure 2).
MATERIALS AND METHODS
Commercially available Colo 205, RC-124, HepG2, THP-1,
and K562, accompanied by authentication certificates, were
used in this study. Mitochondria isolation, Western blot,
on-cell assays, qRT-PCR, ELISA, and FACS analysis were
performed as described before (Nicholas et al., 2011; Gonçalves
Silva et al., 2016, 2017; Yasinska et al., 2018a). Detailed
description of materials and methods used is provided in
Supplementary Information.
DISCUSSION
Our results indicate that colorectal cancer cells operate the
Tim-3-galectin-9 secretory pathway, where Tim-3 acts as
a galectin-9 binding partner and possible trafficker. Pro-
apoptotic mitochondrial dysfunction leads to a decreased
transcription of galectin-9 mRNA leading to its reduced
translation. However, exocytosis of galectin-9 is affected by
mitochondrial defunctionalization leading to a re-distribution of
the Tim-3-galectin-9 complex into mitochondria where galectin-
9 could possibly interact with mitochondrial glycoproteins.
The physiological relevance of this process is unclear but
may well be a part of the regulated cell suicide programme
which might involve transfer of galectin-9 into mitochondria
so that it can’t be involved in protection of a dying cell
thus allowing its smooth elimination. Our further studies
indicate that this phenomenon might be applicable mainly to
malignant epithelial cells (Figure 1, Supplementary Figure 2).
Importantly, targeted defunctionalization of mitochondria
in malignant cells may be a novel strategy for anti-cancer
immunotherapy since it reduces cell surface presence of
galectin-9 capable of suppressing anti-cancer activity of
cytotoxic lymphoid cells.
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Human cancer cells operate a variety of effective molecular and signaling mechanisms
which allow them to escape host immune surveillance and thus progress the disease. We
have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9
are involved in the immune escape of human acute myeloid leukemia (AML) cells. These
cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich
transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway.
We hypothesized that the Tim-3-galectin-9 pathway may be involved in the immune
escape of cancer cells of different origins. We found that studied breast tumors expressed
significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues
of the same patients and that these proteins were co-localized. Increased levels of LPHN2
and expressions of LPHN3 as well as FLRT3 were also detected in breast tumor cells.
Activation of this pathway facilitated the translocation of galectin-9 onto the tumor cell
surface, however no secretion of galectin-9 by tumor cells was observed. Surface-based
galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced
death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast
cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3
and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms
and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range
of human cancer cells and is possibly involved in prevention of anti-tumor immunity.
Keywords: galectin-9, TIM-3, breast cancer, immune evasion, immune surveillance
Yasinska et al. The Tim-3-Galectin-9 Pathway in Breast Cancer
INTRODUCTION
Human malignant tumors have developed a variety of
biochemical mechanisms which allow them to escape host
immune surveillance, thus leading to disease progression
(1, 2). This applies to both liquid and solid tumors (1). It has
recently become evident that acute myeloid leukemia (AML)
cells, originating from self-renewing myeloid haematopoietic
precursors, operate an immunosuppressive pathway which
includes facilitation of exocytosis of the T cell immunoglobulin
and mucin domain containing protein 3 (Tim-3) and its natural
ligand, galectin-9 (2–4). Galectin-9 is a tandem protein which
contains two ligand-binding domains fused together by a peptide
linker (several isoforms have been identified) (5). As with other
galectins, galectin-9 lacks a secretory domain and thus requires
trafficking in order to be translocated onto the cell surface
where it could be secreted by proteolytic shedding (5). Tim-3
acts both as a receptor and a possible trafficker for galectin-9
(2, 4, 6). When associated with the plasma membrane, the Tim-
3-galectin-9 complex triggers downstream signaling contributing
to cell renewal, thus forming an autocrine loop (6). On the other
hand, proteolytic shedding results in release of both a soluble
form of Tim-3 and galectin-9 (2). Both Tim-3 and galectin-9
act to suppress anti-cancer immune surveillance (2). Secreted
galectin-9 contributes to anti-cancer immune suppression by
killing cytotoxic T lymphocytes and impairing the activity of
natural killer (NK) cells, thus allowing for disease progression
(2, 4). Soluble Tim-3 also downregulates the production of
interleukin-2 (IL-2), a cytokine required for the activation of
both NK cells and cytotoxic T lymphocytes (2).
AML cells express the G-protein coupled neuronal receptor
latrophilin 1 (LPHN1) which is produced by haematopoietic
stem cells (HSCs) but disappears upon their maturation (7,
8). In case that HSCs undergo malignant transformation, thus
becoming AML cells, they preserve the ability to express LPHN1
(7, 8). Interacting with its natural ligand, fibronectin leucine rich
transmembrane protein 3 (FLRT3) and possibly other ligands (2,
3), LPHN1 facilitates translocation of Tim-3 and galectin-9 onto
the cell surface via GαQ [G protein transducing the signal from
LPHN (7)]—phospholipase C (PLC)—protein kinase C alpha
(PKCα) biochemical pathway, which is followed by proteolytic
shedding of the complex or ligand-free Tim-3 (2), creating an
immune suppressive “double edged sword.” Translation of Tim-
3 and galectin-9 in these cells is controlled by the mammalian
target of rapamycin (mTOR) pathway (2), one of the master
regulators of protein biosynthesis.
Interestingly, other LPHN isoforms, in particular LPHN2,
were found to be ubiquitously expressed especially in breast
tumors (9). Human breast tumor cells were also found to express
galectin-9, where it was shown to be involved in cell aggregation,
thus preventing metastasis (10). On the other hand, the Tim-3-
galectin-9 pathway plays a role in suppressing cytotoxic T cells
in solid tumors, for example in colon cancer (11). However, the
biochemical events underlying these processes have not been
studied yet and it is therefore important to investigate whether
the activity of the Tim-3-galectin-9 secretory pathway is specific
solely to AML cells or whether it is also common for breast
and other solid tumors. This will help us to understand the
fundamental pathophysiological role of the pathway and its
underlying biochemistry.
Therefore, the aim of our work was to investigate the
biochemical activity of the Tim-3-galectin-9 pathway in human
breast cancer and its possible role in suppressing cytotoxic T cell
activity. In addition, we assessed the differential expression of
the components of the Tim-3-galectin-9 pathway in human solid
tumor cells.
Here we report that primary breast tumors express
significantly higher levels of Tim-3, and especially galectin-
9, compared to healthy tissues of the same patients. Importantly,
Tim-3 and galectin-9 were co-localized. Breast tumors also
expressed LPHN2 and LPHN3 as well as FLRT3. The PLC/PKC
secretory biochemical pathway was significantly upregulated in
breast tumors compared to healthy tissues. Breast cancer cell
lines expressed all these components and biochemical studies
were conducted using MCF-7 cells. Breast cancer cells were
unable to secrete galectin-9, but were capable of maintaining
its cell surface expression. The process of externalization was
upregulated by exogenous FLRT3 most likely in a PLC/PKC-
dependent manner. Surface-based galectin-9 was able to protect
MCF-7 cells against T cell-induced death. Furthermore, we
found that human cell lines originating from a wide range of
different cancers express detectable amounts of both Tim-3 and
galectin-9 proteins. The majority of these cell lines expressed at
least one of the LPHN isoforms as well as FLRT3, suggesting that




RPMI-1640 medium, fetal bovine serum and supplements as
well as basic laboratory chemicals were purchased from Sigma
(Suffolk, UK). Maxisorp
TM
microtitre plates were provided
either by Oxley Hughes Ltd (London, UK) or Nunc (Roskilde,
Denmark). Mouse monoclonal antibodies directed against
mTOR and β-actin, as well as rabbit polyclonal antibodies
against phospho-S2448 mTOR, galectin-9, HRP-labeled rabbit
anti-mouse secondary antibody were purchased from Abcam
(Cambridge, UK). Mouse monoclonal antibody against FLRT3
was obtained from Santa Cruz Biotechnology (Heidelberg,
Germany). Antibodies against phospho-S65 and total eIF4E-
BP were obtained from Cell Signaling Technology (Danvers,
MA USA). The polyclonal rabbit anti-peptide antibodies (PAL1,
PAL2, and PAL3) against LPHN1, LPHN2, and LPHN3,
respectively, were previously described (12). Rabbit polyclonal
antibody against poly-(ADP-ribose)-polymerase (PAR) was
purchased from Enzo Life Sciences LTD (Exeter, UK). Goat anti-
mouse and goat anti-rabbit fluorescence dye-labeled antibodies
were obtained from LI-COR (Lincoln, Nebraska USA). ELISA
kits for the quantitation of galectin-9, Tim-3, and IL-2 were
purchased from Bio-Techne (R&D Systems, Abingdon, UK).
Anti-Tim-3 mouse monoclonal antibody was employed as
previously described (13). Secondary antibodies for confocal laser
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microscopy (TRITC labeled antibody (goat anti-mouse IgG) and
t FITC labeled antibody (goat anti-rabbit IgG) were from Abcam
(Cambridge, UK). All other chemicals purchased were of the
highest grade of purity.
Cell Lines and Primary Human Cells
Cell lines, listed in Supplementary Table 1, were obtained from
either European Collection of Cell Cultures, American Tissue
Culture Collection (ATTC) or CLS Cell Lines Service GmbH.
Cell lines were accompanied by identification test certificates and
were grown according to corresponding tissue culture collection
protocols. LAD2mast cells were kindly provided by ProfMetcalfe
andDr. Kirshenbaum (NAID, NHI, USA) and cultured according
to the protocol described before (14).
MCF-7 breast cancer cells were purchased from the European
Collection of Cell Cultures (the cell lines provided were
accompanied by identification test certificates). Cells were
cultured in RPMI 1640 media supplemented with 10% fetal
bovine serum, penicillin (50 IU/ml), and streptomycin sulfate
(50 µg/ml).
TALL-104 cytotoxic T lymphocytes derived from human
acute lymphoblastic leukemia (TALL) were purchased from
the American Tissue Culture Collection. Cells were cultured
according to the ATCC instructions. Briefly, ATCC-formulated
Iscove’s Modified Dulbecco’s Medium was used. To make the
complete growth medium we added 100 units/ml recombinant
human IL-2; 2.5µg/ml human albumin; 0.5µg/ml D-mannitol
and fetal bovine serum to a final concentration of 20%. Primary
human leukocytes (PHL) were isolated from buffy coat blood
(originated from healthy donors though routine blood donation).
The buffy coat blood was obtained from the National Health
Blood and Transfusion Service (NHSBT, UK) following ethical
approval (REC reference: 16-SS-033).
Human Tissue Samples
Primary human tumor tissue samples paired together with
peripheral tissues (also called “normal” or “healthy” of the same
patients) were collected surgically from breast cancer patients
treated at the Colchester General Hospital, following informed,
and written consent taken before surgery. Paired normal
(healthy) peripheral tissues were removed during macroscopic
examination of a tumor by pathologists. Blood samples were
collected before breast surgery from patients with primary breast
cancer (PBC) and before treatment from patients with metastatic
breast cancer (MBC). Samples were also collected from healthy
donors (individuals with no diagnosed pathology), which were
used as control samples. Blood separation was performed using
buoyancy density method employing Histopaque 1119-1 (Sigma,
St. Louis, MO) according to the manufacturer’s protocol. Ethical
approval documentation for these studies was obtained from the
NRES Essex Research Ethics Committee and the Research &
Innovation Department of the Colchester Hospitals University,
NHS Foundation Trust [MH 363 (AM03) and 09/H0301/37].
Western Blot Analysis
The components of the Tim-3, galectin-9, FLRT3, LPHNs 2/3,
and mTOR pathways as well as GαQ, PARP, and CD3 were
detected in cell and tissue lysates byWestern blot and normalized
to β-actin levels in order to confirm equal protein loading as
reported earlier (2). Cells were lysed in 50mM Tris–HCl, 5mM
EDTA, 150mM NaCl, 0.5% Nonidet-40, 1mM PMSF, pH 8.0.
Tissue lysates for Western blot analysis were prepared as
described previously (15). Briefly, 100mg of frozen tissues were
grounded into a powder in dry ice, followed by the addition
of 100 µl of the tissue lysis buffer (20mM Tris/HEPES pH
8.0, 2mM EDTA, 0.5M NaCl, 0.5% sodium deoxycholate,
0.5% Triton X-100, 0.25M Sucrose, supplemented with 50mM
2-mercaptoethanol, 50µM PMSF, 1µM pepstatin supplied
just before use). Tissues were homogenized using a Polytron
Homogenizer (Capitol Scientific, USA) and a syringe was used
in order to acquire a homogenous cell suspension. These tissue
suspensions were then filtered through medical gauzes and
centrifuged at +4◦C at 10,000 g for 15min. Proteins present in
supernatants were precipitated by incubation of the samples on
ice for 30min with equal volumes of ice-cold acetone. Protein
pellets were obtained by centrifugation at +4◦C, 10,000 g for
15min followed by air drying at room temperature and then lysed
using the SDS-lysis buffer described above.
Li-Cor goat secondary antibodies (dilution 1:2,000),
conjugated with infrared fluorescent dyes, were used as
described in the manufacturer’s protocol to visualize target
proteins (Li-Cor Odyssey imaging system was applied). Western
blot data were quantitatively analyzed using Odyssey software
and values were subsequently normalized against those of β-actin
or total protein loaded.
Enzyme-Linked Immunosorbent
Assays (ELISAs)
Galectin-9, soluble Tim3 (sTim-3) and IL-2 were measured by
ELISA using R&D Systems kits according to manufacturer’s
protocols. Phosphorylation of mTOR was analyzed by ELISA as
previously described (16).
ELISA was also used to detect Tim-3-galectin-9 complex as
described before (4) in the tissue homogenates. Homogenates
were prepared in the ratio 1 g of tissue and 4ml of lysis
(extraction) buffer containing 50mMTris pH 7.5, 150mMNaCl,
5mM EDTA, and 0.5% NP-40. Mouse anti-Tim-3 (mAnti-Tim-
3) was used as a capture antibody and biotinylated goat anti-
galectin-9 (gAnti-Galectin-9, R&D Systems) for detection. The
reaction was visualized using HRP-labeled streptavidin (R&D
Systems; Figure 2A—see the scheme). In all cases plates were
washed with TBST and bound secondary antibodies visualized
using peroxidase reaction (ortho-phenylenediamine/H2O2).
Quantitative Real-Time PCR (qRT-PCR)
To detect galectin-9 mRNA levels, we used qRT-PCR (4).
We isolated total RNA using a GenElute
TM
mammalian total
RNA preparation kit (Sigma-Aldrich), followed by reverse
transcriptase–polymerase chain reaction (RT-PCR) of a target
protein mRNA (performed according to the manufacturer’s
protocol). This was followed by qRT-PCR. The following primers
were used: Galectin-9, 5′-CTTTCATCACCACCATTCTG-3′ and
5′-ATGTGGAACCTCTGAGCACTG-3′ actin, 5′-TGACGGGG
TCACCCACACT-GTGCCCATCTA-3′, 5′-CTAGAAGCATTT
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GCGGTCG-ACGATGGAGGG-3′. Reactions were performed
using a LightCycler R© 480 qRT-PCR machine and SYBR Green I
Master kit (obtained from Roche, Burgess Hill, UK). The work
was performed according to the manufacturer’s protocol. Values
representing galectin-9 mRNA levels were normalized against
those of β-actin.
On Cell Assays
On cell assays were employed to detect surface presence of
galectin-9 and CD8. We used Li-Cor secondary antibody to
recognize anti CD8 primary antibody and then visualized as
described before (4, 17).
Confocal Microscopy
Tissue Sectioning
Tissue sections were produced using a freezing microtome with
the cutting thickness of 5–6µm. Each tissue section was sliced
onto a poly-D-lysine-coated microscope slide (BDH).
Immunofluorescence Staining for Bioimaging
Analysis
Endogenous peroxidase activity was blocked by incubating
slides in 3% in H2O2 for 15min. The slides were then
permeabilised using PBS containing 0.26% Triton for 20min
at room temperature and blocked with serum obtained from
the same species as the secondary antibody in the following
buffer: PBS, 0.05% Tween, 2% serum, 1% BSA for at least 30min.
Tim-3 and galectin-9 expressions were detected by incubating
slides with antibodies described above diluted in PBS (pH 7.4
containing 0.05% Tween, 1% BSA (1:200 dilution) for 2 h at
room temperature and washed three times with PBS. Slides
were then incubated in the dark for 1 h with anti-IgG-FITC-
labeled secondary antibody (1:400 dilution) and then washed
three times with PBS followed by Fluoro-Gel mounting media
containing DAPI nuclei-staining reagent. Negative controls were
prepared by incubating the slides with secondary antibody alone.
Images were taken using Confocal Laser Scanning Microscopy
(BioRad Hercules).
Fluorescence Co-localization Imaging
For image acquisition, a Nikon A1si laser scanning confocal
microscope was used with a Plan Fluor DIC 40x magnifying,
1.3-numerical aperture (N.A.) oil-immersion objective. NIS
Elements software (version 3.21.03, Nikon, Tokyo, Japan) was
employed for data analysis. Cell images were acquired in
three channels for DAPI (excitation at 399 nm with laser
power 10 arbitrary units [AU], emission collection at 450 nm;
nuclei labeling), Alexa Fluor 488 (excitation wavelength 488 nm
with laser power 10AU and, emission wavelength at 525 nm
(corresponds to a green channel, galectin-9), Alexa Fluor 555
(excitation 561 nm with laser power 10AU, emission collection
at 595 nm, red channel, Tim-3), with a photomultiplier tube gain
of 100AU. No offset was used, and pinhole size was set between
1.2 and 2 times the Airy disk size of the used objective, depending
on signal strength.
PLC and PKCα Activity Assays
The activity of PLC was measured based on the ability of
this enzyme to cleave the ester bond between glycerol and
phosphoric acid of the substrate phosphatidylinositol-4,5-bis-
phosphate (PIP2). PIP2 (150µM), was re-suspended in the assay
buffer containing 20mM Tris-HCl buffer (pH 7.2) containing
0.1% sodium deoxycholate, 300µM CaCl2, 100µM EDTA,
and 100mM NaCl by sonication. Reaction was started by
adding the substrate followed by incubation for 60min at
37◦C. Uncleaved substrate and IP3 (the reaction product) were
then measured using electrophoretic (33% polyacrylamide gel)
separation, followed by toluidine blue staining and colorimetric
assay (13, 18). The catalytic activity of PKCα was measured
as described before based on its ability to phosphorylate
specific substrate in a reaction buffer containing 20mM Tris-
HCl (pH7.5), 20µM ATP, 5mM MgCl2, and 200µM CaCl2
(19). Phosphate groups attached to the substrate were detected
spectrophotometrically (20).
Cell Viability Assay
Cell viability was analyzed using a commercial assay kit (Promega
UK Ltd., Southampton, UK). We used an MTS colorimetric
assay for assessing cell metabolic activity. NAD(P)H-dependent
cellular oxidoreductase enzymes playing a crucial role in human
myeloid cell survival reflect the number of viable cells present.
Cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) and then absorbance was measured at 490 nm in
accordance with the manufacturer’s protocol.
Synchrotron Radiation Circular Dichroism
(SRCD) Spectroscopy
Human recombinant LPHN2 (olfactomedin-like domain,
MyBioSource, San Diego, CA, USA) and FLRT3, either alone or
in combination (equimolar ratio), were analyzed using SRCD
spectroscopy at beamline B23, Diamond Light Source (Didcot,
UK) (3, 21, 22). SRCD measurements were performed using
0.7µM of samples in a 1 cm path length cell of 3mm aperture
diameter and 60 µl capacity using a Module B instrument
at 23◦C. Integration time was 1 s, the increment−1 nm and
bandwidth−1.2 nm. The results obtained were processed using
CDApps and OriginPro R©.
Statistical Analysis
Each experiment was performed at least three times and statistical
analysis when comparing two events at a time was conducted
using a two-tailed Student’s t-test. Multiple comparisons were
performed using ANOVA. Post-hoc Bonferroni correction was
applied. Statistical probabilities (p) were expressed as ∗ for p <
0.05; ∗∗ for p < 0.01, and ∗∗∗ for p < 0.001.
RESULTS
Expression and Activity of the
FLRT3/LPHN/Tim3/galectin-9 Pathway in
Breast Tumors
We found that primary breast tumors expressed galectin-9, Tim-
3, LPHN2, and FLRT3 (Figures 1A,B); as well as detectable
amounts of LPHN3 (Supplementary Figure 1). Interestingly, in
addition to a specific FLRT3 bands, a clear band appears at
around 55 kDa (highlighted by a question mark). This may
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FIGURE 1 | Expression of FLRT3/LPHN/Tim-3/galectin-9 pathway components and activities of PLC/PKCα and mTOR pathways in primary human breast tumors.
Expression levels of Tim-3, galectin-9 (A), FLRT3, and LPHN2 (B) were analyzed in primary breast malignant tumors and healthy breast tissues (HT) of five patients
(n = 5) by Western blot. Activities of PLC, PKCα, and the levels of phospho-S2448 mTOR were detected as outlined in the Materials and Methods (C). The amounts
of phospho-S65 and total eIF4E-BP (mTOR substrate) were analyzed using Western blot (D). The levels of CD3 (biomarker of T cells) were also measured using lysate
of Jurkat T cells as a positive control (E). Molecular weight markers (MW) are expressed in kDa. Images are from one experiment representative of five which gave
similar results. Other results are shown as mean values ± SEM. *p < 0.05; **p < 0.01, and ***when p < 0.001 vs. control.
represent FLRT3 which underwent proteolytic processing (3).
Importantly, expression levels of Tim-3, galectin-9 and LPHN2
were significantly higher (about 15–20 fold for galectin-9, p <
0.001, 2 fold for Tim-3, p < 0.05 and 2.5–3 fold for LPHN2,
p < 0.01) in tumors compared to healthy tissues isolated from
the same patients. A band specific for galectin-9 appeared at
around 55 kDa when 12% PAGE was used (this is the gel
concentration normally used for galectin-9 detection) in each
case and was not detectable by the anti-Tim-3 antibody. This
indicates that this band is not the Tim-3-galectin-9 complex
but probably a galectin-9 isoform bound to carbohydrates (as
a lectin) which is unlikely to be secreted. This was confirmed
when the same sample was ran using 10% PAGE and the
specific band appeared above 31 kDa molecular weight marker
(Supplementary Figure 2) confirming that, in a 12 % gel, protein
running was “delayed” possibly due to the presence of glycosides
or other post-translational modifications affecting the protein
properties/shape but not the molecular weight. Activities of PLC
and PKCα were significantly higher (p < 0.01 for PLC and p
< 0.001 for PKCα) in tumor tissue homogenates compared to
those of healthy tissues (Figure 1C). However, unlike in AML
cells (2), the S2448 phosphorylation level of mTOR was similar in
both healthy and tumor tissues (Figure 1C). The ratio between
phospho-S65 eIF4E-BP and its total amount was also similar in
both tissue types, although the amount of both phospho-S65 and
total eIF4E-BP was higher in tumor tissues (Figure 1D).
Importantly, analysis of CD3 (a marker of T cells)
demonstrated that this protein is undetectable in healthy
and barely detectable in tumor tissue lysates suggesting that the
analyzed proteins are mainly expressed by breast tumor cells and
not tumor-infiltrated lymphocytes (Figure 1E).
In order to assess if Tim-3 is complexed to galectin-9 as in
leukemia cells, we performed detection of the Tim-3-galectin-9
complex in tissue homogenates as outlined in the Materials and
Methods. We found that the complex was barely detectable in
normal tissue homogenates but was clearly detectable in tumor
tissue extracts (Figure 2A). Next, measurement of Tim-3 and
galectin-9 in tissues was performed using confocal microscopy.
In line with the data shown in Figures 1, 2A, we observed
that both proteins are abundant in tumor tissue slices and are
also co-localized (Figure 2B). Analysis of blood plasma samples
obtained from patients with both primary and metastatic breast
tumors showed that levels of galectin-9 and soluble Tim-3 were
lower compared to healthy donors (Figure 3). Respectively, both
patient groups demonstrated non-significantly higher levels of
IL-2 (Figure 3).
MCF-7, BC-8701, and MDA-MB-231 breast cancer cells
(Supplementary Table 1 and Supplementary Figure 1) all
expressed Tim-3, galectin-9, FLRT3, and at least one LPHN
isoform. The highest level of LPHN2was expressed byMDA-MB-
231 cells, which is in line with previously reported observations
(9). To further investigate the mechanism we selected MCF-7
Frontiers in Immunology | www.frontiersin.org 5 July 2019 | Volume 10 | Article 1594
Yasinska et al. The Tim-3-Galectin-9 Pathway in Breast Cancer
FIGURE 2 | Expression, interaction, and co-localization of Tim-3 and galectin-9 in primary human breast tumors. (A) Presence of the Tim-3-galectin-9 complex in
primary normal and tumor tissue extracts was analyzed using ELISA as outlined in the Materials and Methods. (B) Expression and co-localization of galectin-9 and
Tim-3 were analyzed in primary human breast tumors and healthy tissues of the same patients using confocal microscopy (see Materials and Methods for further
details). Images are from one experiment representative of five which gave similar results. Scale bars correspond to 20µm.
FIGURE 3 | Levels of galectin-9, Tim-3, and IL-2 in blood plasma of human healthy donors and patients suffering from primary and metastatic breast tumors.
Concentrations of galectin-9, soluble Tim-3, and IL-2 were analyzed in blood plasma of healthy donors and breast cancer patients by ELISA. Data are shown as mean
values ± SEM of 20 for healthy donors (HD), 42 for primary breast cancer (PBC) patients, and 20 for metastatic breast cancer (MBC) patients. *p < 0.05; **p < 0.01
and vs. HD.
breast cancer cells since they are the only cell line analyzed
which expressed detectable amounts of both LPHNs 2 and 3
(as in primary breast tumors, Supplementary Figures 1A,C).
They also expressed Tim-3 and galectin-9 (Tim-3-galectin-9
complex was also detectable, Figure 4A). Galectin-9 mRNA
levels in MCF-7 cells were also significantly higher compared
to normal human breast tissue (Supplementary Figure 1B).
The level of galectin-9 mRNA in primary human breast
tumor tissues was much higher compared to the normal tissue
(Supplementary Figure 1B) and, importantly, the ratio of
galectin-9 mRNA in tumor and normal tissues was similar to
the respective levels of protein detected (Figure 1A). Also these
results suggest that MCF-7 cells as well as primary healthy and
malignant cells express identical galectin-9, thus re-confirming
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FIGURE 4 | FLRT3 induces translocation of galectin-9 onto the surface of MCF-7 breast cancer cells. (A) MCF-7 cells were exposed for 4 h to 10 nM FLRT3 and
activities of PLC, PKCα, the levels of phospho-S2448 mTOR and the amounts of phospho-S65 and total eIF4E-BP (an mTOR substrate) were analyzed as described
in the Materials and Methods. (B) MCF-7 cells were exposed for 4 h to 10 nM FLRT3 with or without 1 h pre-treatment with 30µM U73122 (PLC inhibitor) or 70 nM
Gö6983 (PKCα inhibitor). Surface presence of galectin-9 was measured by on-cell assay. (C) Secondary structure and conformational changes of LPHN2
olfacomedin-like domain (FLRT3-inding region), FLRT3, and the complex of the two proteins mixed at the equimolar ratio were characterized using SRCD
spectroscopy as outlined in the Materials and Methods. An interaction between olfactomedin-like domain of LPHN3 and FLRT3 generated by Swiss PDB viewer
[5 cmn.pdb file downloaded through PubMed database was used (13)] is presented to illustrate the structural basis of this interaction. Images are from one experiment
representative of four which gave similar results. Other results are shown as mean values ± SEM of at least three independent experiments. *p < 0.05; **p < 0.01 vs.
control.
that the same protein was detected by Western blot (Figure 1
and Supplementary Figure 1A).
LPHN2 expression in MCF-7 cells was lower than in MDA-
MB-231 but comparable with primary tumors. Furthermore,
primary breast tumors and MCF-7 cells expressed comparable
amounts of LPHN3 (Supplementary Figure 1C). It is important
to mention that there are possible minor variations in LPHN2
gene in breast cancer cells lines (23) and possibly in primary
breast tumors, however the translated protein has no variations
in amino acid sequence. Both primary breast tumor and
MCF-7 cells expressed GαQ (Supplementary Figure 1D), which
indicates the presence of an adaptor protein required for
transduction of signals via G-protein-coupled receptors (LPHN
isoforms). Cells were also exposed for 4 h to 10 nM human
recombinant FLRT3 followed by detection of phospho-S65/total
eIF4E-BP, phospho-S2448 mTOR, activities of PLC and PKCα as
well as cell surface presence of galectin-9. As shown in Figure 4A,
exposure to FLRT3 did not affect mTOR activity but significantly
upregulated the activities of PLC and PKCα. Galectin-9 surface
presence was also significantly upregulated as measured by on-
cell assay (Figure 4B). Importantly, pre-treatment of the cells
for 1 h with 30µM U73122 (PLC inhibitor) and 70 nM Gö6983
(PKCα inhibitor) before 4 h exposure to 10 nM FLRT3 attenuated
FLRT3-induced galectin-9 translocation onto the cell surface
(Figure 4B). This confirms that FLRT3-induced translocation of
galectin-9 onto the surface of MCF-7 cells is controlled by the
PLC/PKCα pathway.
To further verify the interaction of FLRT3 with the
olfactomedin-like domain of LPHN2 [for LPHNs 1 and 3 this
has already been confirmed (3, 24–26)] we performed SRCD
spectroscopy analyzing spectra (thus characterizing secondary
structure and conformational changes) of the olfactomedin-
like domain of LPHN2 and FLRT3 alone and their equimolar
combination. We found that binding of FLRT3 took place in a
similar fashion as previously reported for LPHN1 (Figure 4C).
This suggests that all three LPHN isoforms interact with FLRT3
in a similar way (a 3D interaction of LPHN3 oflactomedin-like
domain and FLRT3 is presented in Figure 4C).
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Galectin-9 Protects Breast Cancer Cells
Against Cytotoxic Immune Attack
To assess the effect of galectin-9 in protecting breast cancer cells
against cytotoxic cell-dependent killing we co-cultured MCF-
7 cells (adherent) with cytotoxic ALL-derived TALL-104 CD8-
positive T lymphocytes (we used these rather than NK cells since
mainly T cells infiltrate solid tumors; as NK cells, TALL-104 cells
express Tim-3, and not galectin-9) for 16 h at a ratio of 4 MCF-
7 cells: 1 TALL-104 cells (Figure 5A—this ratio was selected
experimentally to achieve moderate effects in order to be able to
trace biochemical mechanisms). The co-culture was performed in
either the absence or presence of 5µg/ml galectin-9 neutralizing
antibody to evaluate the contribution of surface-based galectin-
9. Following the treatment TALL-104 cells were collected, lysed,
and subjected to Western blot analysis of full-length and cleaved
PARP (marker of apoptosis). We found that in TALL-104 cells
co-cultured with MCF-7 cells the level of PARP cleavage was
significantly (about 3 fold, p < 0.05) increased and the presence
of anti-galectin-9 antibody attenuated the effect (Figure 5B).
Increased level of PARP cleavage indicates a higher number of
apoptotic cells. An on-cell assay was used to assess the level of
infiltration of TALL-104 cells into the MCF-7 cell monolayer. We
observed that CD8 was absent in the MCF-7 cells when cultured
on their own, but it was detected when MCF-7 cells were co-
cultured with TALL-104. It was further significantly increased
when the cells were co-cultured in the presence of galectin-9
neutralizing antibody, suggesting that the ability of TALL-104
cells to attack MCF-7 cells is increased when galectin-9 activity is
disabled (Figure 5B). Isotype control antibody (used at the same
concentration of 5µg/ml) did not affect interactions between
TALL-104 and MCF-7 cells, confirming the role of galectin-9 in
this process (Figure 5C). Importantly, cell surface presence of
galectin-9 was significantly upregulated in the presence of TALL-
104 cells as measured by the on-cell assay (Figure 5D). Similar
effect was observed before in other solid tumors (27). Viability of
MCF-7 cells was also decreased in the presence of TALL-104 cells
and galectin-9 neutralizing antibody (but not isotype control) as
measured by an MTS test (Figure 5E). This is a strong indication
that galectin-9 is capable of protecting breast tumor cells against
cytotoxic cell-dependent killing.
The Majority of Solid and Liquid Tumors
Express Key Components of the
FLRT3/LPHN/Tim-3/galectin-9 Pathway
To investigate the expression of FLRT3/LPHN/Tim-3/galectin-
9 pathway components in cancer cells of different origins,
we screened various human cancer cell lines (derived from
brain, colorectal, kidney, blood/mast cell, liver, breast, prostate,
lung, and skin tumors) and various non-malignant cell lines
and primary cells, using Western blot analysis. Comparative
analysis was performed by measuring infrared fluorescence
of the bands divided by the total quantity of the loaded
protein. This approach was taken because the cells analyzed
originated from different tissues and thus the levels of each
housekeeping protein (such as beta-actin, for example) vary
depending on the origin of the cells. Results of quantitative
analysis are summarized in Figure 6 and Western blot images
are presented in Supplementary Table 1. Tim-3 and galectin-
9 were present in all the studied cancer cells, except for
the chronic myeloid leukemia (CML) cell line, K562, which
expressed Tim-3 but only traces of galectin-9, in agreement
with previously reported observations (2). Of note, this could
be one of the reasons why CML cells entering the circulation
are rapidly eliminated by cytotoxic lymphoid cells. As indicated
above, we also measured the levels of secreted galectin-9 in
different cells lines and observed variations dependent on
their origin (Supplementary Table 1). The highest levels of
galectin-9 were detected in hematological (except for K562
cells) and colorectal cancer cells. Other cell types expressed
moderate levels and prostate cancer cells expressed lower but
detectable levels of at least one variant of galectin-9 (Figure 6,
Supplementary Table 1). Non-malignant cells, expressed lower
amounts of galectin-9 and also Tim-3 compared to cancerous
cells of similar origins. Furthermore, the majority of the cells
expressed at least one LPHN isoform, as well as FLRT3. Some
of the cells did not express FLRT3 but expressed LPHN isoforms
(Figure 6, Supplementary Table 1). This most likely means that
LPHN expressing cells use blood-based soluble FLRT3 to trigger
the pathway since blood does not contain the other LPHN ligand
teneurin-2 (7).
DISCUSSION
The molecular mechanisms underlying the ability of cancer cells
to escape host immune surveillance remain poorly understood.
Recent evidence clearly demonstrated that some tumor cells
(AML in particular) operate the Tim-3-galectin-9 secretory
pathway which is capable of disabling cytotoxic lymphoid cells
(2, 3). However, a growing body of evidence suggests that some
solid tumors [for example colorectal tumors (11)] also express
Tim-3 and galectin-9 and use these proteins to escape host
immune attack. We studied the activity of this pathway in
breast and other solid and liquid tumors. We also investigated
the pathway in both breast tumors and healthy breast tissues
obtained from the same patients as well as in breast tumor
cell lines.
Using Western blot analysis and confocal microscopy we
found very low levels of galectin-9 in human breast tissue cells
peripheral to tumor (Figures 1, 2), which were significantly
increased in tumor cells. Importantly, as in AML cells, Tim-3, and
galectin-9 are co-localized in breast tumor cells and are capable
to form complex (Figure 2A and Supplementary Figure 1A).
However, this tumor-associated galectin-9 is unlikely to be
secreted since blood plasma levels of galectin-9 are lower than
in healthy donors. Interestingly, high levels of Tim-3 are known
to be expressed by solid tumor-infiltrating lymphocytes (27,
28), which could be used by tumor-derived galectin-9 to kill
them. Our results have confirmed that Tim-3 and galectin-9 are
expressed mainly by tumor cells, since CD3 (a T cell biomarker)
was barely detectable in tumor and undetectable in healthy
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FIGURE 5 | Galectin-9 protects MCF-7 cells against T cell-dependent cytotoxic immune attack. (A) MCF-7 cells were co-cultured with TALL-104 cytotoxic T
lymphocytes at a ratio of 4 : 1 for 16 h (the ratio was determined by the aggressive behavior of TALL-104 cells) in the absence or presence of 5µg/ml galectin-9
neutralizing antibody or 5µg/ml isotype control antibody. (B) After the experiment TALL-104 cells were lysed and PARP cleavage, as an indicator of the rate of
apoptotic cells, was measured using Western blot analysis. (C) CD8 expressions (reflecting the infiltration of TALL-104 into the MCF-7 layer) were measured by on-cell
assay. (D) Galectin-9 surface presence was measured using on-cell assay in resting MCF-7 cells and those co-cultured with TALL-104 cells (E) Viability of MCF-7 cells
was measured by MTS test. Images are from one experiment representative of five which gave similar results. Other results are presented as mean values ± SEM of
five independent experiments. *p < 0.05 vs. control.
FIGURE 6 | Expression of Tim-3, galectin-9, LPHNs 1, 2, and 3 as well as FLRT3 proteins in various human cancer cell lines. Lysates of indicated cells were
subjected to Western blot analysis as outlined in Materials and Methods (images are presented in Supplementary Table 1). Detected infrared fluorescence of the
bands divided by the total protein amounts loaded (measured using Bradford assay) was used as a measure of protein quantity. Levels of Tim-3 & total galectin-9
(A) and LPHNs 1, 2, & 3 (B) were expressed as a % of those levels present in THP-1 cells (expressed as 100%). Since THP-1 cells lack FLRT3 expression, the levels
of this protein were expressed as % RCC-FG1 (C), respectively considering FLRT3 level in these cells as 100%. Bn, brain; CR, colorectal; Ki, kidney; BBM, blood,
bone marrow and mast cells; Li, liver; Br, breast; Pr, prostate; Lu, lung; Sk, skin. Data are presented as mean values ± SEM of three independent experiments.
tissue lysates (Figure 1E). Furthermore, both proteins are co-
localized suggesting that they are expressed by the same cells
(Figure 2B). Levels of soluble Tim-3 were also downregulated
in blood plasma of breast cancer patients which is in line with
galectin-9 values. Importantly, as indicated above, our results
indicate that galectin-9 is unlikely to be secreted by breast tumors,
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since its levels do not increase in patient blood plasma and the
studied human breast cancer cell lines were incapable of secreting
galectin-9. Furthermore, the molecular weight of tissue-based
galectin-9 suggests that it is most likely associated with plasma
membrane-based glycosides, as previously described in somatic
cells (29–31). This binding would of course keep it attached to
the cell surface and prevent its release.
Taken together, these results suggest that the FLRT3/LPHN/
Tim-3/galectin-9 pathway possibly functions mainly to transfer
galectin-9 onto the cell surface rather than to secrete it as in the
case with AML cells. This would explain the lower level of mTOR
pathway activation in breast tumor cells compared to AML
cells (2), where secretion takes place and subsequently requires
replacement of the proteins through biosynthesis. Interestingly,
the findings reported here on the protein level are in line with
gene expression data for human breast cancer presented in The
Cancer Genome Atlas.
Remarkably, the level of IL-2 was non-significantly increased
in blood plasma of breast cancer patients, but not in AML
patients, including those with primary and metastatic breast
tumors. This suggests that induction of the cytotoxic activity of
NK cells and cytotoxic T cells can still take place. This observation
is supported by the fact that plasma levels of soluble Tim-3 are
also lower, since Tim-3 was shown to downregulate IL-2 secretion
by specialized T cells (2).
Tumor tissue cells expressed LPHN2 (significantly higher
levels compared to healthy tissues), LPHN3, and FLRT3 (LPHN
ligand). In line with this, the activities of PLC and PKCα were
significantly higher in tumors compared to healthy tissues. The
activity of mTOR was not upregulated, although basal levels
FIGURE 7 | Breast cancer cell-based pathobiochemical pathways showing LPHN-induced activation of PKCα, which triggers the translocation of Tim-3 and galectin-9
onto the cell surface which is required for immune escape. The interaction of FLRT3 with LPHN isoform leads to the activation of PKCα, most likely through the classic
Gq/PLC/Ca2+pathway. Ligand-bound LPHN activates Gq, which in turn stimulates PLC. This leads to phosphatidyl-inositol-bisphosphate (PIP2) degradation and
production of inositol-trisphospate (IP3) and diacylglycerol (DAG). PKCα is then activated by DAG and cytosolic Ca
2+. PKCα provokes the formation of SNARE
complexes that tether vesicles to the plasma membrane. Galectin-9 impairs the cancer cell killing activity of cytotoxic T cells (and other cytotoxic lymphocytes).
Possible (not directly confirmed) interactions of galectin-9 with glycoside component and T cell receptor (TCR)/CD8, with MHC I, and antigen are highlighted with
question mark “?” to indicate the fact that it is a hypothetic interaction, since TALL-104 cells used in the study kill tumor cells in MHC-independent manner (32).
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of the mTOR substrate (eIF4E-BP) were significantly higher in
tumor cells.
We found that exposure of MCF-7 breast cancer cells to
10 nM FLRT3 induces activation of PLC and PKCα. Recently
it has been found that FLRT3 activates the PKCα pathway via
LPHN isoforms (2). The activity of mTOR was not increased
after 4 h of exposure to FLRT3. FLRT3-induced externalization
of galectin-9 onto the cell surface was observed. This is in
line with previous observations made in AML cells where
galectin-9 secretion was shown to be triggered by LPHN in a
PKCα-dependent manner (2). Importantly, in both leukemia
(2) and MCF-7 cells FLRT-3-induced effects are moderate.
The effects observed with latrotoxin (a LPHN1 ligand) in
AML cells are much stronger compared to those of FLRT3
(2). These moderate effects indicate that they are most likely
continuous and thus keep the pathway operating in order
to protect malignant cells against cytotoxic lymphoid cells
on an ongoing basis but in a manner that does not allow
exhaustion of the cell. On the other hand, there are clearly
other pathways operated by breast cancer cells to suppress
the activity of cytotoxic immune cells. For example presence
of TALL-104 cells significantly upregulates galectin-9 surface
presence in MCF-7 breast cancer cells. Biochemical pathways
underlying this phenomenon remain to be identified. Based
on these observations, it can be concluded that the FLRT3-
LPHN-Tim-3-galectin-9 pathway is functional in other cancer
cells and in particular in breast cancer cell lines and primary
tumors. In this case, however, we do not observe a FLRT3-
LPHN-dependent activation of mTOR but rather a moderate,
yet significant, activation of PLC/PKCα. In contrast, FLRT3-
LPHN1 interactions in AML cells are capable of activating the
mTOR pathway. The biological effect of LPHN2-FLRT3 results
in the translocation of the Tim-3-galectin-9 complex onto the
cell surface but since there is no proteolytic shedding/secretion,
constant protein renewal is not required as it is in AML cells.
A scheme representing the involvement of FLRT3-LPHN and
other possible interactions in the activation of Tim-3-galectin-9
immunosuppressive pathway is shown in Figure 7. Intriguingly,
in line with our observations that galectin-9 levels in PC3 prostate
cancer cells are low compared to other cancer cells, these cells
were recently reported to be rapidly killed by TALL-104 cells used
in our work (32).
Interestingly, it has been previously reported that galectin-
9 demonstrates anti-metastatic potential in breast cancer
(10, 33). Possible reasons underlying such an activity were
suggested to be galectin-9-induced cell aggregation and reduced
adhesion of breast cancer cells to the extracellular matrix (10).
These studies support our hypothesis regarding the possible
interaction of galectin-9 with membrane-associated glycosides,
since this process is known to participate in determining the
membrane potential (30, 31, 34), which is a crucial factor
affecting cell aggregation. Importantly, as a result of alternative
splicing, galectin-9 may be present in three main isoforms
characterized by the length of the linker peptide: long (49
amino acids), medium (27 amino acids) and short (15 amino
acids) (5, 29–31, 33, 34). As one can see from the data
reported in Supplementary Table 1, some of the cell types can
express only one isoform, others two, or all three but the
biochemical reasons underlying this phenomenon remain to
be understood.
Additionally, NK cells interacting with galectin-9 on the
breast cancer cell surface may release interferon gamma (IFN-
γ) in response (2, 35) which could activate cytotoxic lymphoid
cells located in the area of the tumor microenvironment. These
cells can attack and kill malignant cells breaking off from the
tumor thus preventing their circulation and metastasis. Overall,
it appears that galectin-9 could protect the tumor which produces
it in order to evade host immune attack, but this may not
promote metastasis.
CONCLUSION
Our findings demonstrate the activity of the Tim-3-galectin-
9 biochemical pathway in breast and various other types of
human cancer cells and its possible implication in suppression
of host anti-cancer immune surveillance. This pathway can be
recommended for targeting in order to design novel anti-cancer
immunotherapeutic approaches based on inhibiting the Tim3-
galectin-9 pathobiochemical pathway thus enabling the immune
system to attack and eradicate malignant tumors.
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